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Background: Smoking during pregnancy is the main preventable cause of poor birth outcomes. Improved
methods are needed to help women to stop smoking during pregnancy. Pregnancy provides a compelling
rationale for physical activity (PA) interventions as cessation medication is contraindicated or ineffective,
and an effective PA intervention could be highly cost-effective.
Objective: To examine the effectiveness and cost-effectiveness of a PA intervention plus standard
behavioural support for smoking cessation relative to behavioural support alone for achieving smoking
cessation at the end of pregnancy.
Design: Multicentre, two-group, pragmatic randomised controlled trial and economic evaluation with
follow-up at the end of pregnancy and 6 months postnatally. Randomisation was stratified by centre and a
computer-generated sequence was used to allocate participants using a 1 : 1 ratio.
DOI: 10.3310/hta19840 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 84
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ussher et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
vii
Setting: 13 hospitals offering antenatal care in the UK.
Participants: Women between 10 and 24 weeks’ gestation smoking five or more cigarettes a day before
pregnancy and one or more during pregnancy.
Interventions: Participants were randomised to behavioural support for smoking cessation (control)
or behavioural support plus a PA intervention consisting of supervised treadmill exercise plus PA
consultations. Neither participants nor researchers were blinded to treatment allocation.
Main outcome measures: The primary outcome was self-reported, continuous smoking abstinence
between a quit date and end of pregnancy, validated by expired carbon monoxide and/or salivary cotinine.
Secondary outcomes were maternal weight, depression, birth outcomes, withdrawal symptoms and urges
to smoke. The economic evaluation investigated the costs of the PA intervention compared with the
control intervention.
Results: In total, 789 women were randomised (n= 394 PA, n= 395 control). Four were excluded post
randomisation (two had been enrolled twice in sequential pregnancies and two were ineligible and
randomised erroneously). The intention-to-treat analysis comprised 785 participants (n= 392 PA, n= 393
control). There was no significant difference in the rate of abstinence at the end of pregnancy between the
PA group (7.7%) and the control group (6.4%) [odds ratio for PA group abstinence 1.21, 95% confidence
interval (CI) 0.70 to 2.10]. For the PA group compared with the control group, there was a 33% (95% CI
14% to 56%), 28% (95% CI 7% to 52%) and 36% (95% CI 12% to 65%) significantly greater increase
in self-reported minutes of moderate- and vigorous-intensity PA from baseline to 1 week, 4 weeks and
6 weeks respectively. Accelerometer data showed that there was no significant difference in PA levels
between the groups. There were no significant differences between the groups for change in maternal
weight, depression, withdrawal symptoms or urges to smoke. Adverse events and birth outcomes were
similar between the groups except for there being significantly more caesarean births in the control group
than in the PA group (28.7% vs. 21.3%; p< 0.023). The PA intervention was less costly than the control
intervention by £35 per participant. This was mainly attributable to increased health-care usage in the
control group. However, there was considerable statistical uncertainty around this estimate.
Conclusions: During pregnancy, offering an intervention combining supervised exercise and PA
counselling does not add to the effectiveness of behavioural support for smoking cessation. Only 10% of
participants had PA levels accessed by accelerometer and it is, therefore, unclear whether or not the lack
of an effect on the primary outcome is the result of insufficient increases in PA. Research is needed to
identify the smoking populations most suitable for PA interventions and methods for increasing
PA adherence.
Trial registration: Current Controlled Trials ISRCTN48600346.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 19, No. 84. See the NIHR Journals Library website
for further project information.
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Plain English summary
Smoking during pregnancy damages the growing baby. Most medicines to help with stopping smokingare unlicensed in pregnancy or have been found to be unhelpful. Physical activity (PA) reduces urges to
smoke, which are the main cause of smoking relapse. Therefore, we tested whether or not offering a
PA programme helps pregnant women to quit smoking.
Women recorded as smokers at their first pregnancy-related visit to the health service were contacted
about the study. The 785 women who participated had an equal chance of being offered standard help
for stopping smoking given by a health professional or help plus a PA programme that encouraged
women to incorporate more activity into their days and provided supervised exercise sessions. We
compared women’s success at quitting at the end of their pregnancy between the two groups. During
their pregnancy women reported how much PA they were doing. Women in the PA group reported doing
more PA, although among the 10% of women wearing devices that measured PA objectively there was no
detectable difference in PA levels between the two groups. The quit rates were low and were similar for
the two groups (7.7% in the PA group, 6.6% in the control group). The PA programme was shown to be
reasonably cost-effective, mainly because health-care usage was lower in the PA group. In conclusion,
there was no evidence that the PA programme helped women to stop smoking. This may be because the
women did not raise their PA levels sufficiently.
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Scientific summary
Background
Maternal smoking in pregnancy is the main preventable cause of morbidity and death among women and
infants. In most high-income countries at least 10% of women smoke during pregnancy and the
prevalence is rising in low- and middle-income nations. There is evidence that behavioural support
increases the rate at which women can stop smoking but there is no evidence that smoking cessation
medication adds to this. The large majority of women who receive behavioural support for cessation
during pregnancy do not manage to stop smoking and thus new options that add to the effectiveness of
behavioural support are needed.
Physical activity (PA) programmes may add to the effectiveness of behavioural support. There is convincing
evidence that PA reduces the intensity of urges to smoke in the general population of smokers, which are
the main cause of relapse to smoking. In non-pregnant smokers, the evidence base showing that PA
programmes improve cessation rates is mixed, but most trials did not have sufficiently large sample sizes to
have a realistic chance of detecting group differences and had other methodological limitations that increase
the risk of bias and make the evidence hard to interpret. Moderate-intensity PA (e.g. brisk walking) is
recommended during pregnancy and has been shown to reduce cigarette cravings, and pregnant smokers,
especially those who are reluctant to use nicotine replacement therapy, are likely to be receptive to
such an intervention. We conducted the London Exercise And Pregnant smokers (LEAP) trial to assess the
effectiveness and cost-effectiveness of a PA intervention for smoking cessation during pregnancy.
Objectives
The main objective of the study was to investigate whether or not behavioural support for smoking cessation
in pregnancy plus a PA intervention is more effective than behavioural support alone in achieving
biochemically validated smoking cessation between a quit date and end of pregnancy. A further objective was
to assess the cost-effectiveness of the intervention for achieving smoking cessation at the end of pregnancy.
Methods
The LEAP trial was a pragmatic, randomised controlled trial with an accompanying health economic
evaluation. Following their first antenatal booking visit, researchers identified pregnant smokers via lists on
the computerised patient administration system at 13 hospital trusts. They discussed the study with
potential participants by telephone and enrolled women who consented to participate and met the
inclusion criteria. We included women who were between 10 and 24 weeks’ gestation, who smoked one
or more cigarettes daily at trial entry and who had smoked at least five cigarettes daily before pregnancy.
Participants set a quit date and researchers offered six weekly sessions of 20 minutes of individual
behavioural cessation support. At enrolment, participants were randomly assigned to behavioural support
alone or to behavioural support plus a PA intervention that included 14 sessions of supervised exercise on
a treadmill combined with nine PA consultations.
Researchers followed up participants at a visit at the end of pregnancy (valid if between 36 weeks’
gestation and 10 weeks after the birth) and by telephone at 6 months postnatally. Researchers retrieved
birth outcome data from medical records. The primary outcome was self-reported continuous abstinence
from smoking between the quit date and end of pregnancy validated by exhaled carbon monoxide and/or
salivary cotinine. Temporary, brief smoking lapses of up to five cigarettes in total were permitted following
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the quit day. Secondary outcomes included validated abstinence at 4 weeks after the quit date and
self-reported abstinence at 6 months postnatally. Self-reports of PA levels were collected at baseline and
weeks 1, 4 and 6 after the quit date, at the end of pregnancy and 6 months post partum. To validate
self-reported PA levels, a 10% random subsample of participants had their PA objectively measured using an
accelerometer (Model GT1M or GT3X; Actigraph, Pensacola, FL, USA). Ratings of withdrawal symptoms,
urges to smoke, confidence for quitting smoking and confidence for participating in PA were recorded.
Changes in maternal depression were examined between baseline and end of pregnancy and 6 months after
the birth. Changes in maternal weight were assessed between baseline and end of pregnancy. Maternal and
fetal adverse events (AEs) and birth outcomes were collected from hospital records.
Based on a systematic review it was anticipated that there would be a cessation rate of 15% in the control
group, on the basis that 9% of pregnant women who are smokers stop smoking with usual care after
their first antenatal visit and an additional 6–7% quit with behavioural support. Based on pilot work, a
cessation rate of 23% was anticipated in the treatment group. The aim was to recruit 866 participants,
providing 83% power at a 5% significance level to detect an 8% absolute difference in the rate of
smoking cessation at the end of pregnancy between the two groups, corresponding to an odds ratio (OR)
of 1.69.
Analysis was on an intention-to-treat (ITT) basis; participants with missing outcome data were assumed to
be smoking. The proportion of women reporting continuous smoking abstinence at the end of pregnancy
was compared between study groups using logistic regression, with adjustment for recruitment centre.
Economic analyses assessed the costs of delivering the intervention for each participant in the intervention
group compared with the control group and the costs of caring for each woman and her infant during
the period between randomisation and the immediate postnatal period.
Results
In total, 789 women were enrolled in the trial. Four women were excluded post randomisation, two
because they were enrolled twice in sequential pregnancies and two because they were ineligible at their
baseline visit and had been erroneously randomised. Of the 785 women (n= 392 in the PA group)
included in the ITT analysis, there were 774 singleton births, 10 twin births and one unknown birth as the
woman withdrew consent. The follow-up rate for the primary outcome was 88.8% and this was similar
for the two study groups.
Adherence
Participants attended a median of four of 14 treatment sessions in the intervention group and three of six
in the control group. Women in the intervention group increased their PA levels more than women in the
control group. For the PA group compared with the control group, the percentage increase in minutes of
moderate- and vigorous-intensity PA was 33%, [95% confidence interval (CI) 14% to 56%] at 1 week,
28% (95% CI 7% to 52%) at 4 weeks and 36% (95% CI 12% to 65%) at 6 weeks (p< 0.001). Relative
to baseline there was a decrease in self-reported minutes of PA at the end of pregnancy and 6 months
after the birth for both groups. According to the accelerometer data there was no significant difference in
PA levels between the groups.
Smoking outcomes
There was no significant difference in smoking abstinence rates between the two groups. The rate of
validated continuous abstinence at the end of pregnancy was 7.7% in the PA group and 6.4% in the control
group (OR for PA group, adjusted for centre only, 1.21, 95% CI 0.70 to 2.10). At 4 weeks the validated
abstinence rate was 12.8% in the PA group and 15.5% in the control group (OR, adjusted for centre only,
0.79, 95% CI 0.53 to 1.18). At 6 months postnatally the self-reported abstinence rate was 6.1% in the
PA group and 4.1% in the control group (OR, adjusted for centre only, 1.55, 95% CI 0.81 to 2.97).
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Psychological outcomes
Between baseline and 1 week post quit, the PA group exhibited a significant increase in ratings of
confidence for participating in PA relative to the control group (p= 0.002); however, across this period
there was no significant difference in change in ratings for individual cigarette withdrawal symptoms
or for urge to smoke or confidence for quitting. There was no evidence of any difference in changes in
depression between the two study groups.
Birth outcomes
Birth outcomes were similar between treatment groups. The only significant difference was that more
caesarean births occurred in the control group than in the PA group (28.7% vs. 21.3%; p< 0.023).
Maternal weight gain
There was no evidence for any difference in maternal weight gain between the two study groups.
Adverse events
The rates of AEs and serious adverse events (SAEs) were similar in the two study groups. The number of
women or their infants who had at least one AE or SAE was 55.4% in the PA group and 55.7% in the
control group.
Economic analyses
The total mean cost (cost of delivering the intervention plus resource use costs) was £35 per participant
lower in the PA group than in the control group. This was mainly attributable to increased health-care
usage in the control group. However, as shown by the scatterplot, there was substantial uncertainty
around this estimate.
Conclusions
Supplementing behavioural support with a PA intervention was no more effective than behavioural
support alone in promoting smoking cessation. These findings were observed despite the PA group
self-reporting 35–47% greater increases in PA than the control group during the intervention period.
There was no evidence that the PA intervention increased AEs or had a harmful effect on birth outcomes
and there was some evidence that the PA intervention resulted in fewer caesarean sections. In pregnancy,
the PA intervention that we tested is not recommended for smoking cessation but remains indicated for
general health benefits.
Recommendations for research
1. It is not recommended to fund further large-scale trials of PA for smoking cessation until much less
expensive observational studies have been conducted to provide promising leads, for example to
investigate the populations most suitable for such interventions and methods for increasing PA adherence.
2. The reasons for pregnant smokers’ low levels of attendance at supervised PA sessions should be
investigated, with the aim of using the findings to increase attendance rates. For example, following on
from recent work on barriers to PA, further research is needed to explore barriers to attendance and to PA
adherence during pregnancy, and to assess whether or not these barriers vary during different stages of
pregnancy and vary among women with different comorbidities, including gestational diabetes and obesity.
3. Further methods of increasing PA adherence among pregnant smokers need to be developed and
tested. For example, financial incentives have shown some benefit for aiding smoking cessation in this
population and they may be used in combination with PA to increase both attendance at exercise
sessions and smoking cessation. In addition, interventions are needed that provide regular prompts to
remind women to exercise (e.g. text messages or brief telephone calls); such interventions have been
successfully piloted with young women but not yet with pregnant women.
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4. The reasons why few inactive pregnant smokers were attracted to a PA trial need to be identified and
methods are needed to attract these less active pregnant smokers.
5. Studies are needed to establish whether or not the previously reported finding of a short bout of PA
reducing cigarette cravings in pregnant smokers is a robust finding. So far, only one study has
investigated this issue. If it is a robust finding, interventions need to be developed that can translate this
benefit into prevention of smoking relapse.
6. There was no evidence of beneficial effects on maternal weight gain or depression. Studies are needed
that focus on women who are at risk of higher maternal weight gain and women who have high levels
of depression at baseline.
7. Among pregnant smokers there was no evidence for a PA intervention having an added benefit for
smoking cessation beyond that of usual care. However, it is possible that in some circumstances a PA
programme alone may be more practical and may aid smoking cessation and this needs to be assessed.
8. There were significantly fewer deliveries by caesarean section in the PA group than in the control
group. Further studies are needed to replicate this finding and to explore the underlying mechanisms.
Implications for health care
There was no evidence that offering regular supervised exercise and PA consultations in addition to routine
smoking cessation support to women following their first antenatal visit was effective for aiding smoking
cessation. Nor was there any evidence for the PA intervention moderating cravings/urges to smoke but
it is possible that there are some acute benefits of PA on reducing cravings during pregnancy and the
recommendation to use PA to manage cravings acutely remains for all smokers, including those who are
pregnant. The PA intervention did not show any benefit for reducing maternal depression and there was
no evidence for an effect on maternal weight gain. There was no evidence of increased AEs in the PA
group and there was some evidence for a reduced incidence of caesarean sections; therefore, in line with
current guidance, PA remains indicated for general health benefits in pregnancy, including among
pregnant smokers.
Trial registration
This trial is registered as ISRCTN48600346.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
The problem of smoking in pregnancy
Maternal smoking in pregnancy is the main preventable cause of morbidity and death among women and
infants. Smoking is associated with adverse pregnancy and birth outcomes, including miscarriage, stillbirth,
prematurity, low birthweight, congenital abnormalities, and neonatal or sudden infant death.1–3 Smoking
also presents immediate risks for the mother, including placental abruption,4 as well as the longer-term
risks reported for smokers in general. In addition, the children of mothers who smoke are twice as likely to
become smokers.5 Smoking in pregnancy is a global public health problem. In high-income countries the
prevalence of smoking in pregnancy is typically between 10% and 25% and it appears to be reducing.6–10
However, rates seem to be rapidly increasing in low- and middle-income countries.11 In the UK it is
estimated that 12% of women smoke during pregnancy7 and, as in other high-income countries, rates
of smoking in pregnancy remain highest among younger women and those who are more socially
disadvantaged.7 Smoking cessation during pregnancy improves maternal and birth outcomes,12 yet only
approximately 25% of pregnant smokers stop for at least part of their pregnancy and around two-thirds of
these relapse after giving birth.13
Treatments to aid smoking cessation in pregnancy
Face-to-face and ‘self-help’ behavioural support are the only two interventions that have been shown to
help pregnant women to stop smoking.12,14 Regular sessions of face-to-face behavioural support can
increase smoking cessation rates in pregnancy by approximately 6%15 and there is a need to identify other
interventions that are effective during pregnancy when combined with this support. The most effective
therapy in non-pregnant smokers is a combination of behavioural support plus nicotine replacement therapy
(NRT), bupropion or varenicline.16–18 However, the efficacy of NRT during pregnancy is not known,19 and
thus many pregnant women are reluctant to use it,20 and other smoking cessation medications are
contraindicated during pregnancy.19 There is a need to identify other non-pharmacological interventions
that are effective for smoking cessation during pregnancy.
Evidence for physical activity aiding smoking cessation
Effective pharmaceutical aids for quitting are thought to work mainly through reducing cigarette cravings18
and there is good evidence from a meta-analysis21 to show that physical activity (PA) reduces these cravings,
particularly at a moderate or vigorous intensity. Therefore, PA interventions could aid smoking cessation. For
non-pregnant smokers, a Cochrane systematic review22 has considered the evidence for PA aiding cessation.
The majority of the 15 randomised controlled trials (RCTs) reviewed had low statistical power to detect a
meaningful difference between the treatment groups, with seven trials having < 25 participants in each
treatment arm. Six adequately powered trials compared a group receiving a PA intervention combined with
behavioural support with a group receiving behavioural support alone. Three of these studies showed
significantly higher smoking abstinence rates in the PA group than in the control group at the end of
treatment.23–25 One of these studies also showed that a PA intervention increased abstinence compared with
a control group at the 3-month follow-up and there was a benefit of exercise of borderline significance
[relative risk (RR) 2.19, 95% CI 0.97 to 4.96; p= 0.05] at the 12-month follow-up.23 A further study showed
significantly higher abstinence rates for the exercise group than for the control group at the 3-month
follow-up, but not at the end of treatment or at the 12-month follow-up.26 The study with the most
intensive PA intervention, entailing thrice-weekly sessions of supervised vigorous-intensity exercise, showed
the strongest effect on abstinence.23 The other studies involved PA interventions that were relatively less
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intense, particularly in terms of the extent of supervised exercise, and it is possible that supervised exercise is
needed for efficacy. Adequately powered trials are needed that involve moderate-intensity exercise, which is
likely to be more acceptable than vigorous exercise for most individuals.27 Moderate-intensity PA (e.g. brisk
walking) is recommended for pregnancy28 and has been shown to reduce cigarette cravings during
pregnancy,29 and pilot work suggests that pregnant smokers are likely to be receptive to a PA intervention.30
The effects of physical activity on maternal depression and
weight gain
Important secondary outcomes included changes in maternal depression and weight. Antenatal and
postnatal depression are important because they are common and are associated with harmful
consequences for the mother and child.31–38 Interventions are needed for preventing and treating these
types of depression. Moreover, pregnant smokers are at a heightened risk of depression during and after
pregnancy, and women who quit smoking during pregnancy are more likely to relapse if they experience
depressive symptoms.12,39,40 Thus, it is important that pregnant women who smoke or who are attempting
to quit are offered effective interventions for depression. The London Exercise And Pregnant smokers
(LEAP) trial was the first study to assess the effectiveness of a PA intervention for symptoms of antenatal
and postnatal depression specifically among smokers.
Excessive gestational weight gain (GWG) is associated with adverse pregnancy outcomes, including
large-for-gestational-age infants and caesarean section.41,42 In addition, smoking cessation is associated
with GWG.43 Interventions for managing GWG are needed, especially among women attempting to quit
smoking, and PA has potential in this regard. Observational studies have demonstrated an association
between participation in PA and reduced risk of excessive GWG,44–46 whereas a recent meta-analysis using
data from 10 RCTs showed an overall benefit of participation in PA compared with a control condition in
terms of reducing GWG.47 We are not aware of any studies that have examined the effect of a PA
intervention on GWG in pregnant smokers. Among non-pregnant smokers, there is some evidence that
PA interventions can limit post-smoking cessation weight gain.48 The LEAP trial was the first large RCT to
examine the effect of a PA intervention on preventing excessive GWG and postnatal weight retention.
Summary
In summary, smoking in pregnancy is extremely harmful for mother and baby and is an enduring global
public health problem. Behavioural support is the only smoking cessation intervention shown to be
effective in pregnancy. The evidence for PA programmes aiding smoking cessation is mixed and pregnancy
provides a compelling rationale for their use because medication is contraindicated or ineffective.
We conducted the LEAP RCT to assess the effectiveness of a PA intervention for smoking cessation
during pregnancy.
Main objective
The main objective of the study was to investigate whether or not standard behavioural support for
smoking cessation in pregnancy plus a PA intervention is more effective than behavioural support alone in
achieving biochemically validated smoking cessation between a quit date and the end of pregnancy for
women between 10 and 24 weeks’ gestation who currently smoke one or more cigarettes daily and
who smoked at least five cigarettes daily before pregnancy. A further objective was to assess the
cost-effectiveness of the intervention for achieving smoking cessation at the end of pregnancy.
INTRODUCTION
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Chapter 2 Methods
Trial design
The LEAP trial was a multicentre, pragmatic, randomised controlled, parallel-group trial of a PA
intervention. Participants were monitored from their recruitment at between 10 and 24 weeks’ gestation
until the end of pregnancy and were then followed up by telephone at 6 months after the birth. The trial
protocol has been published.49
Participants and recruitment
Eligibility criteria
Eligible participants were aged 16–50 years, were between 10 and 24 weeks’ gestation (subject to
confirmation that they had a scan to show a viable pregnancy), were currently smoking at least one
cigarette per day, were smoking at least five cigarettes per day before pregnancy, were prepared to quit
smoking 1 week after enrolment and could confirm that they were able to walk continuously for at least
15 minutes. Women were excluded if they were unable to complete self-administered questionnaires in
English (because of a lack of resources for translators) or if they reported any medical condition that might
be exacerbated by exercise. There are no documented contraindications to moderate-intensity exercise but
if a woman had been advised by her doctor or midwife not to take exercise during pregnancy, if she
had any complications during her pregnancy or if she had been cautioned against taking exercise,28,50
a consultant obstetrician and gynaecologist at her hospital were consulted to check that it was safe for
her to participate. Participants joining the trial were monitored at each treatment session for cautions to
exercise and adverse events (AEs). Those with drug or alcohol dependence were excluded as the
intervention described was not comprehensive enough to address these issues.
Although NRT is licensed for use in pregnancy, there is no evidence for its effectiveness at this time19 and
many pregnant smokers prefer not to use it.20 Allowing study participants to use NRT might create
confounding; therefore, women who indicated that they wished to use NRT on commencing their quit
attempt were excluded. Following guidelines,51 those women who were unable to stop smoking after their
quit day and who expressed a wish to receive NRT were prescribed NRT by their general practitioner (GP).
The participants’ GPs, midwives and obstetricians were informed of their patients’ participation in the trial.
Recruiting centres
Participants were recruited from 13 hospital antenatal clinics in England. Initially these were at hospitals
in the Greater London area: St George’s Healthcare NHS Trust (St George’s Hospital), Chelsea and
Westminster Hospital NHS Foundation Trust (Chelsea and Westminster Hospital), Guy’s and St Thomas’ NHS
Foundation Trust (St Thomas’ Hospital), Croydon Health Services NHS Trust (Croydon University Hospital,
previously known as Mayday Hospital), Imperial College Healthcare NHS Trust (Queen Charlotte’s and
Chelsea Hospital and St Mary’s Hospital), Epsom and St Helier University Hospitals NHS Trust (Epsom
Hospital) and Kingston Hospital NHS Foundation Trust (Kingston Hospital). Five further sites around England
were later added to improve recruitment rates: Surrey and Sussex Healthcare NHS Trust (Crawley Hospital),
West Middlesex University Hospital NHS Trust (West Middlesex University Hospital), Mid Cheshire Hospitals
NHS Foundation Trust (Leighton Hospital), King’s College Hospital NHS Foundation Trust (King’s College
Hospital) and Medway Foundation Trust (Medway Maritime Hospital).
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Researchers
At each centre a dedicated research midwife, research nurse or research psychologist undertook all
trial-related procedures, including delivering all of the interventions and administering all of the outcome
measures. Researchers were trained by the chief investigator/trial manager (Professor Ussher) in research
procedures, including screening, enrolment and consent procedures. They also attended certified Good
Clinical Practice training. Researchers were trained to national standards to provide behavioural support
for smoking cessation and PA.52
Recruitment and consent
The smoking status of all pregnant women is routinely recorded in the hospital computerised patient
administration system (PAS) at the first antenatal booking visit, which is typically at 9–14 weeks of
gestation. At this time, the hospital midwife informs all women recorded as smokers that it is hospital
policy to telephone them to offer smoking cessation support. This support would usually be offered by
their local NHS Stop Smoking Service but during the period of recruitment to the study a trial researcher
telephoned the women. The following methods of recruitment were used:
l On recording women as smokers, hospital midwives routinely passed referral forms to the researcher.
In some cases these referral forms would be available before the smoking status of the women was
recorded in the PAS and in these cases the researcher extracted the women’s contact details from the
referral forms rather than from the PAS.
l In cases in which a woman’s smoking status appeared in the PAS before a midwife referral form was
received, the researcher extracted the woman’s contact details from the PAS and telephoned her.
Following our consultation with the Patient Information Advisory Group, the ethics committee gave us
permission to contact all pregnant women recorded as smokers. This is because during the trial the
researchers were considered as part of the clinical care team and it is routine practice to contact
women in this way.
l A flyer containing brief information about the trial was included in women’s packs for their first
antenatal booking appointment and women were invited to call a researcher if they were interested in
finding out more about the study.
l Women who had seen posters advertising the study in hospitals or children’s centres could contact a
researcher directly.
l We had initially planned to distribute a questionnaire at the first ultrasound visit inviting women to take
part. This approach was piloted at several sites in the first month of the study; however, it had a low
response rate and was labour intensive and, therefore, was abandoned.
Those who were interested in receiving help with quitting were invited to join the trial or were offered
referral to the primary care trust (PCT), as per usual practice. Those women expressing an interest in
volunteering were screened for eligibility by the researcher by telephone (see Appendix 1) and eligible
women were sent a participant information sheet.
After having the chance to consider the participant information sheet for at least 24 hours and to discuss the
study with the researcher, women who volunteered were offered an appointment at a community-based
children’s centre or at their local hospital. At the first appointment they gave their written informed consent
before trial data were collected. In addition to trial participation, women were asked to give consent for
researchers to have access to their and their child’s medical records, for information held by the NHS to be
used to keep in touch with them and to follow their health status, and for the researcher to inform their GP,
midwife and obstetrician about their participation in the study.
METHODS
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Interventions
The interventions followed Consolidated Standards of Reporting Trials (CONSORT) guidelines for
non-pharmacological interventions.53,54 Delivery of the interventions was standardised by training and by
the therapists following manuals (see Appendices 2 and 3). The initial competence of the therapists was
assessed by the trial manager/chief investigator by observing role-play scenarios during training. The fidelity
of the interventions was monitored during the first 6 months by regular observations (at least five
intervention sessions) by the trial manager/chief investigator, with the tasks listed in Appendices 2 and 3
used as a checklist. All sessions were face to face and one to one and were delivered in a private room at
the hospital or in a community health centre/children’s centre. Social cognitive (learning) theory55 was the
theoretical basis for the interventions. This theory recognises the interplay of individual factors (e.g.
self-efficacy to quit smoking or increase PA) and social/environmental factors (e.g. social support) in health
behaviour change. For each session that they attended, the women were paid £7 for their travel expenses.
Control group
Those in the control group received behavioural support for smoking cessation, which is generally provided
by the NHS Stop Smoking Service to pregnant women as part of ‘usual care’. By extracting the elements of
the intervention from written manuals and materials provided by the programme (see Appendix 2), the
contents of the intervention were classified in accordance with the taxonomy of behaviour change
techniques (BCTs) described by Michie and colleagues56 and used in individual behavioural support for
smoking cessation (Table 1). Participants were offered six weekly sessions of 20 minutes of behavioural
support for smoking cessation, commencing 1 week before the quit date and ending 4 weeks afterwards.
The intervention (see Table 1) incorporated all 43 BCTs for smoking cessation defined by Michie and
colleagues,56 except for the BCT ‘provide rewards contingent on successfully stopping smoking’, although
financial rewards were offered to increase compliance (Table 2). Continued support was offered to women
who failed to quit or who relapsed to smoking.
Treatment group
In addition to behavioural support for smoking cessation, those in the PA group received a PA intervention,
combining PA consultations and supervised exercise. By extracting the elements of the PA consultation
from the written manuals and materials of the PA programme (Table 3), the contents of the PA
consultation have been classified in accordance with the taxonomy of Michie and colleagues57 of BCTs
used to help people change their PA behaviours. There were 14 sessions of supervised exercise, twice a
week for 6 weeks (one session with behavioural support for smoking cessation) and then weekly for
2 weeks. Following a familiarisation session at the first visit, participants were advised to aim for 30 minutes
of continuous treadmill walking during each session. Following guidelines,58 moderate-intensity exercise
was prescribed according to age and current activity levels and was monitored using a polar heart-rate
monitor. The intensity of exercise was also guided by a rating of perceived exertion59 (‘fairly light’ to
‘somewhat hard’) and by the ‘talk test’, which indicates that the intensity of activity is too high if it is not
possible to hold a conversation.
At the first two treadmill sessions and then on every other occasion women were offered a 20-minute PA
consultation (total of nine sessions) on increasing their additional ‘home-based’ PA. The researcher worked
through a booklet with each participant (see Appendix 4), which the participant retained. The intervention
(see Table 3) incorporates 19 of 40 BCTs for increasing PA as defined by Michie and colleagues.57 In
general, the consultations aimed to identify opportunities to incorporate PA into women’s lives, to
motivate them to use PA to aid smoking cessation and to help them use behavioural strategies to improve
adherence to these plans. These consultations were tailored towards the women’s preferences for PA and
their environment, including preference for type of PA, level of support from family or friends and
availability of time and facilities for exercise. The participants were encouraged to view PA as a self-control
strategy for reducing cigarette cravings and withdrawal60 and to maintain any increases in PA after their
pregnancy. Following recommendations for pregnancy,28,61 the women were advised to be active for
continuous periods of at least 10 minutes at a time, progressing towards accumulating 30 minutes of
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TABLE 1 Behaviour change techniques used in the smoking cessation consultations
Week
Session
number Session content
BCTs used
(Michie
categoriesa)
1 Session 1
(1 week before
quit day)
Explain the treatment, including the timing of quit RC4, BS4
Measure expired CO level and explain purpose RC3
Assess and discuss current and past smoking behaviour RI1
Identify reasons for wanting and not wanting to quit BM9
Assess current motivation/confidence for quitting RI2
Discuss past attempts at quitting RI3
Prepare for the quit attempt BM6, BS3
Discuss use of social support A2
Advise on reducing smoking cues BS8
Advise subject to note the times when they are likely to relapse BS6
Facilitate relapse prevention planning and coping BS2
Identify barriers to quitting and address these barriers BS1
Emphasise choice (e.g. when they take their final smoke) RD2
Provide information about the consequences of smoking during pregnancy BM1, RC5
Explain about quitting abruptly, rather than cutting down BM10
For all sessions:
Allow time for questions RC2
Summarise RC9
Use reflective listening RC7
Elicit participant’s views RC8
Build a general rapport RC1
Give praise for progress BM7
Tailor the interactions RD1
2 Session 2
(quit day)
Look for reasons why the woman is a good prospect BM2, BM3
Explain about cigarette withdrawal symptoms and strategies for dealing
with them
RC6
Identify barriers to quitting and address these barriers BS1
Advise on avoiding social cues for smoking BS11
Advise on changing routine BS7
Advise on conserving mental resources BS10
Set graded tasks (e.g. take 1 hour/day at a time) BS9
3 Session 3
(1 week after
quit day)
Check smoking status BS5
Assess withdrawal symptoms RI4
Reassure about the norms for these symptoms RC10, BM5
Advise subjects to monitor when they want to smoke BS6
Assess CO level and give feedback about whether or not reading has reduced BM11, BM3
Discuss planning and coping strategies to prevent relapse BS2
If they have relapsed ask them to commit to a new quit date BM6
Advise about use of NRT A1
Liaise with PCT about obtaining NRT A3
Encourage subject to see themselves as a non-smoker BM8
Remind them of lottery prize for attending all sessions BM7
METHODS
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TABLE 1 Behaviour change techniques used in the smoking cessation consultations (continued )
Week
Session
number Session content
BCTs used
(Michie
categoriesa)
4 Session 4
(2 weeks after
quit day)
onwards
Assess CO level BM11
Check smoking status BS5
If they are struggling offer further support from PCT A5
Discuss relapse prevention planning and coping strategies for after birth BS2, BM8
Emphasise importance of not having a single puff BM6
If subject has relapsed, set a new quit date and review use of NRT A4
CO, carbon monoxide.
a Michie categories are defined as follows:
Specific focus on the target behaviour (B) and maximising motivation (M). BM1: provide information on the
consequences of smoking and smoking cessation; BM2: boost motivation and self-efficacy; BM3: provide feedback on
current behaviour; BM5: provide normative information about others’ behaviour and experiences; BM6: prompt
commitment from the client there and then; BM7: provide rewards contingent on effort or progress; BM8: strengthen
ex-smoker identity; BM9: identify reasons for wanting and not wanting to stop smoking; BM10: explain the importance
of abrupt cessation; BM11: measure CO level.
Maximising self-regulatory capacity and skill (BS). BS1: facilitate barrier identification and problem-solving; BS2: facilitate
relapse prevention and coping; BS3: facilitate action planning/develop treatment plan; BS4: facilitate goal setting;
BS5: prompt review of goals; BS6: prompt self-recording; BS7: advise on changing routine; BS8: advise on environmental
restructuring; BS9: set graded tasks; BS10: advise on conserving mental resources; BS11: advise on avoiding social cues
for smoking.
Promoting adjuvant activities (A). A1: advise on stop-smoking medication; A2: advise on/facilitate use of social support;
A3: adopt appropriate local procedures to enable clients to obtain free medication; A4: ask about experiences of
stop-smoking medication that the smoker is using; A5: give options for additional and later support.
General aspects of interaction focusing on delivery of the intervention (RD). RD1: tailor interactions appropriately;
RD2: emphasise choice.
General aspects of interaction focusing on information gathering (RI). RI1: assess current and past smoking behaviour;
RI2: assess current readiness and ability to quit; RI3: assess history of quit attempts; RI4: assess withdrawal symptoms.
General aspects of interaction focusing on general communication (RC). RC1: build general rapport; RC2: elicit and
answer questions; RC3: explain the purpose of CO monitoring; RC4: explain expectations regarding treatment
programme; RC5: offer/direct towards appropriate written materials; RC6: provide information on withdrawal symptoms;
RC7: use reflective listening; RC8: elicit client views; RC9: summarise information/confirm client decisions;
RC10: provide reassurance.
TABLE 2 Financial incentives offered to trial participants
Incentive occasion
Maximum financial incentive (£)
PA group Control group
Annual lottery with three prizes of £100 for attending
at least 80% of the treatment sessions
100a 100a
Travel expenses (£7) for each session attended 98b (14 sessions) 42b (six sessions)
Follow-up at end of pregnancy 10a 10a
Follow-up at 6 months after birth 10a 10a
≥ 5 days of accelerometer data recorded 25a NA
Total 243 162
NA, not applicable.
a Shopping vouchers.
b Cash.
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TABLE 3 Behaviour change techniques used in the PA consultations
Week Session number Session content
BCTs used
(Michie categoriesa)
1 Session 1 (1 week
before quit day)
Review current PA and discuss PA benefits 1, 2
Explain and demonstrate use of treadmill and pedometer 7, 21, 22, 26
Check PA confidence levels using scaling questions 16
All sessions:
Agree PA goals 10
Provide weekly PA and step-count diaries 16
Allow time for questions, summarise, use reflective listening,
elicit participant’s views, build a general rapport
NA
Give praise for effort and for achieving PA goals 12, 13
1 Session 2 Review PA goals and effect of PA on cravings 7, 9, 10
Complete cost–benefit analysis for increasing PA 2
Identify PA barriers and problem solve 8
Explain and demonstrate exercises in booklet 21, 22, 26
Provide information on places to exercise 20
Discuss time management and exercise habits 23, 38
Plan social support 29
Provide weekly PA diary and step-count diary 16
2 Session 3 (quit day) Review PA goals, set heart-rate targets on treadmill 10
Identify PA barriers and problem solve 8
Provide weekly PA diary and step-count diary 16
Check PA confidence levels with scaling questions 8
3 Session 4 (1 week
after quit day)
onwards
Review PA goals, set heart-rate targets on treadmill 10
Plan for relapse prevention/coping 35
Review exercises in booklet 21, 22, 26
Review social support 29
Use imagery to encourage identity as an ‘exerciser’ 34
Provide weekly PA diary and step-count diary 16
Reminder that sessions reduce to once per week for the last
2 weeks of the programme
27
Check PA confidence levels with scaling questions 8
NA, not applicable.
a Michie categories are defined as follows: (1) provide information on consequences of behaviour in general; (2) provide
information on consequences of behaviour to the individual; (7) action planning; (8) barrier identification/problem-solving;
(9) set graded tasks; (10) prompt review of behavioural goals; (12) prompt rewards contingent on effort or progress
towards behaviour; (13) provide rewards contingent on successful behaviour; (16) prompt self-monitoring of behaviour;
(20) provide information on where and when to perform the behaviour; (21) provide instruction on how to perform the
behaviour; (22) model/demonstrate the behaviour; (23) teach subject to use prompts/cues; (26) prompt practice; (27) use
of follow-up prompts; (29) plan social support/social change; (34) prompt use of imagery; (35) relapse prevention/coping
planning; (38) time management.
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activity on at least 5 days of the week. The emphasis was on brisk walking, which is popular among
pregnant smokers.62 As a further option, a home-based antenatal exercise digital versatile disc (DVD) and
booklet were provided. In addition, participants were given a pedometer for monitoring their daily steps
(Digi-Walker SW-200; Great Performance Ltd, London, UK). Pedometers have been shown to increase
activity levels in women63 and are acceptable during pregnancy64 and among pregnant smokers.30
Participants were asked to log their daily steps, with the researcher calculating a 10% increment every
2 weeks, gradually progressing towards 10,000 steps a day.65
Randomisation and blinding
An independent statistician generated a randomisation list using Stata version 11.2 (StataCorp LP, College
Station, TX, USA), with random permuted blocks of random size stratified by recruitment centre. At enrolment
the sequence was concealed from researchers, who had to confirm consent and eligibility on an online
database before allocation was revealed. The online database was created by the Nottingham Clinical Trials
Unit (NCTU) and held on a secure server in accordance with their standard operating procedures. Allocation
was concealed from the participant until all baseline assessments had been completed. The sequence of
treatment allocations was concealed until interventions had all been assigned and recruitment, data collection
and laboratory analyses were complete. Thus, neither participants nor researchers were blinded to treatment
allocation during intervention delivery or during outcome assessment.
Data collection
At baseline, researchers recorded demographic characteristics (including age, marital status, number of
children, highest educational qualification, ethnicity, occupation, weeks of gestation and history of
premature births) and smoking characteristics [including cigarettes smoked per day (now and before
pregnancy), weekly urge to smoke (combining ratings of strength and frequency of urges),66,67 cigarette
withdrawal symptoms,66,67 Fagerström Test for Cigarette Dependence (FTCD) score68,69 and partner’s
smoking status]. Depression was assessed with the 10-item Edinburgh Postnatal Depression Scale (EPDS).70
PA levels in the previous week (bouts of ≥ 10 minutes) were assessed for both groups using the 7-day
PA interview (see Appendix 5).71 Confidence levels with regard to taking up regular PA72 and stopping
smoking73 were also recorded. Clothed weight (without shoes) was measured on a digital scale at the first
antenatal booking visit by the midwife. The questionnaire showing assessments at baseline, including
assessments repeated at further time points, is provided in Appendix 6. The timing of data collection is
provided in Outcome measures.
Recording of adverse events
During all contacts, participants were asked about AEs. Medical records were examined monthly by
research midwives for AEs and after delivery for maternal and infant outcome data. Researchers then
summarised the descriptions in the case report forms and in the online study database. Descriptions were
used to code the AEs according to standard terms in the Medical Dictionary for Regulatory Activities
[see www.meddra.org (accessed 25 August 2015)]. Fetal deaths were recorded including miscarriage
(non-live birth before 24 weeks’ gestation), stillbirth (non-live birth at ≥ 24 weeks’ gestation) and neonatal
death (i.e. from live birth to 28 days).
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Outcome measures
Timing of outcome measures
During the intervention period, the main assessment points were at 1 week, 4 weeks and 6 weeks after
the quit day. The assessment at 1 week, when the vast majority of the sample was retained, was to
assess the early impact of the intervention on cigarette withdrawal symptoms, urges to smoke, confidence
for quitting and participating in PA and reports of PA. The 4-week assessment is a standard time for
measuring short-term abstinence and is when the NHS Stop Smoking Service assesses abstinence. The
6-week assessment was timed to coincide with the end of the stop smoking programme. There were also
follow-ups at the end of pregnancy and 6 months after the birth.
Primary outcome to end of pregnancy
The primary outcome was self-reported continuous abstinence from smoking between the quit date
and the end of pregnancy, validated by exhaled carbon monoxide (CO) (Smokerlyzer; Bedfont Scientific Ltd,
Maidstone, UK) or salivary cotinine (Salimetrics Europe Ltd, Newmarket, UK). Expired CO levels were
assessed weekly up to 4 weeks after the quit day and at the end of pregnancy. Saliva cotinine levels were
measured at 4 weeks after the quit day and at the end of pregnancy only among those who self-reported
having smoked less than five cigarettes in total (on up to five occasions) since the quit day.
The primary outcome was operationalised as follows. Continuous abstinence was defined as having smoked
less than five cigarettes in total (on up to five occasions) since the quit day.74 Following an attempt to stop
smoking, it is common for smokers to lapse on several occasions before finally succeeding in maintaining
long-term abstinence; therefore, within the definition of continuous smoking abstinence it has become
standard to allow five such lapses. With regard to exhaled CO, the criterion for confirming abstinence was a
reading of < 8 parts per million (p.p.m.).75 CO was assessed weekly up to 4 weeks after the quit day and at
the end of pregnancy. With regard to salivary cotinine, the criterion for confirming abstinence was a value
of < 10 ng/ml.76 Cotinine was measured at 4 weeks post quit day and at the end of pregnancy.
The aim was to follow up women within 2 weeks of birth; however, it was acceptable for the primary
outcome to be taken at any time between 36 weeks’ gestation and 10 weeks after the birth.
The primary outcome was dichotomous, that is, abstinent or non-abstinent. For a participant to be classed
as abstinent from smoking at the end of pregnancy (i.e. positive primary outcome), the following criteria
had to be satisfied:
l At 4 weeks post quit (it was acceptable for this measure to be taken between 25 days and 6 weeks
post quit):
¢ ‘Have you smoked at all since your quit day?’= ‘no not even a puff’ or ‘yes just a few puffs’ or
‘yes, between one and five cigarettes’ or ‘missing’ (i.e. any response other than ‘yes, more than
five cigarettes’) and CO is < 8 p.p.m. and/or cotinine is < 10 ng/ml or CO or cotinine is missing.
l At the end of pregnancy:
¢ ‘Have you smoked at all since your quit day?’= ‘no not even a puff’ or ‘yes just a few puffs’ or
‘yes, between one and five cigarettes’ (i.e. any response other than ‘yes, more than five cigarettes’)
and CO is < 8 p.p.m. and/or cotinine is < 10 ng/ml.
The concentration of either exhaled CO or salivary cotinine was used to validate abstinence; if both
measures were available both were required. Some women will not have data for self-report of smoking or
biochemical validation at 4 weeks. If these women are confirmed as abstinent at the end of pregnancy it
will be considered as a positive primary outcome.
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For a participant to be considered as non-abstinent from smoking at the end of pregnancy (i.e. negative
primary outcome), the following criteria had to be satisfied:
l At 4 weeks or the end of pregnancy:
¢ ‘Have you smoked at all since your quit day?’= ‘yes, more than five cigarettes’
¢ CO or salivary cotinine values do not confirm abstinence
¢ has withdrawn from the study (i.e. refuses follow-up)
¢ fails to set a quit date that the follow-up assessment can be referenced against.
l At the end of pregnancy:
¢ refuses to allow biochemical validation
¢ refuses to self-report number of cigarettes smoked
¢ unable to contact to confirm smoking status (i.e. lost to follow-up).
Secondary outcomes
Biochemically validated continuous smoking abstinence was also assessed at 4 weeks after the quit day
and 6 months after the birth. In addition, we assessed biochemically validated continuous smoking
abstinence using a stricter criterion whereby no cigarettes were allowed after the quit day, at 4 weeks
after the quit date, at the end of pregnancy and at 6 months postnatally. Self-reported smoking status at
6 months after the birth was reported by telephone and was not biochemically validated. Many women
report that, rather than stopping smoking, they reduce their smoking during pregnancy77,78 and there is
some evidence to suggest that a reduction in smoking of ≥ 50% is associated with an increased infant
birthweight.79 Therefore, levels of smoking reduction were assessed for those women who relapsed.
Other secondary outcome measures were changes in urge to smoke, tobacco withdrawal symptoms and
confidence for stopping smoking and maintaining regular PA between baseline and 1 week after the quit
day. We also assessed changes in depression between baseline, the end of pregnancy and 6 months
after the birth, as well as changes in maternal weight between baseline, 4 weeks after the quit date and
the end of pregnancy (the women were weighed again at the end of pregnancy by a researcher using the
same method as used by the midwife at the first antenatal booking visit).
Further self-reports of PA levels were collected at weeks 1, 4 and 6 after the quit date and at both
follow-ups (i.e. the end of pregnancy and 6 months postnatally). To validate self-reported PA levels, a 10%
random subsample of participants had their PA levels objectively measured using an accelerometer (Model
GT1M or GT3X; Actigraph, Pensacola, FL, USA). Only 90 women were asked to wear an accelerometer as
our pilot work showed that most women would not tolerate waist-worn devices and at the start of the
study validated wrist-worn accelerometers were not commercially available; therefore, as the only
practicable alternative, we used self-reported PA levels in the primary analysis of PA. During the fourth
week after the quit date, the accelerometer was worn over the right hip for 7 consecutive days, recording
non-water-based activities during waking hours at 1-minute epochs. The Actigraph has been shown to be
practicable and valid during pregnancy.80–82
The duration of treadmill exercise and attendance rates were also recorded and use of NRT was monitored
throughout the intervention period. At the end of pregnancy, follow-up participants were asked if they
had received any face-to-face support to stop smoking during their pregnancy beyond that provided in
the study.
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Finally, the following birth and maternal outcomes were extracted from participants’ hospital records:
1. birthweight
2. gestational age at delivery
3. preterm birth (< 37 weeks’ gestation)
4. Apgar score
5. cord blood pH
6. neonatal intensive care unit admission
7. elective termination
8. maternal mortality
9. mode of delivery.
Statistical methods
The statistical analysis plan, which is presented in Appendix 7, was finalised before any analyses started. The
analysis for the primary outcome was conducted by an independent statistician, with allocation to the two
study groups concealed until the analysis was completed. Analyses were performed using Stata version 11.2
and IBM SPSS Statistics version 19 (IBM Corporation, Armonk, NY, USA). Throughout, a p-value of < 0.05
was taken to indicate statistical significance and 95% confidence intervals (CIs) were calculated.
Sample size
We anticipated a cessation rate of 15% in the control group on the basis that 9% of pregnant women
who are smokers stop smoking with usual care after their first antenatal visit and that with behavioural
support another 6–7% quit.15 Based on pilot work,30 a cessation rate of 23% was anticipated in the
treatment group. We calculated that 866 participants would provide 83% power at a 5% significance
level (two-sided) to detect an absolute difference of 8 percentage points in the rate of the primary
outcome between the two groups, corresponding to an odds ratio (OR) of 1.69 or a RR of 1.53.
The prime aim of assisting smoking cessation in pregnancy is to improve the outcome of the pregnancy.
The latest version of the Cochrane review of psychosocial interventions for supporting women to stop
smoking in pregnancy showed evidence that such interventions were effective in helping women
stop smoking and improving perinatal outcome.12 For example, the main subgroup in the review consisting
of counselling compared with usual care showed a RR of 1.44 for achieving abstinence in late pregnancy,
the same outcome that we used. No individual trial of smoking cessation in pregnancy detected
differences in perinatal outcomes by intervention status, but the meta-analysis of all trials in the review
showed evidence of this. When pooled together, these interventions produced the following RRs for the
intervention compared with the control condition: low birthweight RR 0.82 (95% CI 0.71 to 0.94); preterm
birth RR 0.82 (95% CI 0.70 to 0.96); increased mean birthweight 41 g (95% CI 18 g to 63 g). Thus,
relative increases in the rate of cessation of a similar size to the one that we were aiming to detect have
led to meaningful improvements in perinatal outcomes and would be expected to do so in this trial.
A power of 80% is generally considered the minimum power for a trial. Based on available evidence,
anticipated recruitment rates and budgeting constraints, we increased the power from the minimum of
80% to 83%. The trial as designed had adequate power for a plausible effect size.
Analysis for the primary outcome at the end of pregnancy
Analysis was on an intention-to-treat (ITT) basis; participants with missing outcome data were assumed
to be smoking.74 The proportion of women reporting continuous smoking abstinence at the end of
pregnancy was compared between study groups using logistic regression, with adjustment for recruitment
centre using fixed effects. Statistical significance was assessed with the likelihood ratio test, with the
estimate of effect given as the OR and 95% CI. A secondary analysis adjusted for centre, nicotine
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dependence, age, depression, maternal educational level and partner’s smoking status, as potentially
important prognostic baseline factors.83 In addition, as it was observed that the vast majority of participants
reported high levels of PA at baseline, we tested for an interaction between baseline PA [< 150 minutes
per week of moderate- and vigorous-intensity PA (MVPA) vs. ≥ 150 minutes per week of MVPA] and the
treatment effect for the primary outcome. For the primary outcome, to assess the influence of the
assumption that missing data equals ‘smoking’ on the effect size, we used the Hedeker method to test
various scenarios of the association between smoking and having missing data.84 Other outcomes for
smoking cessation were analysed in a similar way.
Analysis for secondary outcomes
For ratings of withdrawal symptoms, urge to smoke, confidence for quitting smoking and confidence for
participating in PA we conducted a series of linear regressions with scores at 1 week post quit as the
dependent variable and the two groups, recruitment centre and baseline scores as independent variables.
We compared the use of NRT and behavioural support between the two groups using chi-squared tests.
Physical activity outcomes
Self-reported weekly minutes of MVPA were log-transformed (log base 10) to normality and the difference
in self-reported PA between the groups over time was analysed using a mixed-effects model to account for
within-person correlations over time. In this model, the difference between treatment groups at each time
point was estimated with adjustment for visit time, baseline minutes of MVPA, the interaction of visit
time and baseline minutes of MVPA, and recruitment centre. The accelerometer data were analysed using
KineSoft software (version 3.3.76; Loughborough, UK). Files with at least 10 hours of valid wear time on
≥ 1 day were retained in the analyses. Standard cut-points were used to determine MVPA.85 Consistent
with the self-report data, only MVPA sustained for at least 10 minutes was included in the assessment
of validity using correlational analysis. The validity of the self-reports was also assessed by examining the
difference between the self-report data and the accelerometer data using a Bland–Altman plot.86 The
two study groups were compared (Mann–Whitney U-tests) for accelerometer reports of MVPA, both when
restricting the analysis to bouts of > 10 minutes (to allow comparison with the self-report data) and when
including all MVPA, irrespective of duration.
Fetal and maternal birth outcomes
For binary outcomes, fetal and maternal birth outcomes were compared using logistic regression adjusted
for recruitment centre. For continuous outcomes we compared study group means using multiple linear
regression, again with adjustment for recruitment centre. For fetal outcomes, the primary analysis was of
singleton births. We also conducted a sensitivity analysis including multiple births, with clustering of
outcomes accounted for using an approach previously published.87 This adapts methodology previously
created for use with cluster RCTs, assuming that each woman is regarded as the ‘cluster’ and her number
of offspring as the cluster size. A chi-squared test was used to compare the total number of women or
their infants who had at least one AE or serious adverse event (SAE).
Depression outcome
One participant was randomised but withdrew consent without reason before providing any data. Thus,
the sample for the depression analysis consisted of 784 women. All 784 participants provided EPDS data at
baseline, with 383 (48.9%) and 279 (35.6%) participants providing data at the end of pregnancy and
6 months postnatally, respectively. First, we checked whether or not those with EPDS data at the two
follow-up points (end of pregnancy, 6 months postnatally) had similar baseline characteristics, quit rate
at the end of pregnancy and amount of PA reported as those from the total trial sample. Then, we
examined whether or not the baseline characteristics of the PA and control participants were similar in the
subsamples with EPDS data at the two follow-up points.
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To maximise statistical power, the EPDS data were treated as a continuous variable. We used a
mixed-effect linear model, adjusted for visit time, baseline EPDS score, the interaction of visit time and
baseline EPDS score, and recruitment centre, and presented the estimated difference in score at the end of
pregnancy and at 6 months’ follow-up for the PA group compared with the control group. This model
allows for correlation between the repeated measurements at the end of pregnancy and at 6 months. In a
final linear mixed-effect model, analysis was further adjusted for the following potential predictors of
postnatal depression: marital status, age at leaving full-time education (as a proxy for socioeconomic
status), body mass index (BMI) and young age (i.e. age ≤ 20 years). At the end of pregnancy, as some of
the women provided EPDS data before the birth and some after the birth, we used t-tests to explore
whether or not EPDS scores were similar at these two times.
Maternal weight outcome
First, we compared the subsample providing maternal weight at the end of pregnancy (n= 271) with the
main LEAP trial sample (n= 785) for baseline characteristics and key end-of-pregnancy outcomes that
might be associated with weight gain (i.e. quit rates, PA levels and depression scores). As we are
conducting separate analyses for those providing an end of pregnancy weight before the birth (GWG) and
those providing an end of pregnancy weight after the birth (postnatal weight retention), we performed the
latter comparison separately for the subsamples before and after birth. Second, in the combined sample
at the end of pregnancy and in the subsamples providing an end of pregnancy weight before and after
delivery we compared baseline characteristics between the two randomisation groups. Subsequent analysis
adjusted for any baseline differences between groups that might affect weight.
For all analyses the main outcome was the mean change in maternal weight (i.e. weight in early pregnancy
minus weight at the end of pregnancy), computed separately for the subsamples providing an end of
pregnancy weight before and after birth. Weight change was first compared between the two randomisation
groups using linear regression analyses, with adjustment for baseline weight and recruitment centre. All of
the regression analyses were then further adjusted for the following potential prognostic factors for weight
change during pregnancy: age and number of previous pregnancies. In a sensitivity analysis we further
adjusted the results for baby’s weight, which is important because women who quit may have bigger babies
than those who do not quit, and continuous rate of smoking abstinence at the end of pregnancy. For the
subsamples providing an end of pregnancy weight before and after birth, the sensitivity analyses were limited
to 140 and 131 participants, respectively, because of missing data for baby’s weight and because three sets of
twins were excluded.
For the subsample with GWG (i.e. weight measured before birth) it is important to consider that women
will have delivered at different weeks of pregnancy; therefore, besides using the change in the crude
measure of weight, we computed the change in mean kilograms per gestational week. This was calculated
by dividing the total weight gain by the number of weeks of pregnancy. The regression models used for
crude weight change were then repeated using weight change adjusted for gestational weeks as the
dependent variable. To assess whether or not weight change is modified by the presence of obesity at
baseline we also added an interaction between the effect of PA and whether or not the individual was
obese at baseline. Weight at early pregnancy was not added to this model because of its colinearity with
the assessment of whether individuals were obese or non-obese.
Next, using Institute of Medicine guidance,88 we investigated what proportion of women gained excessive
gestational weight (coded ‘yes’ or ‘no’) relative to their early pregnancy BMI. A woman was considered to
have gained excessive gestational weight if she was underweight according to her early pregnancy BMI
and her GWG was > 18 kg, her weight was healthy and her GWG was > 16 kg, she was overweight and
her GWG was > 11.5 kg or she was obese and her GWG was > 9 kg. We used logistic regression analyses
to compute ORs of excessive GWG for each BMI category and for the randomised groups. In the final
logistic regression model, the results were adjusted for all prognostic factors that were used in the above
main analyses, except weight at early pregnancy.
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Ethics and governance
An independent Trial Steering Committee met once or twice per year to monitor the conduct and progress
of the trial and to address any safety issues. London Wandsworth Research Ethics Committee granted
national research ethical approval (reference number 08/H0803/177), with additional local approvals for
each recruitment centre.
Trial management
The trial was co-ordinated from a central trial office located within St George’s, University of London
(SGUL), with the day-to-day running supervised and organised by the trial manager and administrator.
The trial was sponsored by SGUL and conducted in accordance with Good Clinical Practice guidelines.89
The chief investigator/trial manager and administrator received Good Clinical Practice training. Monthly
research staff meetings were held at SGUL. There were no stopping rules or plans for interim analysis.
The NCTU provided a web-based database and randomisation system and data management reports.
The system was held on a secure server in the NCTU, had a full electronic audit trail and full back-ups
of the database were made every 24 hours. All of the outcome data were entered directly into the online
forms by the participants or researchers. The database included validation checks whereby responses not
meeting expected criteria would be flagged so that data entry errors were minimised.
The National Institute for Health Research (NIHR) Primary Care Research Network adopted the study.
For public and patient involvement in the study see Appendix 8.
The protocol49 has been published and includes a description of approved amendments made to the
original protocol after the start of recruitment; details of these amendments are given in the
following section.
Protocol amendments
1. For the follow-up at the end of pregnancy, the valid period for assessment was originally defined as
from 38 weeks’ gestation to 2 weeks after the birth. As there were a number of women who could not
be contacted during this time frame, the valid period was extended to 36 weeks’ gestation to 4 weeks
after the birth (approved by the research ethics committee on 18 May 2010). However, because there
were still some women being followed up later than 4 weeks after the birth, the valid period was
further revised to 36 weeks’ gestation to 10 weeks after the birth (approved 31 January 2012). The aim
remained to attempt to follow up as many women as possible within 2 weeks of the birth.
2. To provide the women with an incentive to complete the follow-ups at the end of pregnancy and
6 months postnatally, all women who completed these follow-ups were given a £10 shopping voucher
for each of the follow-up sessions attended (approved 18 May 2010).
3. Originally, to be eligible women had to report smoking at least 10 cigarettes a day before their
pregnancy. We found that a good number of women reported smoking five to nine cigarettes a day
at this time. Therefore, we extended the eligibility criteria to include women smoking at least
five cigarettes a day before pregnancy (approved 15 September 2010). These women are still likely
to be dependent on smoking as there is evidence that women who say they were smoking five to
nine cigarettes before pregnancy are back to smoking 14 cigarettes a day at 18 months postnatally.90
4. Initially, women had to be between 12 and 24 weeks’ gestation to be eligible for the trial. However,
after the trial started most of the hospital trusts began offering earlier antenatal booking appointments
(before 12 weeks’ gestation) and, because we wished to recruit women as early as possible in
pregnancy, we revised this eligibility criterion to 10–24 weeks’ gestation (approved 31 January 2012).
5. ‘Partner’s smoking status’ was adjusted for in the final model for all of the outcomes related to
smoking abstinence; this amendment was approved after publication of the protocol.
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Trial extension
The NIHR agreed a 12-month time extension to the trial. This was necessary as the rate of recruitment had
been slower than anticipated and several additional recruitment sites had been established. Through
careful budgeting, mostly as a result of the researchers working fewer hours and the chief investigator
taking the role of trial manager, the majority of this extension was funded within the original budget.
An addition to the budget was awarded to extend the contract of the trial administrator.
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Chapter 3 Results
Recruitment of participants
Recruitment took place between April 2009 and November 2012. Follow-up at 6 months after birth
continued until January 2014. Figure 1 shows accrual for the original recruitment target of
866 participants, the revised target of 774 participants [agreed with the NIHR Health Technology
Assessment (HTA) programme following approval of the trial extension] and the 789 participants who
were actually randomised. Four women were excluded post randomisation. Two women (PA group) were
enrolled twice in sequential pregnancies and their second enrolment was removed. The other two women
(control group) were excluded because they were found to be ineligible at their baseline visit before any
data were collected and had been randomised erroneously. When ineligible participants are mistakenly
randomised into a trial it is acceptable, within an ITT approach, to exclude their data without risking bias.91
Table 4 shows the recruitment numbers for each centre for the final sample size of 785 participants
included in the analysis. As shown in Table 5, over two-thirds of participants were recruited through
midwife referral and over one-quarter through direct calling, through extracting contact information from
the PAS. Fewer than 4% of participants were recruited using the other methods combined.
The CONSORT diagram (Figure 2) shows the flow of participants through the study to the primary end
point at the end of pregnancy. Around 8100 women were recorded as smokers in the PAS. Of these,
approximately one-quarter were uncontactable, just over one-quarter said that they were not interested in
participating and just under one-third did not meet the inclusion criteria. A breakdown of the reasons for
excluding participants is presented in Table 6. The main reason for exclusion was ‘reports smoking less
than one cigarette a day’. Overall, of the 8096 women recorded as smokers at their first antenatal visit,
9.7% (785) were included in the ITT analysis. Of 785 pregnancies, 774 were singleton pregnancies,
10 were twin pregnancies and one was unknown as the woman withdrew consent.
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TABLE 4 Recruitment numbers by study centre
Centre
PA group
(n= 392), n
Control group
(n= 393), n
Total
(N= 785),
n (%)
St George’s Healthcare NHS Trust (St George’s Hospital) 44 44 88 (11.2)
Chelsea and Westminster Hospital NHS Foundation Trust
(Chelsea and Westminster Hospital)
26 25 51 (6.5)
Imperial College Healthcare NHS Trust (Queen Charlotte’s and
Chelsea Hospital)
78 76 154 (19.6)
Imperial College Healthcare NHS Trust (St Mary’s Hospital) 52 51 103 (13.1)
Guy’s and St Thomas’ NHS Foundation Trust (St Thomas’ Hospital) 21 22 43 (5.5)
Croydon Health Services NHS Trust (Croydon University Hospital) 38 37 75 (9.6)
Kingston Hospital NHS Foundation Trust (Kingston Hospital) 40 41 81 (10.3)
Epsom and St Helier University Hospitals NHS Trust (Epsom Hospital) 47 46 93 (11.8)
Surrey and Sussex Healthcare NHS Trust (Crawley Hospital) 20 20 40 (5.1)
King’s College Hospital NHS Foundation Trust (King’s College Hospital) 5 5 10 (1.3)
Medway Foundation Trust (Medway Maritime Hospital) 6 7 13 (1.7)
West Middlesex University Hospital NHS Trust (West Middlesex Hospital) 8 10 18 (2.3)
Mid Cheshire Hospitals NHS Foundation Trust (Leighton Hospital) 7 9 16 (2.0)
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FIGURE 1 Cumulative trial recruitment.
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Excluded (n = 7307) 
• Unable to contact, n = 2169
• Declined to participate, n = 2324
• Did not meet inclusion criteria, n = 2583
• Had other reasons, n = 231 
Included in primary analysis (n = 392)
Excluded from analysis owing to enrolling 
twice (n = 2)
Included in primary analysis (n = 393)
Excluded from analysis owing to not meeting 
inclusion criteria at baseline visit (n = 2)
Assigned to and received behavioural 
support alone (n = 395) 
Assigned to behavioural support
plus physical activity intervention (n = 394) 
• Received behavioural support plus
   physical activity intervention, n = 393 
• Withdrew consent before receiving any
   intervention, n = 1   
Lost to follow-up (n = 35)
Fetal/infant deaths (n = 9)
Withdrew consent before providing baseline 
data (n = 1)
Lost to follow-up (n = 53)
Fetal/infant deaths (n = 15)
Underwent randomisation
(n = 789)
Women recorded as smokers 
at first antenatal visit 
(n = 8096)
FIGURE 2 Numbers of participants who were enrolled in the study and included in the primary analysis. The
participants lost to follow-up included some who had fetal or infant loss and were not assessed for smoking status.
TABLE 5 Recruitment methods
Recruitment method % n
Midwife referral 69.3 544
Direct calling after consulting the PAS 27.1 213
Flyer/poster 1.3 10
Ultrasound questionnaire 1.4 11
Referral from PCT or other health professional 0.9 7
Total 100 785
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Baseline characteristics
Participants in the two groups had similar baseline characteristics (Table 7). Women were recruited to the
trial at a mean gestational age of 16 weeks and on average they were 27 years of age. Over half (53.6%)
were smoking at least 10 cigarettes a day. By self-report, 70% were achieving the recommendation of
150 minutes a week of MVPA.27,28
Follow-up rates
At 4 weeks after the quit day, 316 (80.6%) women were successfully followed up in the PA group and
319 (81.2%) in the control group. At the end of pregnancy follow-up, 587 (74.8%) women were assessed
before the birth and 198 (25.2%) were assessed after the birth. The overall follow-up rate for the primary
outcome at the end of pregnancy (see Figure 2) was 88.8% (697 participants) and there was no evidence
of a significant difference in the follow-up rate between study groups. Of the 88 participants (11.2%) who
did not complete the assessments necessary for analysis of the primary outcome, 43 (48.9%) were known
to have smoked from the follow-up assessments (PA group n= 19, control n= 24). In addition, of the
remaining 45 participants (5.7% of total), 24 had a fetal or infant death and were not asked about
smoking status, and one individual withdrew consent; all were assumed to be smoking at the end
of pregnancy.
Rates of biochemical validation of smoking status
For the majority of participants who reported that they were not smoking, biochemical validation was
obtained. At the end of pregnancy, validation rates for smoking status were 71.4% (30/42) in the PA
group and 56.8% (25/44) in the control group (p= 0.158); at 4 weeks, the rates were 98.0% (50/51) and
100.0% (61/61) respectively (p= 0.272).
TABLE 6 Reasons for exclusion
Reason for exclusion % n
Reports smoking less than one cigarette a day now 27.5 710
Gestation > 24 weeks 26.1 673
Gestation < 10 weeks 8.0 207
Unable to attend all visits 13.9 359
Wants to use NRT from commencing quit attempt 11.2 290
Poor English 5.8 149
Drug or alcohol problem 3.1 80
Reports smoking < 10 cigarettes a day before pregnancy 2.1 53
Medical contraindication to exercise 1.2 31
Age < 16 years 0.7 17
Unable to walk for 15 minutes 0.5 13
No permission to contact GP/obstetrician 0.04 1
Total 100 2583
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TABLE 7 Baseline characteristics according to study group
Characteristic
PA group
(n= 391a), n (%)
Control group
(n= 393), n (%)
Age (years), mean (SD) 27.2 (6.1) 27.8 (6.5)
Age at leaving full-time education (years), mean (SD)b 17.8 (3.0) 18.0 (3.3)
Maternal weight at first antenatal booking appointment (kg), mean (SD)c 68.3 (14.4) 70.4 (15.6)
BMI (kg/m2), mean (SD)c 25.6 (5.0) 26.6 (5.6)
Gestational age (weeks), mean (SD) 15.6 (3.3) 15.6 (3.3)
Number of cigarettes smoked daily before pregnancy, median (IQR) 20 (12–20) 20 (12–20)
Number of cigarettes smoked daily at randomisation, median (IQR) 10 (5–12) 10 (5–15)
FTCD score, median (IQR)d 4 (2–5) 4 (2–5)
Expired CO level (p.p.m.), median (IQR)e 10 (7–14) 10 (6–14)
Self-report of weekly MVPA (minutes), median (IQR) 210 (125–350) 225 (130–360)
Married or living with partner 230 (58.8) 221 (56.2)
Women with partner who smokesf 261 (66.8) 250 (63.6)
Caucasiang 308 (78.8) 298 (75.8)
Professional/managerial occupation 46 (11.8) 53 (13.5)
Smoked in a previous pregnancyh 186 (78.2) 193 (77.5)
EPDS score of ≥ 13 68 (17.4) 75 (19.1)
Self-report of > 150 minutes per week of MVPA 275 (70.3) 273 (69.5)
Self-report walking as main type of PA 301 (77.0) 313 (79.6)
Parityi
0–1 317 (81.1) 309 (78.6)
2–3 67 (17.1) 75 (19.1)
≥ 4 7 (1.8) 9 (2.3)
Previous preterm birth
j
68 (17.4) 61 (15.5)
Very or extremely high confidence for quitting smoking 89 (22.8) 98 (24.9)
Very or extremely confident of doing 30 minutes of PA on at least 5 days a week
during pregnancy
274 (70.1) 277 (70.5)
Drinks alcohol more than twice a week 6 (1.5) 5 (1.3)
Consumes more than three alcoholic drinks on a drinking dayk 14 (15.9) 3 (3.8)
IQR, interquartile range; SD, standard deviation.
a Baseline data were not recorded for one participant in the PA group who withdrew consent shortly after randomisation.
b Excludes 41 women who were still in full-time education.
c Weight/BMI not recorded for one participant in the control group.
d Score not recorded for one participant in the PA group.
e CO level not recorded for one participant in the PA group and two in the control group.
f Excludes 92 women who had no partner.
g Race or ethnic group was self-reported and categorised according to standard UK census categories.
h Excludes 297 women who had had no previous pregnancies.
i Parity was defined as the number of previous pregnancies progressing beyond 24 weeks.
j Previous preterm birth was defined as any previous pregnancy that lasted from 24 to 37 weeks.
k Excludes 617 women responding ‘not applicable’ (i.e. not drinking alcohol).
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Attendance at treatment sessions and compliance with the
physical activity intervention
Participants attended a median of four of 14 treatment sessions in the PA group and three of six in the
control group (Table 8). For the PA group compared with the control group, there was a 33% (95% CI 14%
to 56%), 28% (95% CI 7% to 52%) and 36% (95% CI 12% to 65%) significantly greater increase
in self-reported minutes of MVPA from baseline to 1 week, 4 weeks and 6 weeks respectively (see Table 8
and Figure 3). There was a decrease in self-reported minutes of PA at the end of pregnancy and at
6 months relative to baseline for both groups.
Of 90 participants asked to wear an accelerometer, 78 (86.7%) provided valid data (n= 37 PA group),
10 provided insufficient data and two were technical failures. Participants providing accelerometer data had
similar baseline characteristics to those in the total sample. The majority (72%) had valid accelerometer data
for at least 4 days. During the week of accelerometer wear, the median number of minutes of MVPA per
day by self-report and according to accelerometer data was 38.2 [interquartile range (IQR) 25.4–54.5] and
7.8 (IQR 0–16.5) respectively. In total, 87% of participants self-reported higher levels of MVPA compared
with the accelerometer data. Self-reports of minutes of MVPA per day were not significantly correlated with
the accelerometer data (Spearman’s rho= 0.133, p= 0.247). Consistent with the correlation, using a
Bland–Altman plot the mean difference between the self-report data and the accelerometer data for MVPA
was 26.85 (95% CI 20.81 to 32.88) minutes (Figure 4). The median number of minutes of MVPA according
to accelerometer data, when including only bouts of at least 10 minutes, was very similar for the PA group
[7.5 (IQR 0–15.5)] and the control group [8.0 (IQR 0–16.2)] (p= 0.816). When including all MVPA,
irrespective of duration, median activity levels per day tended to be higher for the PA group [38.00
(IQR 20.00–52.60)] than the control group [31.17 (IQR 19.00–44.10)], although this difference did not
reach significance (p= 0.538).
Only 28 women reported receiving face-to-face behavioural support for smoking cessation besides that
offered in the trial and 60 women reported using NRT; the numbers reporting this support were similar in
the two groups.
TABLE 8 Compliance with interventions
Variable PA group Control group
Relative change in PA
(95% CI): mixed-effect
model for the log of PA p-value
Self-reported weekly minutes of MVPA, n, median (IQR)
Baseline 391, 210 (125–350) 393, 225 (130–360)
1 week post quit 162, 280 (190–425) 206, 240 (140–420) 1.33 (1.14 to 1.56) < 0.001
4 weeks post quit 135, 270 (180–420) 157, 210 (120–340) 1.28 (1.07 to 1.52) 0.006
6 weeks post quit 90, 277 (180–400) 121, 220 (130–350) 1.36 (1.12 to 1.65) 0.002
End of pregnancy 188, 155 (100–240) 187, 140 (60–240) 1.25 (0.96 to 1.61) 0.093
6-month follow-up 147, 180 (80–330) 136, 135 (60–285) 1.16 (0.85 to 1.59) 0.339
Number of treatment sessions
attended, n, median (IQR)
391, 4 (2–8)a 393, 3 (2–6) NA
Time walked on treadmill during supervised exercise (minutes), n, mean (SD)
Baseline 390, 12.2 (7.5) NA NA
1 week post quit 163, 19.0 (8.5)
4 weeks post quit 134, 15.2 (10.8)
6 weeks post quit 90, 17.7 (10.9)
IQR, interquartile range; NA, not applicable; SD, standard deviation.
a The median (IQR) number of sessions attended for PA counselling= 2 (1–4) and for smoking cessation behavioural
support= 2 (1–4). Women participated in supervised exercise at all sessions.
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FIGURE 3 Comparisona of predicted self-reported levels of MVPA on a log-scale in the trial groups at different time
points (bars represent CIs). EOP, end of pregnancy, FU, follow-up; PQ, post quit. a, Prediction on log scale from the
mixed-effect model.
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FIGURE 4 Bland–Altman plot of the difference between self-reported MVPA and accelerometer data for MVPA
against the average of these measures (n= 78) showing the distribution of differences and how they relate to the
average. Limits of agreement (reference range for difference) –26.698 to 80.390; range 0.714–72.286.
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Smoking abstinence and reduction rates
There was no significant difference in smoking abstinence rates or smoking reduction rates between the two
groups at follow-up (Table 9). The rate of validated continuous abstinence at the end of pregnancy (primary
outcome) was 7.7% in the PA group and 6.4% in the control group (OR for PA group, adjusted for centre
only, 1.21, 95% CI 0.70 to 2.10). At 4 weeks the validated abstinence rate was 12.8% in the PA group and
15.5% in the control group (OR, adjusted for centre only, 0.79, 95% CI 0.53 to 1.18). At 6 months
postnatally the self-reported abstinence rate was 6.1% in the PA group and 4.1% in the control group (OR,
adjusted for centre only, 1.55, 95% CI 0.81 to 2.97). Fully adjusted analyses yielded similar findings (at end of
pregnancy: OR 1.37, 95% CI 0.78 to 2.41). The sensitivity analyses showed that the observed effect size and
TABLE 9 Primary and secondary smoking abstinence and reduction outcomes
Abstinence/reduction outcomesa
PA group
(n= 392), n (%)
Control group
(n= 393), n (%) OR (95% CI)b
Adjusted OR
(95% CI)c
Primary
Self-reported continuous abstinence
at end of pregnancy with
biochemical validationd
30 (7.7) 25 (6.4) 1.21 (0.70 to 2.10) 1.37 (0.78 to 2.41)
Secondary
Self-reported continuous abstinence
at 4 weeks after quit day with
biochemical validatione
50 (12.8) 61 (15.5) 0.79 (0.53 to 1.18) 0.87 (0.57 to 1.31)
Self-reported continuous abstinence
at 6 months after birth
24 (6.1) 16 (4.1) 1.55 (0.81 to 2.97) 1.66 (0.82 to 3.37)
Self-reported lapse-free abstinence
with biochemical validation
At 4 weeks after quit day 17 (4.3) 16 (4.1) 0.68 (0.38 to 1.22) 0.74 (0.41 to 1.34)
At end of pregnancy 20 (5.1) 29 (7.4) 1.07 (0.53 to 2.14) 1.22 (0.60 to 2.48)
At 6 months after birth 10 (2.6) 10 (2.5) 1.04 (0.43 to 2.56) 1.12 (0.45 to 2.78)
PA group,
n, mean (SD)
Control group,
n, mean (SD)
Mean difference
(95% CI)
Mean difference
(95% CI)
Self-reported reduction in no. of cigarettes smoked dailyf
Between baseline and 4 weeks
after quit day
67, 4.3 (4.4) 70, 4.0 (4.7) 0.23 (–1.22 to 1.73) 0.27 (–1.16 to 1.65)
Between baseline and end
of pregnancy
130, 4.0 (4.7) 119, 2.9 (5.9) 1.13 (–0.26 to 2.55) 1.08 (–0.11 to 2.32)
Between baseline and 6 months
after birth
97, 1.4 (4.5) 100, 1.0 (5.3) 0.37 (–0.99 to 1.74) 0.21 (–1.14 to 1.58)
SD, standard deviation.
a Continuous abstinence was defined as having smoked fewer than five cigarettes since the quit day. End of pregnancy
was defined as between 36 weeks’ gestation and 10 weeks after the birth. Biochemical validation was by exhaled
CO level and/or salivary cotinine level; if both measures were available both were required for validation.
b ORs were adjusted for recruitment centre only (as a stratification factor).
c ORs were adjusted for centre, FTCD score at baseline, participant age at randomisation, EPDS score at baseline, age on
leaving full-time education and partner’s smoking status at baseline.
d The biochemical tests did not validate the report of not smoking (i.e. probable false reporting of cessation) in 12 of
42 women (28.6%) in the PA group and 19 of 44 women (43.2%) in the control group.
e The biochemical tests did not validate the report of not smoking in four of 51 women (7.8%) in the PA group and seven
of 61 women (11.5%) in the control group.
f Using linear regression analysis with bootstrap method.
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its statistical significance were independent of the influence of missing data for the primary outcome. There
was no significant interaction between baseline self-reports of MVPA (< 150 vs. ≥ 150 minutes per week) and
the treatment effect for the primary outcome [logistic regression model adjusted for site only: likelihood ratio
test (LR chi-squared)= 2.31, p= 0.129; similar results were found for the fully adjusted model].
Withdrawal symptoms and urge to smoke
Tables 10 and 11 show the withdrawal symptom and urge to smoke scores, respectively, at baseline and
1 week post quit. When controlling for baseline score and treatment centre there was no significant group
difference in total withdrawal score or urge to smoke score at 1 week post quit. When withdrawal
symptoms were examined individually there were still no significant group differences.
TABLE 10 Comparison of withdrawal symptom scores between randomisation groups at baseline and 1 week
post quit
Follow-up
PA group, n,
mean (SD) score
Control group, n,
mean (SD) score
Linear regression: β (95% CI) for
PA group vs. control group; p-valuea
Baseline
Withdrawal symptoms scale
total score (range 1–35)
391, 16.3 (4.9) 393, 16.4 (4.7)
Symptoms
Restless 2.3 (1.2) 2.3 (1.2)
Irritable 2.6 (1.2) 2.7 (1.2)
Depressed 1.8 (1.1) 1.7 (1.0)
Hungry 2.8 (1.3) 3.0 (1.2)
Poor concentration 2.0 (1.1) 2.0 (1.1)
Poor sleep at night 2.5 (1.3) 2.5 (1.3)
Anxious 2.2 (1.2) 2.2 (1.2)
1 week post quit
Withdrawal symptoms scale
total score (range 1–35)
163, 16.0 (4.6) 206, 16.6 (4.6) –0.56 (–1.45 to 0.33); 0.256
Symptoms
Restless 2.4 (1.1) 2.4 (1.1)
Irritable 2.7 (1.1) 2.9 (1.2)
Depressed 1.7 (1.0) 1.8 (1.0)
Hungry 2.7 (1.2) 2.9 (1.2)
Poor concentration 2.1 (1.0) 2.1 (1.1)
Poor sleep at night 2.3 (1.2) 2.3 (1.2)
Anxious 2.1 (1.0) 2.2 (1.1)
SD, standard deviation.
a Coefficient (95% CI) for PA group obtained from the linear regression with withdrawal total score at 1 week post quit as
the dependent variable and the two groups, recruitment centre and withdrawal total score measured at baseline as
independent variables; thus, it is the adjusted difference in withdrawal total score at 1 week post quit for the PA group
group vs. the control group.
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Confidence for participating in physical activity and
stopping smoking
Tables 12 and 13 present the scores for confidence for participating in PA and for stopping smoking,
respectively, at baseline and 1 week post quit. When controlling for baseline score and treatment centre,
ratings for confidence for participating in PA were significantly higher at 1 week post quit in the PA group
than in the control group. When making the same adjustments, there was no significant group difference
in confidence for quitting smoking at 1 week post quit.
TABLE 11 Comparison of urge to smoke scoresa (range 0–10) between randomisation groups at baseline and
1 week post quit
Follow-up
PA group, n,
mean (SD) score
Control group, n,
mean (SD) score
Linear regression: β (95% CI) for
PA group vs. control group; p-valueb
Baseline 391, 6.2 (2.0) 393, 6.2 (1.9)
1 week post quit 163, 5.3 (2.0) 206, 5.5 (2.0) –0.23 (–0.62 to 0.16); 0.242
SD, standard deviation.
a Combination of item for strength of urges and item for frequency of urges.
b Coefficient (95% CI) for PA group obtained from the linear regression with urge to smoke score at 1 week post quit as
the dependent variable and the two groups, recruitment centre and urge to smoke score at baseline as independent
variables; thus, it is the adjusted difference in urge to smoke score at 1 week post quit for the PA group vs. the
control group.
TABLE 12 Comparison of self-confidence for participating in PA between randomisation groups at baseline and
1 week post quit
Follow-up
PA group, n,
mean (SD) score
Control, n,
mean (SD) score
Linear regression: β (95% CI) for
PA group vs. control group; p-valuea
Baseline 391, 3.9 (1.1) 393, 3.9 (1.0)
1 week post quit 163, 3.9 (1.0) 157, 3.7 (1.0) 0.30 (0.10 to 0.49); 0.002
SD, standard deviation.
a Coefficient (95% CI) for PA group obtained from the linear regression with self-confidence score at 1 week post quit as
the dependent variable and the two groups, recruitment centre and self-confidence score at baseline as independent
variables; thus, it is the adjusted difference in self-confidence score at 1 week post quit for the PA group vs. the
control group.
TABLE 13 Comparison of self-confidence for stopping smoking between randomisation groups at baseline and
1 week post quit
Follow-up
PA group, n,
mean (SD) score
Control group, n,
mean (SD) score
Linear regression: β (95% CI) for
PA group vs. control group; p-valuea
Baseline 391, 3.9 (0.9) 393, 4.0 (1.0)
1 week post quit 163, 4.4 (1.0) 206, 4.3 (0.9) 0.15 (–0.03 to 0.33); 0.097
SD, standard deviation.
a Coefficient (95% CI) for PA group obtained from the linear regression with self-confidence score at 1 week post quit as
the dependent variable and the two groups, recruitment centre and self-confidence score at baseline as independent
variables; thus, it is the adjusted difference in self-confidence score at 1 week post quit for the PA group vs. the
control group.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
26
Birth outcomes
Table 14 shows outcomes for singleton births. These outcomes were very similar between the two study
groups except that there were significantly fewer deliveries by caesarean section in the PA group than in
the control group (21.3% vs. 28.7%). Analyses that included twin births gave very similar findings.
TABLE 14 Birth outcomes by treatment groupa
Fetal outcomes (singleton births only)
PA group
(n= 384), n/N (%)
Control group
(n= 391), n/N (%) OR (95% CI)b
Miscarriagec 6/383 (1.6) 10/389 (2.6) 0.60 (0.22 to 1.67)
Stillbirthc 2/377 (0.5) 2/379 (0.5) 1.01 (0.14 to 7.24)
Neonatal deathc 0 1/391 (0.3) Not calculated
Preterm birth (< 37 weeks’ gestation) 35/356 (9.8) 26/348 (7.5) 1.36 (0.80 to 2.31)
Low birthweight (< 2.5 kg) 38/353 (10.8) 44/359 (12.3) 0.87 (0.55 to 1.38)
NICU admission 27/352 (7.7) 36/356 (10.1) 0.74 (0.44 to 1.25)
Apgar score at 5 minutes < 7 8/344 (2.3) 11/351 (3.1) 0.74 (0.29 to 1.85)
Cord blood arterial pH < 7 2/130 (1.5) 0/125 Not calculated
Congenital abnormalitiesd 9/346 (2.6) 6/348 (1.7) 1.43 (0.50 to 4.12)
Assisted vaginal delivery 46/357 (12.9) 32/359 (8.9) 1.51 (0.94 to 2.43)
Caesarean delivery 76/357 (21.3) 103/359 (28.7) 0.67 (0.48 to 0.95)e
PA group
(n=384), mean (SD)
Control group
(n= 391), mean (SD)
Mean difference
(95% CI)b
Birthweight (kg) (n= 354) 3.13 (0.58) (n= 359) 3.15 (0.64) –0.01 (−0.11 to 0.08)
Gestational age at delivery (weeks) (n= 356) 39.24 (2.1) (n= 348) 39.26 (2.1) –0.02 (–0.36 to 0.31)
NICU, neonatal intensive care unit; SD, standard deviation.
a For all outcomes, 10 women with twins (n= 8 PA group) were removed from the denominator.
b ORs and mean differences were adjusted for recruitment centre (as a stratification factor).
c These outcomes were defined a priori as SAEs. There were no maternal deaths and no SAEs were judged to be related
to the PA intervention. The denominator for miscarriage was calculated as the number randomised minus the number
of elective terminations (n= 3) (elective terminations are excluded as they do not have the potential to miscarry). The
denominator for stillbirth was calculated as the number randomised minus the number of miscarriages and elective
terminations (elective terminations and miscarriages were excluded as they do not have the potential to result in a
stillbirth). For all other outcomes, the denominator is the number of singleton live births, excluding those births for which
outcome data were missing.
d For a list of congenital abnormalities see Appendix 9.
e p< 0.023.
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Adverse events
There were similar numbers of AEs and SAEs in the two groups (Table 15). The total number of women or
their infants who had at least one AE or SAE was 217 (55.4%) in the PA group and 219 (55.7%) in the
control group (OR 0.99, 95% CI 0.75 to 1.32). The full breakdown of the data for less frequent AEs is
provided in Appendix 9.
TABLE 15 Adverse events according to study groupa
Event
PA group
(n= 392), n (%)
Control group
(n= 393), n (%)
SAEs
Maternal death 0 0
Other eventsb 12 (3.1) 13 (3.3)
Maternal AEs potentially related to treatmentc 2 (0.5) 0
Maternal AEs as probable complications of pregnancy
Vaginal bleeding or haemorrhage 37 (9.4) 35 (8.9)
Abdominal pain 79 (20.2) 83 (21.1)
Infection in pregnancy 61 (15.6) 55 (14.0)
Premature rupture of membranes at < 37 weeks’ gestation 19 (4.8) 16 (4.1)
Gestational diabetes 7 (1.8) 8 (2.0)
Gestational hypertension 13 (3.3) 13 (3.3)
Pre-eclampsia 4 (1.0) 11 (2.8)
Other, less frequent eventsd 105 (26.8) 114 (29.0)
Fetal AEs as probable complications of pregnancy
Decreased fetal movement 41 (10.5) 49 (12.5)
Intrauterine growth restriction 15 (3.8) 18 (4.6)
Other, less frequent eventsd 7 (1.8) 6 (1.5)
Neonatal AEs 15 (3.8) 14 (3.6)
Total AEs 417 435
a For each study group percentages were calculated as the number of women who had at least one event in any category
of AE divided by the number of women who underwent randomisation. Participants may have had AEs in more than
one category.
b Other SAEs included miscarriage, stillbirth and neonatal death plus events resulting in a significant disability or incapacity
and/or life-threatening events.
c Spotting, nausea.
d Events occurring in < 3% of women or infants; for a list of these see Appendix 9.
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Maternal depression
All 784 participants provided EPDS data at baseline, with 383 (48.9%) and 279 (35.6%) participants
providing these data at the end of pregnancy and at 6 months postnatally, respectively. The baseline
characteristics of the subsamples used for the EPDS analysis at the two follow-up points were similar to
those for the total trial sample. The baseline characteristics of the two trial groups were also similar in the
subsamples at the end of pregnancy and at 6 months postnatally.
In both models the EPDS score was significantly higher in the PA group than in the control group at the
end of pregnancy (Table 16). At this time there was a mean increase in EPDS score of 0.4 in the PA group
and a mean reduction in EPDS score of 0.5 in the control group (mean difference between groups in fully
adjusted model 0.95, 95% CI 0.08 to 1.83). When examining the data separately for end of pregnancy
outcomes before and after the birth the findings were very similar. There was no significant difference in
EPDS score between the groups at 6 months’ follow-up (fully adjusted mean difference 0.37, 95% CI
–0.59 to 1.33).
TABLE 16 Comparisona of maternal depression scores between the randomisation groups at the end of pregnancy
and 6 months after birth
Follow-up
EPDS score, n, mean (SD) β (difference between PA
and control group, adjusted
for baseline EPDS and centre
onlyb) (95% CI); p-value
β (difference between
PA and control group,
fully adjustedc) (95% CI);
p-valueControl group PA group
Baseline 393, 7.7 (5.0) 391, 7.6 (5.3) 0 0
End of pregnancy 194, 7.2 (5.0) 189, 8.0 (4.9) 1.06 (0.19 to 1.94); 0.017 0.95 (0.08 to 1.83); 0.033
6 months 133, 6.6 (4.7) 146, 6.8 (4.8) 0.52 (–0.45 to 1.50); 0.293 0.37 (–0.59 to 1.33); 0.450
SD, standard deviation.
a Results from mixed-effect linear model.
b EPDS score as the dependent variable and randomisation groups, follow-up times, baseline EPDS score, interaction
between follow-up time and baseline EPDS score, and recruitment centre as independent variables.
c Further adjustment for age at leaving full-time education, young age (≤ 20 years), BMI and marital status in the model in
footnote b.
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Maternal weight
The combined sample for the analysis of maternal weight at the end of pregnancy was 271 participants,
with 140 (51.7%) providing maternal weight before the birth and 131 (48.3%) providing maternal weight
after the birth. The characteristics of these two subsamples (i.e. maternal weight provided before and after
birth) were comparable with those of the main trial sample except that the rate of continuous smoking
abstinence at the end of pregnancy was higher in both the subsample with maternal weight provided
before delivery [n= 35 (25.0%)] and the subsample with maternal weight provided after delivery [n= 14
(10.7%)] than in the main sample [n= 55 (7.0%)]. In the combined sample at the end of pregnancy the
characteristics were very similar between the two randomisation groups except that there was an
approximately 1-kg difference in weight at early pregnancy between the two groups and therefore the
results were adjusted for weight at early pregnancy. Rates of smoking abstinence were higher in the
PA group than in the control group at the end of pregnancy [n= 29 (21.2%) vs. n= 20 (14.9%)] but this
difference was not significant. When comparing the characteristics between the randomisation groups
separately for the subsamples providing maternal weight before and after birth the findings were
very similar.
At the end of pregnancy the mean GWG (subsample providing maternal weight before birth) in the PA
group was 12.4 kg [standard deviation (SD) 6.1 kg] and in the control group was 11.2 kg (SD 7.0 kg) and
the postnatal weight retention (subsample providing maternal weight after birth) was 4.7 kg (SD 7.2 kg)
and 4.9 kg (SD 7.3 kg), respectively. With the basic adjustment the mean difference in GWG and postnatal
weight retention for the PA group compared with the control group was 1.08 kg (95% CI –1.08 kg to
3.23 kg) and 0.11 kg (95% CI –2.27 kg to 2.49 kg), respectively (Table 17). In the fully adjusted model
these mean differences were reduced and neither of them achieved statistical significance. The estimated
mean weight change per gestation week was 0.31 kg (SD 0.15 kg) in the PA group and 0.27 kg (SD 0.17 kg)
in the control group, and the difference was not significant. In contrast, the difference in estimated mean
weight change per gestation week between the groups was significantly lower for those classed as obese
at baseline than for those classed as non-obese at baseline (–0.12 kg, 95% CI –0.21 kg to –0.03 kg;
p= 0.010). There was no significant interaction between the effect of PA compared with the control and
whether or not the individual was obese at baseline (p= 0.599), such that, in those who were not obese,
the difference between the PA group and the control group was 0.03 kg (95% CI –0.03 kg to 0.08 kg)
and in those who were obese the difference between the PA group and the control group was 0.06 kg
(95% CI –0.09 kg to 0.21 kg).
According to Institute of Medicine guidelines88 the overall proportion of women with excessive GWG was
38.6%. The risk of excessive GWG was slightly higher in the PA group than in the control group (fully
adjusted OR 1.35, 95% CI 0.63 to 2.88), but the difference was not significant (see Table 17). The risk
was significantly higher for the overweight and obese categories than for the healthy weight category
(overweight: fully adjusted OR 4.0, 95% CI 1.69 to 9.58; obese: fully adjusted OR 3.29, 95% CI 1.20 to
8.99). Those in the underweight category were less likely to gain excessive gestational weight than those
with a healthy weight but this was not significant (fully adjusted OR 0.57, 95% CI 0.06 to 5.31). In
sensitivity analyses, when adjusted for the effect of baby’s weight and rates of smoking abstinence, the
mean difference in the weight change between the two groups was slightly changed and the effect of
baby’s weight was significant in the regression models (see Table 17).
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TABLE 17 Comparison of maternal weight change (kg) between early pregnancy and the end of pregnancy
(separate analysis for subsamples providing maternal weight before and after delivery) by randomisation group
Variable
PA group
(n= 74),
mean (SD)
Control group
(n= 66),
mean (SD)
Basic adjustment, mean
difference PA vs. control
(95% CI);a p-value
Fully adjusted, mean
difference PA vs. control
(95% CI);b p-value
Subsample at end of pregnancy with maternal weights measured before birth (n = 140)
Early pregnancy weight 68.3 (14.4) 70.3 (15.6)
EOP weight 80.7 (14.9) 81.4 (14.7)
Weight change 12.4 (6.1) 11.2 (7.0) 1.08 (–1.08 to 3.23); 0.325 0.92 (–1.15 to 2.99)
0.99 (–0.98 to 2.95)c
Weight change per
gestational week
0.31 (0.15) 0.27 (0.17) 0.04 (–0.01 to 0.10);d 0.113 0.02 (–0.03 to 0.08);e 0.449
0.02 (–0.04 to 0.08);c,e 0.555
PA group
(n= 74),
n (%)
Control group
(n= 66), n (%)
OR adjusted for centre
(95% CI);f p-value
Fully adjusted OR
(95% CI);g p-value
Excessive gestational
weight relative to early
pregnancy BMI
30 (40.5) 24 (36.4) 1.26 (0.63 to 2.53); 0.520 1.35 (0.63 to 2.88); 0.440
1.36 (0.60 to 3.09);c 0.456
PA group
(n= 63),
mean (SD)
Control group
(n= 68),
mean (SD)
Basic adjustment, mean
difference PA vs. control
(95% CI);a p-value
Fully adjusted, mean
difference PA vs. control
(95% CI);b p-value
Subsample at end of pregnancy with maternal weights measured after birth (n = 131)
Early pregnancy weight 66.1 (14.6) 66.2 (13.8)
EOP weight 70.7 (14.1) 71.3 (13.4)
Weight change 4.7 (7.2) 4.9 (7.3) –0.11 (–2.27 to 2.49); 0.928 –0.25 (–2.59 to 2.09)
–0.19 (–2.53 to 2.15)c
EOP, end of pregnancy.
a Linear regression model with maternal weight change at EOP as the dependent variable and randomisation groups, early
pregnancy weight and recruitment centre as independent variables.
b In multiple linear regression models, adjusted for randomisation groups, early pregnancy weight, recruitment centre, age,
number of previous pregnancies and weight at early pregnancy.
c Sensitivity analysis: in all analyses, further adjustment for continuous smoking abstinence at EOP and baby’s weight.
Sample sizes for these analyses are n= 134 (subsample providing maternal weight before birth) and n= 127 (subsample
providing maternal weight after birth) because of missing data for baby’s weight and the exclusion of twin births.
d Multiple linear regression analysis with maternal weight change (kg) per gestational week at EOP as the dependent
variable, and randomisation groups and recruitment centre as independent variables, (n= 132).
e Multiple linear regression analysis with maternal weight change (kg) per gestational week at EOP as the dependent
variable and randomisation groups, early pregnancy obesity, interaction between randomisation groups and early
pregnancy obesity, recruitment centre, age and number of previous pregnancies as independent variables, (n= 132).
f Logistic regression model with excessive gestational weight relative to early pregnancy BMI (yes/no) as the dependent
variable and randomisation groups as the independent variable.
g Adding BMI categories at early pregnancy (healthy weight, underweight, overweight and obese) to the above model and
adjusting for age and number of previous pregnancies.
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Chapter 4 Health economic analysis and results
Introduction
Several studies have investigated the potential cost saving of smoking cessation interventions in
pregnancy92 but only one study could be identified that has used empirical data on costs to calculate the
incremental cost-effectiveness of these interventions.93 This chapter reports on an economic evaluation
conducted alongside the LEAP trial to address the cost-effectiveness of a PA intervention plus behavioural
support compared with behavioural support alone.
The objectives were:
1. to compare the costs associated with the control and intervention strategies
2. to estimate the consequences of these alternatives
3. to assess the cost-effectiveness of the PA intervention used in addition to behavioural support for
smoking cessation at the end of pregnancy.
Methods
Overview
A cost-effectiveness analysis was undertaken to compare a PA intervention plus behavioural support with
behavioural support only for women who were smoking in pregnancy. The main outcome for the
economic evaluation was biochemically validated abstinence from smoking between a quit date and the
end of pregnancy. As recommended by the National Institute for Health and Care Excellence (NICE),94
a cost–utility analysis with a fully incremental analysis was conducted from a NHS and personal social
services viewpoint, including direct health effects (maternal smoking cessation) and costs (or cost savings)
to the NHS. Women were eligible for inclusion in the trial if they were between 10 and 24 weeks’
gestation and outcomes were collected at the end of pregnancy (between 36 weeks’ gestation and
10 weeks post partum); therefore, the time horizon of the trial was up to 9 months. A clinical trial of NRT
for smoking cessation (Smoking, Nicotine, and Pregnancy; SNAP)95,96 was approved by the NIHR HTA
programme shortly before this study began and, as both studies used similar outcome measures, a similar
approach has been taken to economic evaluation to permit comparison.
Cost estimation
Two main costings were included: first, the costs of the interventions and, second, the costs of caring for
each woman and her infant during the period between randomisation and the immediate postnatal period
(up to 6 weeks post partum).
Intervention costs
The cost of the interventions included training and time for staff to deliver the behavioural support and PA
consultations (costed as Band 6 midwife, including overheads) as well as equipment and consumable costs
[CO monitors (breath testing equipment), consumables associated with CO breath testing, equipment
(treadmills and pedometers to count steps when walking), exercise DVDs, printing of PA manual for
participants], and childcare costs. Participants in both arms were offered up to six sessions of behavioural
support for smoking cessation. In addition, those in the PA arm were offered 14 sessions of supervised
treadmill exercise and nine PA consultations, which were combined with the smoking cessation support.
All of the support was provided face to face. The time spent providing support in the trial was multiplied
by salary and overhead costs to calculate a cost per session.
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The cost per use of CO monitoring in the trial was calculated by first summing the costs of equipment
and consumables and then dividing the total cost by the total number of uses. The equipment and
consumables included 12 CO monitors [two calibration kits, semi-disposable mouth pieces (assuming that
these were changed every 60 uses), batteries (assuming that these were changed every 210 uses) and
additional mouth pieces per each use (used in combination with semi-disposable mouth pieces)]
and alcohol-free wipe per use. Assumptions concerning the need to change semi-disposable mouth
pieces and batteries were taken from the SNAP trial.96
It was assumed that a treadmill would last for 10 years and that three midwives would require training in
that time; therefore, annual costs were calculated as one-tenth of the cost of a treadmill plus one-tenth of
the cost of training three midwives, calculated as 1 day of PA training and 1 day of smoking cessation
training received by each midwife. The costs of training were derived from the costs of training in the LEAP
trial. In the control arm, only the cost of smoking cessation training was included. A professor of clinical
psychology provided the smoking cessation training and a private PA consultant, specialising in exercise
and pregnancy, delivered the PA training; both of these trainers regularly provide training in the NHS.
We wanted to present findings for an ‘average/typical’ hospital and so made the following additional
assumptions: given a hospital with 5000 births per year with 600 (12%) pregnant smokers (based on
national data)7 and using the recruitment rate in the LEAP trial of 9.7% (785/8096 eligible women
randomised), 58 (9.7% of 600) women would be recruited annually per hospital. Therefore, per-participant
costs for the treadmill and training were estimated by dividing the annual costs by 58. The robustness of
the results to this assumption was tested in sensitivity analysis.
Health-care resource use costs
Information about antenatal and postnatal hospital admissions and mode of delivery was collected from
maternal medical records and data on admissions to neonatal special care came from infant
medical records.
Valuation of costs
All data were valued in monetary terms and unit costs were reported in UK pounds for the financial year
2012/13 (representing the end point of the trial). As follow-up did not continue beyond 9 months post
randomisation, the question of discounting future costs did not arise. For standard NHS health care, UK
unit costs were applied from national sources, increasing the generalisability of the results. Table 18
presents a summary of the resource use and unit costs.
Calculating costs
To calculate the cost of face-to-face support for each trial participant we multiplied the number of
treatment sessions by the duration of support in minutes. For the PA group we assumed that the midwife
engaged with the woman only when she was off the treadmill, except that during the first 5 minutes of
each treadmill walking session the midwife provided some PA counselling; the estimate of 5 minutes
is based on interviews with the researchers who provided the interventions. Besides these 5 minutes, for
the rest of the time that the woman was on the treadmill the midwife was able to proceed with her
normal work.
Example
Suppose that a patient has 11 treatment sessions lasting 471 minutes (including treadmill time) and
uses the treadmill in 10 of these sessions for a total of 279 minutes. This patient will have spent
471 – 279= 192 minutes in treatment sessions when not using the treadmill. It is assumed that the
midwife contact time consists of these 192 minutes plus a further 5 minutes for each of the 10 sessions in
which a treadmill was used. Total midwife time is therefore (471 – 279)+ (10 × 5)= 242 minutes.
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TABLE 18 Unit costs (2012/13 prices)
Resource item Unit cost (£) Unit Source
PA group only
Treadmill 775 Per treadmill LEAP trial estimation
Pedometer 7.12 Per pedometer LEAP trial estimation
Printing 0.58 Nine-page PA manual LEAP trial estimation
Exercise DVD 0.80 Per DVD LEAP trial estimation
PA training costs 120 Per midwife trained LEAP trial estimation
Both groups
Smoking cessation training 250 Per midwife trained LEAP trial estimation
Band 6 (midpoint) midwife time
(including overheads)
31.95 Per hour Curtis97
CO monitors and consumables 1.37 Per use LEAP trial estimation
Childcare 15 Per crèche visit LEAP trial estimation
Health-care use (both groups)
Maternal antenatal admission 582.24 Per day Department of Health98
Mode of delivery
Unassisted vaginal delivery 2313.60 Per obstetric delivery Department of Health98
Assisted vaginal delivery 2788.86
Caesarean section 3848.83
Miscarriage 1376.76 aPetrou et al.99
Baby admission to neonatal unit (assumes
an average of 4 days in hospital)
2967.18 Per admission Department of Health98
Maternal postnatal admission 782.68 Per day Department of Health98
a Average NHS cost of miscarriage management inflated to 2012–13 prices using the Hospital and Community Health
Services Pay and Price Index.97
Note
To calculate the cost of a baby’s admission to neonatal care, a weighted average of bed-day costs for neonatal critical care
taken from NHS reference costs was multiplied by a weighted average length of stay for neonates with major diagnoses
derived from Hospital Episode Statistics for 2012–13.98 The daily costs of antenatal and postnatal admissions were
established by calculating a weighted average of daily unit costs of different health-care resource group activities recorded
in NHS reference costs.98 For settings with a length of stay longer than 1 day, information on bed-days was used to
calculate a weighted average daily cost. Quantities of services used were multiplied by the relevant unit costs to estimate
overall cost profiles for women in the trial.
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The cost of mode of delivery was established by calculating a weighted average of unit costs for different
modes of delivery activities recorded in NHS reference costs.98 A similar method was used to calculate an
average cost of a maternal antenatal admission and postnatal admission, based on antenatal observations
and investigations.
Outcome measure
The measure of health benefit for the economic evaluation was the same as the primary measure of
clinical effectiveness in the LEAP trial: self-reported and biochemically validated maternal smoking cessation
from the quit date to the end of pregnancy. Temporary smoking lapses of up to a total of five cigarettes
(on up to five occasions) were permitted.
Analysis
An incremental cost-effectiveness analysis was undertaken, following the NICE guidance for health-care
evaluations,94 comparing the additional costs of a PA intervention with those of behavioural support alone,
as well as the additional benefits, to give a cost per additional quitter.
Results are first presented as the per-participant quit rate and costs including fixed costs apportioned as
described earlier in Cost estimation. The same results have also been scaled up to the expected annual costs
and outcomes for a typical hospital with 58 participants per year as used for the estimation of fixed costs.
When two interventions are compared in a cost-effectiveness analysis it may be the case that the more
effective intervention is also the less costly. In this case, the strategy that is both more effective and
less costly is said to dominate the other strategy. The dominating strategy is then unconditionally preferred
regardless of any considerations of budget. When no dominance relationship exists, the results are
summarised in the incremental cost-effectiveness ratio (ICER), which is the additional cost of achieving one
extra quitter. It can be calculated as the expected per-participant cost of the intervention group over and
above that of the control group divided by the expected difference in quit rate. The following is the
formula for the ICER, where Δ represents change, C represents the costs, E represents the effects and
subscripts I and C refer to the intervention and control respectively:
ICER=
ΔC
ΔE
=
C I−CC
EI−EC
. (1)
(Note that when a dominance relationship exists, the ICER as calculated above is negative, but the
numerical value is not informative. This can be seen because doubling either ΔC or ΔE makes the
dominance relationship stronger but these two possible changes have opposite effects on the numerical
value of the ICER.)
A total of 785 women were included in the primary ITT analysis, 392 in the PA group and 393 in the
control group. However, one individual in the PA group withdrew consent before providing any data or
receiving any treatment and was therefore excluded from the economic evaluation. Thus, we analysed
data for 391 in the PA group and 393 in the control group. Analyses were conducted in Microsoft Excel
2010 (Microsoft Corporation, Redmond, WA, USA).
There were no missing data for the effectiveness outcome (validated smoking cessation from quit date to
the end of pregnancy) as any women without validated smoking cessation data were assumed to be
smokers. The average resource use of each cost item was estimated from the available data for the
relevant arm of the trial, effectively imputing an average for each woman with missing data. This was
justified following preliminary analysis, which showed no significant association between any of the
resource use items and key patient baseline characteristics associated with smoking cessation (age, FTCD
score, EPDS score, partner’s smoking status, age leaving full-time education) plus quit status at the end of
pregnancy. Age was significantly associated with mode of birth, such that those who were older were
HEALTH ECONOMIC ANALYSIS AND RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
36
more likely to have a caesarean section. In addition, those with a higher EPDS score were significantly
more likely to report at least one antenatal hospital admission and one postnatal admission. However, as
neither age nor EPDS score was significantly associated with smoking status at the end of pregnancy, these
associations with resource use were not considered a concern when imputing missing data.
Bootstrapping was used to assess the joint uncertainty in cost and effectiveness outcomes. Missing data
were imputed individually for the relevant resource use items to produce a complete data set. Bootstrapped
data sets of the same size as the original patient groups were then constructed by sampling at random with
replacement. Incremental cost and effectiveness estimates were then calculated using the same methods
as described earlier. This was repeated 2000 times to produce a joint distribution of incremental costs and
effectiveness, which was plotted on a cost-effectiveness plane.100 A cost-effectiveness acceptability curve101
was generated showing the proportion of bootstrapped replications that would be cost-effective at a range
of threshold ICERs.
The baseline characteristics of age and nicotine dependence are reliable predictors of smoking cessation.
Therefore, in a subgroup analysis, cost-effectiveness calculations were repeated using only data for the
following subgroups: women aged < 28 years, women aged > 27 years, women with a FTCD score of < 4,
women with a FTCD score of ≥ 4.
Results
In the PA group 30 of 391 women (7.7%) were abstinent from smoking with biochemical validation from
the quit date to the end of pregnancy; the equivalent figure for the control group was 25 of 393 women
(6.4%), a non-significant difference (see Chapter 3, Results).
Table 19 reports the health-care resources utilised in the two arms of the trial. Quantities of services were
multiplied by the relevant unit costs in Table 18 to calculate the resource use for each woman. Maternal
antenatal and postnatal hospital admissions and admissions to neonatal care were similar in the two
groups. With regard to mode of birth, the PA group underwent more assisted and spontaneous vaginal
births and the control group underwent more caesarean sections and miscarriages. A chi-squared test
including all four modes of birth showed a significant difference between the groups (χ2= 8.7, p< 0.035).
On average, the PA group attended 5.3 of 14 treatment sessions offered and the control group attended
3.5 of six sessions offered. The total duration of treatment sessions was around twice that for the PA
group compared with the control group.
The point estimate results shown in Table 20 suggest that the PA intervention is somewhat less costly than
the control intervention, by a margin of £35 per participant, but produces a small increase in the expected
number of quitters. Taken in isolation, this suggests that the PA intervention should be adopted, regardless
of the decision-maker’s willingness to pay for an additional quitter. However, this result must be
interpreted with great caution because there is considerable statistical uncertainty, as reflected in the
scatterplot (Figure 5), which shows that neither the cost difference nor the effect difference is statistically
significant as there are an appreciable number of points in each quadrant. This is confirmed by the
cost-effectiveness acceptability curve (Figure 6), which shows that the proportion of bootstrapping
replications deemed cost-effective does not exceed 80% for any willingness-to-pay threshold up to £50,000
per additional quitter.
The ‘stripey’ effect in the cost-effectiveness scatterplot (see Figure 5) reflects the discrete nature of the
outcome measure. One additional quitter selected in the bootstrapping moves the point to the next stripe.
It appears that the estimated cost saving from the PA intervention is driven by the increased use of
health-care resources in the control group, particularly with regard to the rate of caesarean section.
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TABLE 19 Health-care resource utilisation
Resource item PA group (n= 391) Control group (n= 393)
Maternal antenatal hospital admissionsa
Missing data, n/N (%) 46/391 (11.8) 56/393 (14.2)
Admissions, n/N (%) 85/345 (24.6) 72/337 (21.4)
Average length of days per admission, mean (SD) 2.9 (10.5) 2.3 (2.5)
Baby admitted to neonatal unit, n/N (%)a
Missing data 31/391 (7.9) 35/393 (8.9)
Admissions 29/360 (8.1) 36/358 (10.1)
Maternal postnatal hospital admissionsa
Missing data, n/N (%) 36/391 (9.2) 42/393 (10.7)
Admissions, n/N (%) 275/355 (77.5) 271/351 (77.2)
Average length of days per admission, mean (SD) 2.1 (1.6) 2.2 (1.9)
Mode of birth, n/N (%)
Missing data 20/391 (5.1) 22/393 (5.6)
Assisted vaginal birthb 49/391 (12.5) 33/393 (8.4)
Caesarean section 77/391 (19.7) 104/393 (26.5)
Spontaneous vaginal birth 239/391 (61.1) 224/393 (57.0)
Miscarriage 6/391 (1.5) 10/393 (2.5)
Number of treatment sessions, mean (SD) 5.3 (4.1) 3.5 (1.9)
Total duration of treatment sessions (minutes), mean (SD) 177.3 (146.0) 86.8 (51.2)
Number of sessions using treadmill, mean (SD) 4.9 (4.0) NA
Total time on treadmill (minutes), mean (SD) 93.3 (92.2) NA
Number of crèche sessions,c mean 0.46 0.22
NA, not applicable.
a The average length of stay is shown for maternal admissions, for which a unit cost per day has been applied.
For neonatal admissions the unit cost is per admission and so length of stay is not needed.
b For three sets of twins the first baby had a spontaneous birth and the second had an assisted birth. In these cases the
resource use for the mother was counted as assisted.
c A crèche was available at only four of 13 hospital sites and the mean has been calculated across all patients;
therefore, in this case reporting the SD is not relevant.
TABLE 20 Results of the incremental cost-effectiveness analysis
Group
Average
per-participant
intervention
cost (£, 2012/13
prices)
Average
per-participant
resource use
cost (£, 2012/13
prices)
Average
per-participant
cost (£, 2012/13
prices)
Quit
rate
(%)
Expected
annual costa
(£, 2012/13
prices)
Expected
annual
quittersa ICER
PA 83 4630 4713 7.7 273,343 4.45 Not calculated:
PA dominates
the comparator
in the point
estimate result
Control 56 4692 4748 6.4 275,373 3.69
Difference 27 –62 −35 1.3 −2029 0.76
a Expected annual costs and number of quitters based on 58 participants per year.
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The results were calculated assuming that the costs for treadmill and midwife training would be based
on a typical hospital size. The effect of these costs is negligible compared with other costs in the analysis
and so varying this assumption makes no appreciable difference to the results. Table 21 presents
illustrative results showing the effect on overall costs and the difference in costs of two possible scenarios.
In the first scenario the per-participant fixed costs were halved, assuming that the treadmill and training
would apply to twice as many participants (116 per year instead of 58). In the second scenario the
per-participant fixed costs were doubled, assuming that the treadmill and training would apply only to
half as many participants (29 per year).
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FIGURE 5 Cost-effectiveness scatterplot.
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FIGURE 6 Cost-effectiveness acceptability curve.
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In a subgroup analysis, when repeating the calculations for the two categories of age and FTCD score, the
point estimates no longer show PA dominating the control, but the bootstrapped results still occupy all
four quadrants of the cost-effectiveness plane and, thus, it cannot be concluded that the intervention is
cost-effective (or not) for any of these subgroups. Further details of the subgroup analysis are provided in
Appendix 10.
Summary
Costs associated with the control and PA interventions were compared and the consequences of these
alternatives were estimated. The main results of the cost-effectiveness analysis can be summarised
as follows:
l Mean costs were £35 per participant lower in the PA group than in the control group. This results from
the fact that the mean intervention costs were £27 higher in the PA group than in the control group
but health-care resource use costs were £62 higher in the control group. An important contributory
factor to this result was the difference in rates of caesarean section (25% control group vs. 19.7%
PA group).
l Taken in isolation, the reduction in mean costs and increase in quit rate suggest that the PA
intervention should be adopted, regardless of the decision-maker’s willingness to pay for an additional
quitter. However, this result must be interpreted with great caution because there is considerable
statistical uncertainty, as reflected in the scatterplot and accompanying cost-effectiveness
acceptability curve.
l Subgroup analysis was performed by age and dependency score. In each subgroup analysis there was
still considerable uncertainty in both the incremental costs and the difference in quit rate.
TABLE 21 Sensitivity analysis for assumption about handling fixed costs
Scenario
Average cost per participant (£, 2012–13 prices)
DifferencePA group Control group
Base case 4713 4748 −35
Halve per-participant fixed costs 4711 4747 −36
Double per-participant fixed costs 4716 4749 −33
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Chapter 5 Discussion
Smoking outcomes
The trial showed that, among women who were recruited at 10–24 weeks of pregnancy, supplementing
behavioural support with a PA intervention was no more effective than behavioural support alone in
promoting smoking cessation at the end of pregnancy. At this time, the self-reported continuous smoking
abstinence rate, with biochemical validation, was 1.3% higher among those in the PA group than among
those in the control group, but this difference was not statistically significant.
Strengths and limitations
This is the first trial to assess the effect of a PA intervention on smoking cessation during pregnancy.
Limitations of previous trials of PA interventions for smoking cessation were overcome22 through offering
an intensive PA intervention (with support to increase PA as an aid for smoking cessation in addition to
supervised exercise sessions), assessing and validating PA in both groups, using a robust outcome of
continuous smoking abstinence and offering a pragmatic intervention that could be readily integrated into
routine health care in the NHS.
This study was approximately twice as large as previous RCTs investigating PA interventions for smoking
cessation delivered via face-to-face support.22 As anticipated, around 10% of pregnant women recorded as
smokers at their first antenatal booking visit were recruited. However, the overall number of women
recorded as smokers was lower than anticipated; therefore, despite extending the recruitment period,
we recruited only 91% of the target population of 866 (i.e. n= 789). Future studies may wish to aid
recruitment by focusing on regions of the UK that have particularly high rates of smoking in pregnancy.
Quit rates were lower than anticipated in our power calculation, which will also have reduced the power
of the study. The CI around the OR for the effect of the intervention shows the level of precision of this
estimate, given the achieved sample size, and implies that we cannot rule out up to a twofold increase in
abstinence at the end of pregnancy in the intervention group compared with the control group at the
upper end of the CI, although our point estimate suggests an effect of the intervention that is unlikely to
be clinically meaningful. Additionally, at the 4-week follow-up point quit rates were higher and CIs
narrower, and the difference in abstinence between the treatment group and the control group was
minimal, even at the upper end of the CI. Thus, despite not reaching the target sample size, our results
suggest that there is unlikely to be a clinically relevant difference between the groups. Quit rates were
lower than in previous pregnancy trials with less rigorous outcome measures but were similar to those in
studies using comparable outcome measures.12 For example, two previous UK-based large trials of a
smoking cessation intervention during pregnancy observed quit rates at the end of pregnancy of 7.6% and
7.8% in a group receiving only behavioural support for smoking;95,102 similarly, we observed a quit rate of
6.4% for this group.
Our finding of a lack of an effect of a PA intervention on smoking abstinence is consistent with most
previous trials of PA for smoking cessation among non-pregnant smokers. However, these trials had low
statistical power or used insufficiently intense interventions.22 One adequately powered trial showed that
regular, supervised, vigorous-intensity PA was effective for smoking cessation in women.23 However,
such an intensive intervention is not likely to be clinically suitable or appealing to most pregnant smokers
and our finding remains that a pragmatic intervention based on moderate-intensity exercise was not
effective for aiding smoking cessation during pregnancy.
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Secondary outcomes
Cigarette withdrawal symptoms and urges to smoke
Reports of cigarette withdrawal symptoms and urges to smoke are important during smoking cessation as
they predict relapse to smoking; pharmaceutical interventions are thought to largely work through
reducing these symptoms.18 There was no evidence of the PA intervention affecting changes in withdrawal
symptoms or urges to smoke, rated for the last week, between baseline and 1 week of abstinence. The
ratings for all of the withdrawal symptoms were fairly low at baseline (mean score 2.3, scale 1–5) and
there may have been a floor effect for these items. The lack of a PA effect on cigarette withdrawal or
urges to smoke is inconsistent with studies showing that brief bouts of PA have an acute effect on
reducing urges to smoke among non-pregnant smokers21 and pregnant smokers.29 However, these studies
included temporarily abstinent smokers and findings from this study are likely to have more clinical
relevance. It is possible that, among women attempting to stop smoking, bouts of PA have acute
beneficial effects on reducing the urge to smoke but that these do not translate into benefits that extend
across the week.
Confidence for participating in physical activity and stopping smoking
Increased confidence for participating in PA and stopping smoking (i.e. self-efficacy) tends to predict
positive changes in these behaviours103,104 and, if the PA intervention has the potential to aid smoking
cessation, we might expect it to increase self-efficacy in both of these domains. There was a significant
difference in self-efficacy for PA between baseline and 1 week for the two groups; however, the difference
was a modest 0.3 (scale 1–5) and was the result of scores remaining unchanged in the PA group and
scores reducing (i.e. reduction in self-efficacy) in the control group. The difference in scores for self-efficacy
for smoking cessation between baseline and 1 week was 0.2 (scale 1–6), which was not statistically
significant. Thus, there was little evidence to show that the intervention positively influenced
these processes.
Birth outcomes
Maternal and fetal birth outcomes were very similar between the two study groups, except that there were
significantly fewer deliveries by caesarean section in the PA group than in the control group (difference of
7%). The finding of a lower incidence of caesarean sections in the PA group is consistent with the results
of a recent meta-analysis of RCTs showing a significantly lower risk of caesarean delivery among women
undergoing a PA intervention compared with a control group.47 Ours is the first study to report this in
pregnant smokers and it is a positive result as caesarean sections are more expensive to the NHS than
other modes of delivery and there are complications associated with abdominal surgery. It has been
hypothesised that this effect may be related to reduced birthweight or maternal weight in a more
physically active group.47 In the meta-analysis maternal weight, but not birthweight, was significantly
reduced in the PA groups compared with the control groups, although for most of the individual studies
either maternal weight was not measured or there was no significant reduction in weight. In the one study
reporting a significantly lower risk of caesarean delivery among women undergoing a PA intervention
compared with a control condition, maternal weight was not reported. Therefore, there is as yet no
evidence to support either of these hypotheses. Moreover, in the current study neither maternal weight
nor birthweight was significantly influenced by the intervention and so these are unlikely as explanations.
There may be another mechanism operating, for example it is possible that more active women have more
efficient uterine contractions and therefore are more likely to avoid caesarean section. Further studies are
needed to replicate this finding and to explore underlying mechanisms.
Adverse events
There were similar numbers of AEs and SAEs in the two study groups and there were only two AEs
potentially related to the PA intervention. This is reassuring as it suggests that a PA intervention is safe and
is unlikely to increase these events in pregnant smokers.
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Maternal weight
There was no evidence that randomisation led to reduced weight gain overall or reduced the tendency to
gain excessive weight during gestation. Obesity did not modify the association between trial arm and
weight gain.
The subsample of the LEAP participants included in the analysis of maternal weight study were much more
likely to have stopped smoking than those who were not included. This was because abstinent participants
had to return for biological confirmation of abstinence and they were obviously keen to return to show their
success. Weighing participants was then possible. Although this is of some concern, it is a much less relevant
concern here than it might appear. Post-cessation weight gain occurs only in those who sustain abstinence
and therefore there is no potential for PA to ameliorate cessation-related weight gain in those not achieving
abstinence. Consequently, the Cochrane review48 of interventions to prevent cessation-related weight gain
confines the analysis to only participants who achieve abstinence in the intervention and control arms.
Pregnancy itself is a period when excessive weight gain occurs commonly, as shown in this trial, in which
38% of women gained an excessive amount of weight. PA might have been expected to ameliorate this,
but there was no evidence it did so. The CIs were wide and encompassed modest effects that are clinically
relevant. We can therefore conclude only that the PA programme had no large effects on GWG but may
still have important, moderate-sized effects, although there is insufficient evidence to assess this.
Maternal depression
The PA intervention was no more effective than standard behavioural support for reducing depression
scores at the end of pregnancy or 6 months after childbirth. Moreover, scores were significantly higher in
the PA group than in the control group at the end of pregnancy, although the margin of this difference was
very small and is unlikely to be clinically important.105,106 AEs were very similar in the two groups and so this
is unlikely to have affected this outcome. As for the smoking outcomes, there may have been limited
potential to show a difference between the groups as both groups were already active at baseline and
reported maintaining fairly high levels of PA through to the end of pregnancy. That said, the self-reported
PA must be treated with caution as the accelerometer data suggest that these reports were overestimated
and, among the sample with accelerometer data, levels of activity were similar for the two groups.
Another explanation for the findings relates to the population of interest and the requirements of the
study/intervention. Those in the PA group were asked to change two health behaviours simultaneously
(i.e. PA and smoking) while also coping with being pregnant, in addition to dealing with the demands of
being asked to attend multiple treatment sessions. This might have demoralised these individuals and they
may have found this difficult to achieve, resulting in marginally higher depression scores at the end
of pregnancy.
In conclusion, although clinical guidelines recommend that pregnant women exercise for mental health
benefits28,61,107 and there is a further recommendation that PA be used to treat and prevent depression
among smokers,108 based on the current findings an intervention that offers supervised exercise combined
with consultations to increase PA cannot be recommended for antenatal or postnatal depression in women
attempting to quit smoking during pregnancy.
Economic evaluation
The total mean cost was £35 per participant lower in the PA group than in the control group. This results
from the mean health-care resource use costs being £62 higher in the control group than in the PA group
and the mean intervention costs being £27 higher in the PA group than in the control group. Control group
health-care costs were higher mostly because of the higher rate of caesarean sections in this group (25%
control group vs. 19.7% PA group). Considering the reduction in mean cost and increase in quit rate for the
PA group compared with the control group, it could be recommended that the PA intervention be used as
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an aid for smoking cessation regardless of the decision-maker’s willingness to pay for an additional quitter.
However, these results must be interpreted with extreme caution as there is considerably statistical
uncertainty, as reflected in the scatterplot and accompanying cost-effectiveness acceptability curve.
Previous studies have investigated the cost-effectiveness of smoking cessation interventions during
pregnancy.92 However, these mainly US-based studies are limited by not including data for infant outcomes
and therefore cannot easily be compared with this study. One previous study (the SNAP trial96), based in
the UK, has considered infant outcomes and conducted a similar analysis as used in the present study.
The SNAP trial assessed the cost-effectiveness of NRT for smoking cessation. The authors reported that the
total mean cost of the intervention was £90.81 higher in the NRT group than in the usual-care group.
While bearing in mind the high levels of statistical uncertainty present in both studies, this suggests that
the PA intervention may be at least as cost-effective, if not more so, than the NRT intervention.
The National Institute for Health and Care Excellence recommends that health outcomes should be
measured in quality-adjusted life-years (QALYs) to facilitate comparisons between different health-care
programmes.94 Ideally, the value to society of each successful quitter in the LEAP trial would be estimated
in QALYs but no method has been found for doing this that can be considered robust and reliable for use
with pregnant smokers. QALYs are commonly calculated from generic health-related quality of life tools
(e.g. the European Quality of Life-5 Dimensions or EQ-5D), which may be inappropriate for use in pregnant
populations. Quality-of-life studies using generic measures have demonstrated that changes in quality of
life, particularly declining physical functioning and vitality, occur over the course of pregnancy.109 These
substantial changes in quality of life may mask any potential short-term quality-of-life gains from smoking
cessation. Moreover, existing models ignore QALY benefits to the fetus and do not take into account
maternal morbidity during pregnancy.92,93,110 It was anticipated that a model and systematic review being
developed for another study at the University of Nottingham would be suitable for this purpose but this
work has yet to be completed. However, once an appropriate economic model that values smoking in
pregnancy is available we will use this to estimate cost-effectiveness in QALYs.
Interpretation and generalisability of the results for
smoking outcomes
The trial had reasonably broad inclusion criteria and few exclusion criteria, and, therefore, the results are
likely to be generalisable to most pregnant smokers, although the women were highly physically active in
both groups at baseline. At baseline, compared with a survey of pregnant smokers similarly recruited in
antenatal hospitals,111 participants were approximately twice as likely to report achieving the recommended
150 minutes per week of MVPA; this may be because more active women were attracted to a trial offering
a PA intervention. Low attendance may have affected efficacy, with the PA group attending a median of
only four (of 14) sessions. Low attendance was not explained by the two potentially treatment-related AEs
in the PA group and there was no indication that the PA intervention increased the overall incidence of
AEs. The vast majority of women who failed in their quit attempt stopped attending, suggesting that it
was failure to quit that led to low attendance rather than low attendance leading to failure of the attempt.
There was no evidence for the intervention influencing processes that might aid cessation, such as
confidence for quitting, urges to smoke or withdrawal symptoms.
Bias in outcome ascertainment is unlikely to explain the findings as follow-up rates were equally high in
the groups and the effect size was independent of the influence of missing outcome data. Fewer than
10% of participants reported using non-study behavioural support or NRT, with similar usage in the
groups. Therefore, it is doubtful that this influenced the results.
Although the intervention group reported significantly higher PA levels throughout pregnancy relative to
the control group, the self-reported PA scores in the control group were also relatively high at follow-up.
For example, at the end of pregnancy the intervention group reported completing a median of
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155 minutes of MVPA per week (22 minutes per day) and the control group reported completing a
median of 140 minutes of MVPA per week (20 minutes per day). This suggests that some intervention
contamination might have occurred in the control group and consequently there was an insufficient
difference in PA levels between the groups to show an appreciable effect on depression outcomes. It is not
clear why the control group participated in more PA than might be expected. One explanation could be
that an atypical motivated sample of participants was recruited who were keen to be active regardless of
their random group allocation; the high baseline PA scores would suggest this explanation is a possibility
as participants were already achieving around 30 minutes per day of MVPA at baseline. The only previous
trial of exercise for smoking cessation showing a long-term benefit for abstinence excluded more active
women,23 and in less active women the LEAP intervention might have had more positive effects. However,
there was no evidence to suggest that the treatment effect for the primary outcome was influenced by
baseline levels of PA. Moreover, as participants were recruited from routine health-care settings, it seems
likely that if the exercise intervention was offered as part of routine care women would be recruited who
are active at a similar level to those taking part in the current trial.
It is also important to consider that, as previously observed,112–114 our accelerometer correlational analysis and
Bland–Altman plot suggest that participants overestimated their self-reported PA levels. Moreover,
participants could not be blinded to treatment allocation and the higher self-reported rates of activity in the
PA group may be the result of a social desirability bias, such that there is a tendency to over-report PA levels
with the belief that this will be positively viewed by the researchers. In addition, in the subsample using the
accelerometer, accelerometer-derived PA levels were similar in the two trial groups, although when including
all MVPA (rather than restricting it to bouts of > 10 minutes) the PA group tended to report more PA per
week than the control group, which suggests that most increases in activity were likely to be in sporadic
bouts lasting < 10 minutes. The accelerometer data were collected for only 10% of participants and
therefore this finding must be treated with caution; however, it is possible that the non-significant effects for
smoking abstinence emerged partly because the PA group failed to adhere fully to the behavioural goals of
the intervention. If this is the case, it is unlikely that such an intervention offered in routine health care would
raise PA levels sufficiently to have an impact on smoking cessation. On the other hand, although attendance
at treatment sessions was low, the PA counselling may have increased PA even without attendance at all
scheduled exercise sessions. A less pragmatic and more efficacy-oriented trial (e.g. with greater incentives to
complete the exercise, such as financial incentives) with accelerometer measurement in the whole sample
would be needed to establish whether or not PA per se aids smoking cessation during pregnancy.
Conclusion
During pregnancy, offering an intervention combining supervised exercise and PA counselling did not add
to the effectiveness of behavioural support for smoking cessation. There was no evidence that the PA
intervention increased AEs or had a harmful effect on birth outcomes, and there was some evidence that
the PA intervention resulted in fewer caesarean sections. There was no evidence for the intervention
reducing maternal depression or weight gain.
Recommendations for research (in priority order)
1. It is not recommended to fund further large-scale trials of PA for smoking cessation until much less
expensive observational studies have been conducted to provide promising leads, for example related to
the populations most suitable for such interventions and methods for increasing PA adherence.
2. Reasons for pregnant smokers’ low levels of attendance at supervised PA sessions should be investigated;
findings could be used to increase attendance rates. For example, following on from recent work on
barriers to PA,115–117 further research is needed to explore barriers to attendance and to PA adherence
during pregnancy, and to assess whether or not these barriers vary during different stages of pregnancy
and among women with different comorbidities, including gestational diabetes and obesity.
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3. Further methods of increasing PA adherence among pregnant smokers need to be developed and
tested. For example, financial incentives have shown some benefit for aiding smoking cessation in this
population and they may be used in combination with PA to increase both attendance at exercise
sessions and smoking cessation.12 In addition, interventions are needed that provide regular prompts to
remind women to exercise (e.g. text messages or brief telephone calls); such interventions have been
successfully piloted with young women but not yet with pregnant women.118
4. The reasons why few inactive pregnant smokers were attracted to a PA trial need to be identified and
methods are needed to attract these less active pregnant smokers.
5. Studies are needed to establish whether or not the previously reported finding of a short bout of PA
reducing cigarette cravings in pregnant smokers is a robust finding. So far, only one study has
investigated this issue. If it is a robust finding, interventions need to be developed that can translate this
benefit into prevention of smoking relapse.
6. There was no evidence of beneficial effects on maternal weight gain or depression. Studies are needed
that focus on women who are at risk of higher maternal weight gain and on women who have high
levels of depression at baseline.
7. Among pregnant smokers there was no evidence for a PA intervention having an added benefit for
smoking cessation beyond that of usual care. However, it is possible that in some circumstances a PA
programme alone may be more practical and may aid smoking cessation, and this needs to be assessed.
8. There were significantly fewer deliveries by caesarean section in the PA group than in the control
group. Further studies are needed to replicate this finding and to explore the underlying mechanisms.
Implications for health care
There was no evidence that offering regular, supervised exercise and PA consultations, in addition to
routine smoking cessation support, to women following their first antenatal visit is effective for aiding
smoking cessation. Therefore, PA is not currently recommended for smoking cessation during pregnancy.
One study showed that PA acutely reduces cigarette cravings in abstinent pregnant smokers29 and, among
smokers in general, PA is recommended for reducing these cravings.21,22 In the present study there was no
evidence for the PA intervention moderating cravings/urges to smoke, but it is possible that there are some
acute benefits of PA on reducing cravings during pregnancy and the recommendation to use PA to
manage cravings acutely remains for all smokers, including those who are pregnant. The PA intervention
did not show any benefit for reducing maternal depression; in fact, there was a slight increase in
depression in the PA group and therefore the intervention cannot be recommended for antenatal or
postnatal depression in women attempting to quit smoking during pregnancy. There was no evidence for
an effect of the intervention on maternal weight gain and therefore the intervention cannot be currently
recommended for moderating this weight gain. There was no evidence of an increased level of AEs in the
PA group and there was some evidence for a reduced incidence of caesarean sections in the PA group;
therefore, in line with current guidance, PA remains indicated for general health benefits in pregnancy,
including among pregnant smokers.
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Appendix 1 Telephone screening sheet
 
 
Please add site ID no.    
To be completed by Researcher by phone: 
Researcher’s name: 
Date: Time: 
Potential participant’s Name: 
Address: 
                                           Email:………………………………………………. 
                                           Daytime tel:…………………………………….. 
                                           Evening tel:……………………………………..  
                                           Mobile:……………………………………………… 
                                           Best time to call is between…………… 
                                           and………………… 
Post Code:                            No. calls made:……………………………….          
GP’s Name: 
Address: 
 
 
                                           Tel: 
Introduction: Name/role, hospital, research study, spare a few minutes to discuss. 
Describe study:  
• Help with stop smoking. 
• Compare usual help/advice with usual help/advice plus exercise. 
• Around 900 women, several hospitals 
• Either once a week for six weeks or twice a week for six weeks then once a 
week for two weeks. 50:50 chance of either group. 
• Quit one week after first appointment. 
• Follow-ups at around 38 weeks pregnant, baby six months (at home if 
preferred) 
• Questionnaires and CO monitor 
• £7 travel expenses 
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 Eligibility Checklist: Inclusion criteria 
1. How old are you? Age 16 – 50 
2. How many weeks pregnant are you? 10-24 weeks 
3. How many cigarettes did you smoke on a 
typical day before you were pregnant? 
≥ 5 cigs 
4. How many cigarettes do you smoke on a 
typical day now? 
≥ 1 cigs 
5. Are you willing to try to stop smoking 
without using nicotine replacement therapy  
(e.g. patches)? 
YES 
6. Can you read and write in English? YES 
7. Are you available and willing to attend up to 
14 appointments over the next 2 months? 
YES 
8. Do you have a drug or alcohol problem? NO 
9. Are you able to walk continuously for at least 
15 minutes? 
YES 
10. Have you been advised by a doctor, 
midwife or another health professional not to 
take exercise during your pregnancy? 
YES NO 
11. Has a doctor ever said you have a heart 
condition and recommended only medically 
supervised physical activity? 
YES NO 
12.  Do you have chest pain brought on by 
physical activity? 
YES NO 
13.  Have you developed chest pain in the last 
month? 
YES NO 
14.  Do you tend to lose consciousness or fall 
over as a result of dizziness? 
YES NO 
5.  Do you have any bone or joint problems 
that become aggravated when you are more 
active? 
YES NO 
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
60
 16.  Has a doctor ever recommended 
medication for your blood pressure or a heart 
condition? 
YES NO 
17.  Are you aware, through your own 
experience or a doctor’s advice, of any other 
medical reason why you shouldn’t be   
physically active without medical supervision? 
YES NO 
18.If woman answers YES to any of Q10-
17: 
Do I have your permission to contact a doctor 
at your hospital to check if it is ok for you to 
exercise? 
If woman answers no: She cannot take part. 
     YES NO 
If yes  to Q10-17: Consultant has 
confirmed that it is safe for woman to 
take part? 
NA   
     YES NO 
For all women who are eligible: 
Do I have your permission to contact your GP, 
midwife and obstetrician to let them know you 
are interested in taking part? 
     YES NO 
Sent letter to GP about participation?            YES  
Suitable for trial?      YES NO 
Information sheet & directions sent?  YES 
 
Date of first appointment: 
 
 
Time:                      Clinic: 
 
Remind the women to bring a pair of shoes comfortable for walking in, in case she is in 
the exercise group. 
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Appendix 2 Therapist manual for delivering
behavioural support for smoking cessation
 
Smoking cessation support manual for LEAP trial 
This manual includes guidance all 43 behaviour change techniques (BCTs), except BM4 
“Provide rewards contingent on successfully stopping smoking”, defined in the following 
taxonomy: 
Michie S, Hyder N, Walia A, West R (2011) Development of a taxonomy of behaviour 
change techniques used in individual behavioural support for smoking cessation. Addictive 
Behaviour, 36, 315-9. The 43 BCTs used are: 
Specific focus on the target behavior (B) and maximizing motivation (M): BM1. Provide 
information on consequences of smoking and smoking cessation; BM2. Boost motivation and 
self-efficacy; BM3. Provide feedback on current behavior; BM5. Provide normative 
information about others’ behavior and experiences; BM6. Prompt commitment from the 
client there and then; BM7. Provide rewards contingent on effort or progress; BM8. 
Strengthen ex-smoker identity; BM9. Identify reasons for wanting and not wanting to stop 
smoking; BM10. Explain the importance of abrupt cessation; BM11. Measure CO.  
Maximizing self-regulatory capacity and skill (BS): BS1. Facilitate barrier identification 
and problem solving; BS2. Facilitate relapse prevention and coping; BS3. Facilitate action 
planning/develop treatment plan; BS4. Facilitate goal setting; BS5. Prompt review of goals; 
BS6. Prompt self-recording, BS7. Advise on changing routine; BS8. Advise on 
environmental restructuring; BS9. Set graded tasks; BS10. Advise on conserving mental 
resources; BS11. Advise on avoiding social cues for smoking. Promoting adjuvant 
activities (A): A1. Advise on stop-smoking medication; A2. Advise on/facilitate use of social 
support; A3. Adopt appropriate local procedures to enable clients to obtain free medication; 
A4. Ask about experiences of stop-smoking medication that the smoker is using; A5. Give 
options for additional and later support. General aspects of interaction focusing on 
delivery of the intervention (RD):  RD1. Tailor interactions appropriately; RD2. Emphasize 
choice; General aspects of interaction focusing on information gathering (RI): RI1 
Assess current and past smoking behaviour; RI2. Assess current readiness and ability to quit; 
RI3. Assess past history of quit attempts; RI4. Assess withdrawal symptoms; General aspects 
of interaction focusing on general communication (RC): RC1. Build general rapport; RC2. 
Elicit and answer questions; RC3. Explain the purpose of CO monitoring; RC4. Explain 
expectations regarding treatment program; RC5. Offer/direct toward appropriate written 
materials; RC6. Provide information on withdrawal symptoms; RC7. Use reflective listening; 
RC8. Elicit client views; RC9. Summarize information/confirm client decisions; RC10. 
Provide reassurance. 
 
The specific BCTs used are indicated in brackets in the manual below. The version of the 
manual used by therapists did not include these BCT labels. 
---------------------------------------------------------------------------------------------------------------------- 
 
Each smoking cessation consultation should take about 20 minutes. 
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 Session 1: Preparation for quitting 
Briefly describe the study and intervention and check volunteer’s understanding: 
• Explain randomisation e.g. ‘A computer will decide whether you will get the standard 
treatment or the exercise programme. Do not be too concerned about which you are getting. 
Whatever you receive, you are in with a good chance of succeeding in stopping smoking. In 
both conditions we shall be providing help and support to help you to stay free of smoking.’ 
• Remind them what the interventions will involve (RC4) e.g. ‘If you are in the exercise 
group you will need to attend 14 appointments over 8 weeks. This will involve waking on a 
treadmill for up to 30 mins and advice and support with stopping smoking and taking regular 
exercise. If you receive the standard treatment you will be asked to attend 6 weekly 
appointments providing advice and support with stopping smoking.  
• Explain the timing of the target quit date (TQD): We will ask you to stop smoking one 
week from today.  (BS4) 
• The volunteer should not be randomised using the online database until you are satisfied that 
she understands what the study will entail (especially the need to attend all appointments) and 
understands the process of randomisation. 
 
IF RANDOMIZED: 
• Explain the purpose of carbon monoxide (CO) monitoring (RC3)  
• Measure CO (BM11) and use the reading to motivate quitting. 
e.g.  ‘This shows how much you inhale the smoke and all the dangerous chemicals in it. A 
non-smoker would normally have a reading of less than eight. You as a smoker have a reading 
of ___.  As soon as you stop smoking, this will start to go down to the non-smoking level. 
This will happen not just in your own body, but in the body of your baby as well. There is an 
immediate health benefit in stopping smoking. We shall repeat this measure once a week.’ 
• Briefly discuss reasons for wanting to quit, level of motivation for quitting and 
confidence for quitting (refer to questions in CRF) (BM9, R12)  
• Assess and discuss current and past smoking behavior (see questions in CRF)  (RI1) 
• Discuss past attempts at quitting (R13) and reasons for relapse. Determine longest periods 
of abstinence and, if these are reasonably lengthy, use these as a reason to be optimistic to 
about being able to quit. 
• Discuss preparing for the quit day (BM6, BS3); e.g. “I suggest you make a list of the things 
you need to do to prepare for your quit day. For example: Tell people you are quitting, 
particularly those who will give you support (A2), decide when you will have your last 
cigarette, tell people that they will not be allowed to smoke in the home, remove all ashtrays 
and from your home (BS8), become aware of times when you are most likely to lapse (e.g. 
after meals, when alone in the house, on phone) and make a note of these (BS6), think about 
how you will deal with these times and be aware that one puff can easily turn into a full 
relapse (BS1).” Also ask them to think about whether there are any events coming up that 
might make it difficult not to smoke (e.g., a stressful event or party, or meeting someone they 
used to smoke with) (BS1). Mention that there will be more time to discuss these strategies on 
their quit day. 
• Discuss whether partner smokes and whether partner or friends or colleagues might want to 
quit with them. Invite partner to join them at their treatment sessions. (A2) 
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 • If they have children: discuss what they will do with children during the sessions. Also, 
suggest they explain to the children that they are quitting and that they ask the children to 
encourage them. (A2) 
• Explain clearly that the woman can have the last cigarette before the session on their quit day 
(e.g. outside the clinic before coming in, on the morning or the night before their quit day. No 
smoking after that) (BS4). If they can, ask them to decide now when they would like to have 
their last cigarette and say that it is their choice (RD2). 
• Give a leaflet about smoking and smoking cessation during pregnancy (BM1, RC5) 
• If they ask whether they should start cutting down in preparation for quitting, explain that it 
is better not to start missing cigarettes before the real quit attempt begins. This is likely to be a 
better way to quit than having long breaks between the last few cigarettes, enjoying them 
greatly, and saying ‘goodbye ciggies’ with tears in their eyes and having strong cravings 
before they have even quit. 
• If volunteer says they are content with cutting down to 2 or 3, consider mentioning the 
following to encourage them to quit abruptly and completely (BM10) 
• It is often anxiety and discomfort that motivates behaviour change rather than logic:   
Encouraging Women to Quit Completely 
Not much benefit to be had by cutting down as you inhale more deeply and more nicotine 
reaches the baby. You have the worst of both worlds as you are experiencing the discomfort of 
cutting down and doing the same harm to yourself and the baby. 
You will be adding more stress making those few cigarettes more precious and there is also the 
stress of withdrawal between those few cigarettes. Better to quit completely. 
It is best to quit completely now because the pressure that comes with having a new baby will 
make it more likely that you will relapse. 
 
• If they ask about self-rolled and low tar cigarettes explain that these are just as harmful. 
(BM1) 
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 Session 2: Quit Day  
Objectives 
• Remind patient that today is their quit day 
 Look for reasons why woman is a good prospect (BM3) (e.g. managed to quit for a period 
of time in the past, she is highly motivated, lessons learned from previous attempts, 
success/change in other areas of their life, is receiving best available support etc.). Express 
your optimism. Make it clear that they need to be prepared for it being very difficult 
(particularly if quitting was difficult in the past, CO is high and/or they smoke their first 
cigarette soon after waking), but that many women in their position quit successfully 
• Stress the importance of a good start.  e.g. ‘You have shown determination by getting as far 
as this. Now is the crunch time. Even if the first few days prove to be difficult, do not go back 
to smoking. As a long-term smoker, you need to expect at least some difficult moments. The 
good news is that there is strong evidence that making it through the first week without a 
single puff massively increases your chances of success. Please remember this when you are 
tempted to smoke.  
• Explain the withdrawal symptoms that they may experience. ‘Besides cravings, many 
people feel irritable, depressed, restless, have poor concentration, sleep disturbance and feel 
hungrier.’ Also some people get more colds, mouth ulcers and headaches. (RC6). Reassure 
that these will gradually decrease across the first 3-4 weeks of quitting. The first week often is 
the hardest and the middle of the first week is often the worst time.  
• Smoking and stress: Explain that smoke increases rather than reduces stress and that most 
people feel less stress within a week or two of quitting. 
• If they are ambivalent about quitting remind them of why they want to quit. 
• Discuss possible obstacles to success and briefly review coping strategies for     week 
ahead: Ask ‘What happened when you tried to stop smoking before? Refer woman to tips in 
the leaflets. Ask “Are there any particular events this week that might increase your   
     temptation to smoke?” (BS1) 
Explain that cravings often only last a few minutes and that they tend to peak and then 
subside. Recommend that they prepare for these cravings (RC6) (e.g. distract yourself, have 
an activity ready, for exercise group suggest a short walk, have someone you can call when 
you are close to lapsing, keep healthy snacks in your bag (e.g. apples, carrot sticks) and water 
(some people say that sipping helps with cravings), have things to keep your hands occupied, 
avoid/minimize difficult/stressful/tempting situations if you can (e.g. parties, time spent with 
smokers,), especially in the first few weeks (BS11). If they cannot avoid these situations 
suggest they be prepared for it to be a challenge. Explain that it can also be useful to change 
their daily routine (e.g. if they usually smoke first thing in the morning suggest they replace 
this with something else, such as a shower or breakfast). (BS7) Suggest that they also 
conserve their energy, particularly in the first few weeks, by not taking on major new projects 
such as making other significant changes in their life (BS10). 
• A typical tempting situation which may lead to smoking is when people are bored with not 
much to do. If this affects you, make plans for distracting yourself. To give you an example, 
Mrs. Palmer found that for her, making a jigsaw helped. She started a jig-saw puzzle on her 
quit day and when tempted to smoke went and looked for the next piece of her jigsaw.  
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 • Suggest cognitive strategies (RC6) . Some people benefit from ‘talking themselves through’ 
difficult situations; e.g. remind yourself that the difficult moment will soon pass, remember 
your reasons for stopping smoking and the danger of having even one slip, think of all you’ve 
achieved so far, think how you will feel if you lapse and have a cigarette, write down all the 
reasons why you don’t want to smoke and keep this with you, keep a picture of the baby’s 
scan with you.  
- ‘If tempted to smoke, have a look at the tips in this leaflet. Distract yourself if it gets tough. 
Take it one day or even one hour at a time. (BS9) 
Remember that if you pull through this week without smoking at all, you are far more likely to 
succeed.  
• If they make these preparations this will build up their resistance when they are tempted to 
smoke. 
• Finish by stressing the importance of not having a single puff of a cigarette as this can 
quickly lead to having more cigarettes and it will increase your cravings. You may feel that 
having just one cigarette won't hurt and will make you feel better. Be on your guard! This is 
how attempts at quitting fail. Do not fool yourself. (BS2) 
 
Session three : one week after quit day 
Main aims : 
• Assess CO and give feedback about whether their reading has reduced (BM11, BM3). 
• How do I handle discrepancies between CO and self-report? 
- Best not to challenge self-reports, but check again that client did not smoke 
- Check ambient CO 
- Check your own reading 
- Ask about the possibility of exposure to secondary tobacco smoke.  
- Ask about possibility of exposure to CO at home (e.g. leaky gas boiler) 
- Say that you will calibrate the CO monitor and check their reading again again next 
week 
• Review how they got on this week with remaining abstinent and discuss whether the strategies 
they prepared were helpful. (BS5) 
• Boost motivation, provide orientation on withdrawal, discuss possible reasons for relapse and 
strategies for dealing with these (BS2). 
• Reinforce abstinence, deal with lapses. 
 
Check smoking status. If abstinent, praise and reinforce: e.g. “If you did not smoke at all, you are 
now free of nicotine and of many other chemicals in cigarette smoke which are bad news for your 
baby” (BM7).  
• If they lapsed, explain again the importance of complete cessation, but do not discourage (e.g. 
‘You still have time to catch up. How do you plan to go about it?’). Discuss a plan. Look for a 
positive angle. Explain to lapsers who complain of withdrawal discomfort that this will only 
go away if they do not smoke at all – see below. Check for unrealistic expectations (‘e.g. 
Despite the exercise/NRT, I still fancied a cigarette’). If they have relapsed back to regular 
smoking encourage them to learn from why they relapsed and to set a new quit date (BM6). If 
they have relapsed, discuss whether they would consider using NRT (RD2) and provide 
advice about NRT (A1). Liaise with the PCT to enable them to get free NRT (A3). 
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 • Discuss withdrawal discomfort and refer to their responses to the withdrawal questions in 
the CRF (R14).  Reassure where appropriate (e.g., ‘Over many years, your brain and body 
have got used to having regular shots of nicotine throughout your waking hours. Once you 
stop smoking, it can take weeks and months to regain your balance.’). Explain the likely 
duration of concrete symptoms patients are concerned about. Reassure them that most 
smokers experience strong withdrawal symptoms and that cravings are the most common 
symptom (BM5, RC10); e.g. “They can be unpleasant, but they will not harm you. You will 
be over the most difficult time soon”. Suggest they continue to be aware of, or make a note of, 
when they are most tempted to smoke (BS6). 
• Discuss triggers for relapse and coping efforts (BS2) where appropriate. Encourage them to 
use: distraction techniques (I go and do something, get away from the situation, etc.), avoiding 
temptations (I do not have any cigarettes in the house, did not go to the pub this week), and 
cognitive approaches (I think of my reasons for stopping, tell myself to take one day at a time, 
I imagine how bad/guilty I will feel if I smoke etc.). 
• Suggest they start seeing themselves as a non-smoker, rather than as a smoker who is trying 
to quit or an ex-smoker. If they do this they are more likely to succeed. (e.g. if someone offers 
them a cigarette suggest they say ‘No thanks, I don’t smoke’, and ask them to imagine saying 
this) (BM8). 
• Allow time at the end of each session for the participant to ask questions (RC2). 
• Remind participant that if they attend all six smoking cessation sessions they will be entered 
into a prize draw for three £100 shopping vouchers. (BM7) 
 
Sessions 4 (two weeks after quitting) onwards 
Main aims: 
Reinforce abstinence or deal with lapses. 
Give reassurance on withdrawal (at later sessions deal with weight gain). 
Discuss obstacles, advise on coping, express support. 
Tailor the content for each individual (RD1) 
• Check smoking status (BS5). Congratulate abstainers and praise them. Explore how they got 
through difficult moments; elicit, reinforce, and develop coping strategies.  Note they are now 
making it (first 2 weeks) or have made it through the most difficult part of quitting. 
If not abstinent, discuss barriers to quitting. Explain the urgency of catching up 
• If a participant is smoking daily, debrief on difficulties that led to smoking, and suggest 
lessons learned and future solutions (BS2). Help patient decide whether to continue current 
quit effort or to set a new quit date  (BM6). Frame the experience positively, and focus on 
future efforts. Offer to refer them to the PCT for further support during or following the 
research intervention (A5).  
• Discuss triggers for relapse and coping strategies (BS2) 
• If you go through a difficult patch, remember that it will get easier soon. Your brain and 
body got used to regular doses of nicotine. It can take a few weeks, or more, to get back your 
balance and to learn to live without smoking. Most people feel OK within some three or four 
weeks.  
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 • Ask about use of NRT: refer to the questions in the CRF and, for those who are using NRT, 
ask how they are getting on with it. (A4) 
• Emphasise the rationale of recommending complete abstinence and the danger of relapse. 
• By now, you have probably saved quite a bit of money you would otherwise spend on 
cigarettes. This saving will grow quickly. Plan how to spend it on yourself. 
FU at six weeks after quitting: remember that you need to conduct a 7 day physical activity 
recall via telephone for control group 6 weeks after quit. 
• Explain the danger of relapse and the need to stay on guard.  ‘Many smokers who make it 
through pregnancy go back to smoking after the birth or within a year of quitting. I would like 
to make sure that this will not happen to you’.  (BS2) 
• Warn against ‘transgression’ cigarettes when stressed, when bored, on holidays, and in 
company. Discuss the temptation people often have ‘to try one cigarette, just to see’, explain 
the dangers, especially in the hours and days after the birth. (BM8, BS2) 
• Discuss likely relapse situations (e.g. smokers they will come in contact with soon after the 
birth) and plan coping strategies. (BS2) 
• Emphasise woman’s ability to cope and implement cessation procedures on their own, 
building on the success to date. 
• The woman may be concerned about what will happen after the visits finish. In case they need 
to contact you, give them your clinic phone number. Offer them the option of being referred 
on to the PCT stop smoking service for further support. Give them information about the NHS 
website for pregnant smokers (www.smokefree.nhs.uk/smoking-and-pregnancy/) (RC5) and 
the smokefree helpline: 0800 022 4332. (A5) 
• If they say they feel tempted in the company of smoking friends/family, suggest they consider 
asking these individuals not to smoke around them, or just plan how to react when one of them 
lights up or offers a cigarette. (BS2) 
• “One of these days you will realise that you have not thought of smoking at all for hours. 
Notice this. It will soon become days and then weeks, until cigarettes will stop being an issue 
at all.”    
• “Every day you make it without smoking, you are learning how to cope without cigarettes and 
finding your own ways to overcome difficult moments. Notice what helps and use it.” 
• “The link between smoking and everyday activities such as getting up in the morning, 
speaking on the phone, or having a meal will by now be weakening – notice such positive 
developments.” 
• “If you still have difficult moments, do not fall into the trap of thinking that one cigarette will 
not hurt. Even a puff could put you in serious danger of undermining all you have achieved so 
far.” (BS2, BM8) 
• “Try to eat a healthy, balanced diet. This includes plenty of fruit and vegetables, and not too 
much fried and fatty food. Keep a supply of healthy snacks with you. Watch out for high 
calorie, high fat snacks, but do not go hungry.” 
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 Tips for preventing relapse (BS2) 
If you have not smoked at all, or very little, for over four weeks now, you are really getting there. 
Once the regular support is over, here are some tips to prevent you going back to smoking: 
• Think ahead of situations which could be dangerous for you. Boredom? Stress? Getting 
drunk? Wanting to enjoy yourself? Think now how you are going to cope. When the situation 
comes, remember how you prepared for it. 
• Do not think that after being a non-smoker for a few months, one cigarette will not make any 
difference. It will be as dangerous as ever. 
• Even if things are still difficult on occasions, sooner or later, you will lose interest in smoking, 
or even start to dislike the very idea of it. You are very close now to join millions of others 
who have stopped smoking for good. 
 
Some women who quit smoking successfully when pregnant start to smoke again after they give 
birth. Stay on your guard.  
• Passive smoking is harmful for your baby.  
• Quitting smoking is very difficult. You have now done the hard part. It would be a shame 
to spoil it all.  
• Sooner or later you will start thinking of yourself as a non-smoker and the idea of smoking 
will start to look rather strange and less appealing.  
Notes on the support process (this also applies to physical activity counselling) 
Key things to remember: 
• Summarise information the women needs to remember (RC9). 
• Reflective listening: reflecting back to the women what they are saying, particularly the 
emotional content (e.g. I can appreciate that it makes you angry and frustrated to see your 
partner continuing to smoke around the house when you have quit). (RC7) 
• Acknowledge their fantasies about smoking, but explain why they are unrealistic (e.g. Yes, I 
can see that you would love to have the occasional cigarette, but smokers who do this very 
quickly start smoking on a daily basis back to their original levels of smoking). In general, try 
and explore their views on smoking cessation (RC8).  
• Descriptive praise: describe what they are specifically doing well at and praising them for 
this (e.g. you did well to throw all your cigarettes away because I know you partly wanted to 
keep some for an emergency), rather than just using general praise (e.g. you are doing very 
well). (BM4) 
• Preparing for success: Focus on helping the women to plan so that things go right (e.g. 
preparing for triggers to smoking), rather than having to ‘react’ when things go wrong (BS1). 
• Maintaining a positive tone e.g. avoid criticism, use pleasant tone of voice and body 
language, focus on solutions rather than problems, keep your sense of humour! (RC1) 
 
For those familiar with psychological counselling, it is important to note that brief smoking 
cessation support is much more directive and goal-oriented than general counselling approaches.  
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Appendix 3 Therapist manual for delivering the
physical activity intervention
 
  
Physical Activity Intervention Manual  
(refer also to participant’s handbook) 
 
This manual includes guidance on 19 of 40 behaviour change techniques (BCTs) defined in 
the following taxonomy: Michie S, Ashford S, Sniehotta FF, Dombrowski SU, Bishop A, 
French DP (2011) A refined taxonomy of behaviour change techniques to help 
people change their physical activity and healthy eating behaviours: the CALO-RE 
taxonomy. Psychological Health, 2, 1479-98.  
The 19 BCTs covered in this manual are: 1. Provide information on consequences of 
behaviour in general; 2. Provide information on consequences of behaviour to the individual; 
7. Action planning; 8. Barrier identification/problem solving; 9. Set graded tasks; 10. Prompt 
review of behavioural goals; 12. Prompt rewards contingent on effort or progress towards 
behaviour; 13. Provide rewards contingent on successful behaviour; 16. Prompt self-
monitoring of behaviour; 20. Provide information on where and when to perform the 
behaviour; 21. Provide instruction on how to perform the behaviour, 22. Model/Demonstrate 
the behaviour; 23. Teach to use prompts/cues; 26. Prompt practice; 27. Use of follow-up 
prompts; 29. Plan social support/social change; 34. Prompt use of imagery; 35. Relapse 
prevention/coping planning; 38. Time management. 
 
The specific BCTs used are indicated in brackets in the manual below. The version of the 
manual used by therapists did not include these BCT labels. 
 
---------------------------------------------------------------------------------------------------------------------- 
 
Each consultation should take about 20 minutes. 
 
Session 1 (one week before quit date) 
 
●  Review her current PA levels (refer to seven day recall of physical activity). 
●  Explain how to use treadmill (BCT 21: Instruction on how to perform behaviour) 
- Explain warm-up (3mins walking, hold stretches for 10 secs for front thighs, calves, hamstrings 
and reach overhead for upper body) and warm down (slow down for final minute of walking, 
repeat stretches) 
- Recommend rating of perceived exertion of 12-14 and show RPE chart. Explain about ‘Talk 
Test’, and that exercise should be intense enough for her to be breathing heavier than normal  
- Demonstrate use of treadmill (BCT 22: Demonstrate behaviour) 
- Ask women to walk on treadmill for 15-30 mins 
- Agree how long she will walk (it is fine if she exceeds this goal, as long as it is no more than 30 
mins) 
●  Discuss benefits of exercise (BCT 1: Provide information on consequences of behaviour in 
general) 
- Mention that regular exercise has been shown to reduce cravings in a similar way to nicotine 
replacement.  
- Mention that exercise is also good for a healthy pregnancy. Say that there will be more time to 
discuss these benefits at the next session. 
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 ●  Agree PA goals for this week (BCT 7: Action planning) for exercise she will do outside the 
treadmill Sessions: 
- Recommend she starts with at least one session of 15 mins PA.  
- Recommend that she gradually progresses towards 30 mins of PA on 3 to 5 days a week (plus 
treadmill sessions). 
- Agree a SMART goal, e.g. ‘I will walk for 20 mins around the park at lunchtime, on 5 days this 
week’.  
●  Explain how to use pedometer 
- Ask her to wear pedometer for the rest of today and to take it off last thing at night and then to 
open it and record the number of steps in the diary.  
- Each morning, ask her to put pedometer on as soon as she gets up and to wear it all day. Again, 
taking it off last thing at night and recording the number of steps (BCT 26: Prompt practice). Say 
that she can keep the pedometer. 
●  Ask her to complete PA and steps diary for everyday this week (BCT 16: Self-monitoring of 
behaviour). Write her PA goal for this week on the top of the diary. 
 
Session 2 (few days before quit day) 
●  Review goals/plans 
- Check whether she has managed to do any PA in her own time since the last session 
- Briefly review woman's goals for taking PA in her own time for week ahead (BCT 10: review of 
behavioural)  
- Check she has been able to use the pedometer OK and is recording her daily steps. If she is 
averaging less than 10,000 steps a day recommend a 10% increase in her current steps over the 
next two weeks (BCT 7: action planning, BCT 9: set graded tasks). 
●  Go though physical activity booklet with woman 
- Ask her to write down what she sees as the main benefits and disadvantages (if any) of becoming 
more active during her pregnancy and remind her of other benefits (BCT 2: Consequences of 
behaviour to the individual). 
- Testing times: ask her to write down any barriers that might prevent her from achieving her PA 
goal and think of ways of overcoming these barriers (BCT 8: Barrier identification problem 
solving). 
- Go though the tips for exercising in the booklet and praise her for any specific adjustments 
she has made to her lifestyle to encourage exercise (BCT 12: Rewards contingent on effort or 
behaviour). Suggest that she rewards herself when she achieves her exercise goals (e.g. a 
special meal at the end of the week) (BCT 13: Reward contingent on successful behaviour). 
- Demonstrate the home exercises in the booklet and ask her to try each of the level 1 
exercises/stretches with you. (BCT 21: Instruction on how to perform behaviour, BCT 22: 
Demonstrate behaviour). Encourage her to practice the exercises at least once before the next 
meeting (BCT 26: prompt practice). When she is confident with the level 1 exercise, go through 
the Level 2 exercises/stretches at a future session. 
- Provide information on local opportunities for exercise (e.g. walking schemes, antenatal exercise 
classes) (BCT 20: information on where and when to exercise). 
 - Encourage her to exercise at regular times (e.g. a walk after lunch) so that it becomes a habit 
(BCT 23: Teach to use prompts/cues). If she has raised lack of time as a barrier to exercise, 
suggest she manages her time to fit in exercise by timetabling exercise slots into her week (BCT 
38: time management). 
- Suggest she tries to find people who will exercise/walk with her (BCT 29: Plan social support). 
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 ●  Ask woman to walk on treadmill for 15-30 mins 
- If she walked for less than 30 mins at the last session recommend that she walks for 5 mins longer 
this time and at each further session, until she is walking continuously for 30 mins. 
- Agree how long she will walk for. 
- After exercise: Remind woman to complete PA and steps diary every day this week. 
 
Session 3 (quit day) 
●  Briefly review physical activity the women has done in her own time and adjust goals for 
physical activity in general and for pedometer (BCT 10: review of behavioural goals)  
●  Discuss any barriers that might prevent her from achieving her PA goal and think of ways of 
overcoming these barriers (BCT 8: Barrier identification problem solving). 
- Praise her for any specific adjustments she has made to her lifestyle to encourage exercise 
(BCT 12: Rewards contingent on effort or behaviour). Discuss how she is rewarding herself 
when she achieves her exercise goals (BCT 13: Reward contingent on successful behaviour). 
 
●  Set heart-rate zone and ask woman to wear HR monitor while on treadmill: 
HEART RATE TARGETS/(training zone): 
 
 Less active (ie reporting less than 150 mins PA in the last week), overweight      
 (BMI=25 – 29.9) or obese (BMI=30+) women:  
Start with light intensity heart-rate range: 
Aged 16-29:    102 -124 bpm 
30 years plus:   101-120 bpm 
 
Gradually progress to moderate intensity HR range: 
Aged 16 -29:    125 -144 bpm 
30 years plus:   121-144 bpm 
 
Active women (ie reporting at least 150 mins/week):  
Moderate intensity HR range: 
Aged 16-29  145-160 bpm 
Aged 30 plus 140-156 bpm 
 
●  Ask woman to walk on treadmill for 15-30 mins 
●  Ask woman to check that she keeps her heart rate in the training zone, and ask her to maintain 
her walking at a level where she is still able to hold a conversation 
●  Give exercise diary and ask her to fill it in each day this week. 
 
 
Consultation Session 4 (one week after quit day) onwards 
●  Review physical activity the women has done in her own time: 
    - Discuss barriers that may prevent her maintaining and increasing her physical activity and how 
she might deal with these (BCT 35: relapse prevention/planning) 
    - Agree plans for PA for the coming week: 
    - Refer back to physical activity booklet if necessary 
●  Praise her for any specific adjustments she has made to her lifestyle to encourage exercise 
(BCT 12: Rewards contingent on effort or behaviour). Discuss how she is rewarding herself 
when she achieves her exercise goals (BCT 13: Reward contingent on successful behaviour). 
●  Review whether she has found people who will exercise/walk with her. 
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 ●  Review exercises in booklet. 
●  Ask woman to walk on treadmill for 15-30 mins 
●  Ask her to imagine herself becoming fitter and healthier and to imagine herself walking briskly 
with energy and with lungs free of tobacco (BCT 34: use of imagery) 
●  Remind her that for the last two weeks of the exercise programme you will see her once a week 
rather than twice a week (BCT 27: use of follow-up prompts).  
 
Notes on the support process  
Key things to remember: 
• Summarise information the women needs to remember  
• Reflective listening: reflecting back to the women what they are saying, particularly the 
emotional content (e.g. I can appreciate that it is very difficult to find the time to exercise).  
• Descriptive praise: describe what they are specifically doing well at and praising them for 
this (e.g. you did well to buy some new trainers; this shows that you are serious about taking 
more physical activity), rather than just using general praise (e.g. you are doing very well).  
• Preparing for success: Focus on helping the women to plan so that things go right (e.g. 
preparing for when it rains), rather than having to ‘react’. 
• Maintaining a positive tone e.g. avoid criticism, use pleasant tone of voice and body 
language, focus on solutions rather than problems, keep your sense of humour!  
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Appendix 4 Participant physical activity booklet
 
                   
                 
     
Guide to physical activity 
during your pregnancy 
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            BENEFITS 
Regular physical activity during your pregnancy has many benefits for 
you and your baby; such as: 
Less varicose veins, leg cramps and swelling of the legs 
Better posture, balance and muscle tone  
Reduced constipation and back ache 
Easier and shorter labour, in many women 
Better mood, sleep and energy 
Less tobacco withdrawal symptoms (such as feeling irritable) 
and cravings, and an increased chance of becoming a non-
smoker 
 
Write down what you feel are the main benefits and 
disadvantages for you of becoming more active during your 
pregnancy:  
           BENEFITS                  DISADVANTAGES 
 
 
 
 
 
 
 
 
Can you think of any way of overcoming the disadvantages?  
If you think of any more benefits add them to the list. 
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 Set a realistic goal each week for how much activity 
you can manage each day  
    MY GOAL:  
Aim to gradually build up to 30 minutes of activity 
each day.  
 
TESTING TIMES 
Write down anything that might stop you from 
achieving this goal 
Try and think of what you can do when this happens 
                    
 
Why I might miss a day’s exercise What I can do when this happens 
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          SOME TIPS 
 
1.  Don’t smoke, walk! 
When you feel a strong craving for a cigarette try going for a brisk walk,  
even if it is only for 5 minutes. Soon you will start feeling like a non-
smoker. 
 
2.  Make it Fun 
● Choose activities which you enjoy, and which fit easily into your day. Try 
walking   part of the way to or from work or the shops. How about 
swimming  
or following your home exercise routine? 
● Play music while you’re exercising. 
● Involve friends or family.  
 
3.  Do it every day  
● Gradually increase the number of days on which you are active.  
● Then increase the time you are active for each day.  
● Gradually build up to 30 minutes of physical activity each day. 
 
4.  Make it a habit 
● Exercise at the same times each day, so that it becomes a habit. 
● Try starting the day with a few gentle exercises or going for a walk.  
 
5. Take it easy 
●  Choose activities that make you breathe slightly harder than normal,  
but are not hard enough to stop you having a conversation.  
● Do just a little more (10-20 minutes extra) each week.   
● Give your body time to adjust to being pregnant and to being without 
cigarettes. 
 
6.  Reward yourself 
● Each extra day that you are a non-smoker and have reached your  
exercise goal give yourself a treat.  
● Give yourself an extra treat at the end of each week; something like a  
special meal. 
 
7.  Plan ahead 
Plan ahead for interruptions such as bad weather - an ideal opportunity  
to try your home exercise routine! 
 
8.  Keep a diary 
Keep a daily record of how many minutes exercise you do and how many  
steps you do. It will help you to see your progress. 
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LOOK AFTER YOURSELF!  
 
1. When to avoid exercise 
●  If you feel unwell, extremely tired or have just eaten a 
meal. 
●  In very hot or very humid conditions. 
 
2. When to stop exercising 
Stop exercising immediately if you feel any dizziness, nausea, 
severe pain or tiredness, extreme breathlessness or cold 
sweats. 
  
3. Breathe Freely 
●  Keep breathing freely whilst you are exercising. 
●  To ease breathing: stop and lift your arms up and out. 
 
4. Drink plenty of water Before, during and after exercise. 
 
5. Have a healthy snack soon after exercising, such as a 
banana. 
 
6.  Avoid exercising on your back. 
●  During the middle and later stages of your pregnancy 
exercising on your back can cause discomfort.  
●  It may also reduce your blood pressure for a short time. 
 
7.  Pace yourself 
Start slowly and gradually work up to a pace where you 
are breathing slightly heavier than normal, but not 
gasping for breath.    
DOI: 10.3310/hta19840 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 84
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ussher et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
79
 HOME EXERCISE PROGRAMME  
1. Build up gradually 
 For each exercise aim for a number of repetitions which 
you can handle comfortably 
 Aim to gradually build up the number of repetitions you 
do, until you can do 20 or  more  
 If you want to exercise for longer you can gradually build 
up to two or more complete circuits of all the exercises 
2. Taking breaks 
 At first you may made need a short break between 
exercises 
 Gradually reduce the length of the breaks, so that 
eventually you do the exercises continuously 
3. To avoid aggravation or injury: 
Start slowly. Give your body time to warm-up 
Avoid locking your knees when you are standing 
Keep good posture, with a straight back.  
Finish by doing some stretches. 
4. Moving up a level 
Start with the exercises at level 1. When you are 
comfortable with level 1 move on to level 2.  
 
If you exercise at home, as opposed to in a class, you 
can choose when, how and at what pace you exercise! 
Alternatively, you may prefer to exercise in a class, in 
which case you should inform the teacher that you are 
pregnant. 
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 LEVEL 1 EXERCISES  
• Try starting with 5 repetitions of each exercise. Over 
several weeks, 
     gradually build to 20 repetitions 
• Do at least 10 minutes of exercise by going through all 
the exercises several times 
 
                            
1. Side arm raise          2. Raise on toes           3. Side leg raise 
 
                                                            
4.  Front arm raise      5. Knee raise            6.  Wall-push up                         
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LEVEL 1 STRETCHES 
• Stretch regularly to help you feel loose and relaxed. Stretching 
also will help you with your posture and balance during 
pregnancy 
• Stretch when you are warm, after you have done your other 
exercises 
• Hold the stretch so that you feel a pleasant stretch, do not force 
the stretch. Avoid any bouncing movements. 
 
                                                 
    1. Pull heel to buttock.  2. Lean over straight leg  
        (for front of thigh)                      (for back of thigh)  
    
         
                                          
3. Reach arms overhead.                            4. Lean on wall,      
    (for arms and sides of body)                            straighten back leg.                
                                                                         (for calves) 
 
               Hold each stretch for 10 seconds 
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LEVEL 2 EXERCISES 
 
Here are some slightly harder exercises for you to 
gradually build in 
 
 
                                        
1. Side arm raise         2. Backwards arm circle          3. Leg circle 
    + toe raise                      + leg bend                          
                                                         
                                                                             
   4. Front arm raise + knee raise            5. Overhead-arm reach + leg bend 
 
 
 
 
                                                                                              
                                                    6. Push-up on chair                                        
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LEVEL 2 STRETCHES 
 
 
Here are some extra stretches 
     
1. Pull arms forward    2. Pull arms back      3. Bend to side 
    (upper back &                (chest & shoulders) (waist) 
     shoulders)      
 
                                      
 
                                                                         
            Hold each stretch for 10 seconds 
5. Press down on    
inner thighs                                    
    (inner thighs)                
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Appendix 5 Physical activity questionnaire
Instructions for carrying out the 7-day physical activity
recall interview
1. Label the days on the recall table (day 1 is yesterday).
2. Introduce interview: Explain that you will be asking about their physical activity, starting with yesterday
and working backwards through the previous 7 days.
3. Define segments of the day: Say that you will be asking separately about activities for the morning,
afternoon and evening.
4. Describe the type of activity that you are interested in: Explain that you are interested in any work,
household or leisure activities lasting at least 10 minutes that are at least at a level of intensity that
makes them breathe slightly harder than normal, makes them warmer and makes them aware that
their heart is beating faster. Say that you are not interested in light activities such as desk work, strolling
or light housework.
5. Ask about activities: For each segment of the day, ask the woman to recall activity episodes lasting at
least 10 minutes and record the information in the table (round to the nearest 5 minutes). For each
activity record the type of activity (using type codes) and duration of activity in minutes (e.g. ‘W 10’
denotes a 10-minute walk). For each day begin by asking ‘What did you do and where did you go on
that morning’.
6. Record the number of minutes of activity for each day and the total minutes for the week. Enter the
latter figure into the database.
TABLE 22 Seven-day recall of physical activity
Day Morning Afternoon Evening Daily minutes of activity
1 (yesterday)
2
3
4
5
6
7
Weekly total:
Cyc, cycling; D, dancing; DIY, do it yourself; Exf, structured exercise facility; Exh, structured home exercise; G, gardening;
H, housework; Occ, occupational; Spi, sport/individual; Spt, sport team; Sw, swimming; W, walk; O, other (please state).
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Appendix 6 Questionnaires
A ll questionnaires were presented on an online server.
Baseline questionnaire
 
Participant enrolment details 
ID No:  
 Briefly describe the study and intervention and check volunteer’s understanding:  
 If they are still willing to participate ask them to sign the consent form and request a 
randomisation code: 
 
 
 Participant's date of birth:  
 Participant's initials: 
 
 Ethnicity   (see below) 
 
 NHS number: 
 
 Hospital no: 
 
 Expected date of delivery:      /       / 
 Midwife's name: 
 
 Midwife's telephone numbers: Work 
Mobile  
 Name and role of person giving 
intervention at enrolment:  
 If research midwife, are you case 
loading the participant? 
Yes/no 
 Please enter the visit date:      /       / 
 
How would you describe your ethnic group? 
(Please check one box only) 
 
British 1  White & Black Caribbean 4  Indian  8  
Irish 2  White and Black African 
Other 3  White & Asian 
Other Mixed  
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Black or Black British               Chinese or Other Ethnic Group 
Black Caribbean 12  
Black African 13  
Other Black 14  
Before you became pregnant how many  
cigarettes did you usually smoke each day?    
How many cigarettes do you usually smoke  
each day now?     
Did you smoke in a previous pregnancy? Yes  1        No   0         Not applicable  2           
How soon after you wake up do you smoke  
your first cigarette?  
 
Within 5 minutes    3     
6-30 minutes     2      
31-60 minutes     1 
After 60 minutes    0 
Do you smoke more frequently during the first  
hours after waking than during the rest of the day?   
Yes    1      No    0 
Do you find it difficult to refrain from smoking in  
places where it is forbidden? 
Yes    1      No    0 
Which cigarette would you hate to give up the most?   
The first one in the morning  1 Any other  0 
 
Do you smoke even  if you are so ill that you are in 
bed most of the day? 
Yes    1      No    0 
If you have a partner, does your partner  
smoke tobacco? 
Yes  1        No   0         Not applicable  2           
Confidence for quitting  
How high would you rate your chances of giving up smoking, at least until your baby is born?  
      Very low            Low       Not very high        Quite high       Very high    Extremely high 
           1              2               3               4            5             6 
Withdrawal symptoms questionnaire  
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 Please show for each of the items below how you have been feeling over the past week. 
        Not at all         Slightly      Somewhat            Very      Extremely 
Restless              1             2            3              4             5 
Irritable              1             2            3              4             5 
Depressed              1             2            3              4             5 
Hungry              1             2            3              4             5 
Poor concentration              1             2            3              4             5 
Poor sleep at night              1             2            3              4             5 
Anxious              1             2            3              4             5 
 
Urges to smoke 
How much of the time have you felt the urge to smoke in the past week? 
        All the 
          time 
     Almost all       
       the time         
      A lot of 
      the time          
   Some of the     
          time            
    A little of  
       the time  
     Not at all 
             5              4             3              2              1              0 
 
How strong have the urges been? 
      Extremely      
         strong 
          Very 
        strong 
        Strong       Moderate          Slight        No urges 
             5              4             3              2              1              0 
 
Pregnancy history and demographics  
How old are you?   years 
How many weeks pregnant  
are you?  weeks 
How many previous pregnancies have you  
had that have gone beyond 24 weeks?     
How many births have you had that were  
between 24 and 37 weeks of pregnancy?     
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How many children are in your household?     
Of these how many are you the biological 
 mother of? 
Are you the biological mother of children 
 in any other household? 
Yes    1      No    0 
 If yes, how many? 
 
Are you…. 
Married or Living with a partner      1
Single/divorced/separated/widowed 0 
How old were you when you left full time  
education?    or tick if still in FT education 
What is your usual occupation?  
    No usual occupation 
 
Use of Alcohol 
How often do you currently have a drink containing alcohol? 
     Never 
Monthly 
or less 
2-4 times a 
month 
     2-3 times 
     a week                 
    4 or more times 
    a week  
 
How many drinks containing alcohol do you have on a typical day when you are drinking? (a drink is 
equivalent to a glass of wine, 1 spirit, or half pint beer) 
 
    1 or 2 3 or 4  5 or 6      7 to 9                     10 or more  
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Feelings questionnaire (EPDS) 
 
1. I have been able to laugh and see the funny side of things. 
 I have looked forward with enjoyment to things.
I have blamed myself unnecessarily when things went wrong. 
4. I have been anxious or worried for no good reason.
have felt scared or panicky for no very good reason. 
Things have been getting on top of me. 
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 I have been so unhappy that I have had difficulty sleeping. 
I have felt sad or miserable. 
I have been so unhappy that I have been crying. 
The thought of harming myself has occurred to me 
Physical activity, height, weight and CO reading  
How confident are you that you will be able to do thirty minutes of physical activity (e.g. take a regular walk)  
on at least 5 days of the week during your pregnancy? 
 Not at all confident   Slightly confident Moderately confident    Very confident  Extremely confident 
             1             2 3               4               5 
 
What effect do you think being physically active (e.g. a brisk walk) will have on your success at quitting? 
 
Large  
negative effect 
Moderate  
negative effect 
Slight  
negative effect  
No effect  
Slight positive  
effect 
 
Moderate  
positive effect  
Large  
positive effect  
         -3           -2            -1          0             +1          +2            +3 
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Maternal height (cm)   
Maternal weight (kg) as measured at booking appointment or tick if unknown  
Maternal weight (kg) as measured at this visit    
 
Exhaled Carbon Monoxide (CO) reading  ppm 
 
Have you conducted an interview of seven day recall of physical activity?  
    tick 
Record total number of minutes of physical activity in the previous week  minutes 
 
Record the main type of physical activity (check one box only): 
 
 Walk 
 Structured home exercise 
 Structured exercise at a facility 
 Housework  
 Swimming 
 Do it yourself 
 Cycling 
 Gardening 
 Dancing  
 Sport/individual 
 Sport Team 
 Occupational 
 Other  
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Smoking quit date, exercise and smoking desire  
Treatment session start time: hh:mm  
Inform the participant that they have been allocated to the physical 
activity group and briefly remind them what this will entail  
Agree  a quit date 
 
Give leaflet about smoking cessation. 
 
Advise patient to identify situations when they are most likely 
to smoke, and to think of how they are going to address them. 
 
Physical activity group only:  
Explain how to use treadmill, recommend a Rating of Perceived 
Exertion (RPE) of 12-14 and explain the talk test: 
 
Agree a target for the number of  minutes of treadmill walking 
for this session. 
 
Ask woman to exercise on treadmill for between  
15-30 minutes 
 
Immediately before exercise (for those in the control group this was asked immediately  
before the behavioural support): 
How strong is your desire to smoke right now? 
Not at 
All strong 
  Somewhat 
strong 
  Extremely 
strong 
          1           2          3          4             5            6           7 
 
Record time walking on treadmill  minutes 
 
 
 
 
 
 
 
Immediately after exercise ask: (for those in the control group this was asked immediately 
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after the behavioural support): 
How strong is your desire to smoke right now? 
Not at 
All strong 
  Somewhat 
strong 
  Extremely 
strong 
          1           2          3          4             5            6           7 
Discuss: benefits of exercise & barriers, aim to progress towards a target  
of at least 30 minutes a day or 10, 000 steps, how to use pedometer  
 
 
Give patient activity diary (including steps diary), ask them to fill it in  
each day this week, and to bring it to the next session.  
 
 
Book further appointments and give appointment card 
 
Give £7 travel expenses and ask them to sign for it 
 
 
Treatment session end time: hh:mm  
 Length of treatment session  minutes 
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Additional questions asked post quit day only
 
Have you smoked at all since your quit day?  
1. No not even a puff 2. Yes just a few puffs 
3. Yes between 1 and 5 
 cigarettes 
4.  Yes more than 5  
cigarettes 
If you have smoked more than  5 cigarettes and have 
returned to smoking on a daily basis, how many 
cigarettes are you currently smoking each day?         
   
 
Have you used any Nicotine Replacement Therapy (NRT) 
this week?                       
YES / NO 
Which type of NRT have you mainly used? 
 
 Not Applicable 
 Patch 
 Gum 
 Inhalator 
 Lozenge 
 Tablets 
 Nasal Spray 
How many days approximately have you used NRT in the past week?  
      N/A    1 day       2 days        3 days       4 days   5 days      6 days 
 
End of pregnancy behavioural support question: 
Besides the help we have given you, have you received any face-to-face support for stop smoking 
during your pregnancy? Yes/no 
If yes, approximately how many sessions have you attended? 
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Antenatal complications and birth out comes
Woman’s age at delivery               years 
Number of Births 
Has there been multiple births (e.g. twins or triplets)? 
 
Yes/ No 
If yes, please state the number of births/infants: 
 
 
Maternal death: Yes/ No 
If yes, please state date of death:  
       dd-mmm-yyyy  
 
 
Antenatal complications  
Gestational hypertension/Pregnancy    
induced hypertension (PIH): 
 
 
   Yes/ No 
Pre-eclampsia (PET):    Yes/ No 
Intrauterine growth restriction (IUGR):    Yes/ No 
 Details of IUGR: 
 Date of diagnosis 
 
       dd-mmm-yyyy  
 
 
Baby 1 (scan @ 20 weeks) 
 Abdominal circumference: mm  
 Head circumference: mm  
 Femur length: mm  
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Baby 2 (scan @ 20 weeks) 
 Abdominal circumference: mm  
 Head circumference: mm  
 Femur length: mm  
  
Baby 3 (scan @ 20 weeks) 
 Abdominal circumference: mm  
 Head circumference: mm  
 Femur length: mm  
 
 
 
● Antepartum haemorrhage (APH) requiring hospital admission      Yes            No 
Incident 
No. 
Date 
 
(dd/mmm/yy
yy) 
        Gestation 
 
Weeks         Days 
Duratio
n 
 
(Days) 
Amount * Cause of 
APH** 
1       
2       
3       
4       
 
 
 
 
 
 
 
 
 
** Options for CAUSE of 
APH:  
-Unknown 
-Placenta Praevia 
* Options for 
AMOUNT: 
-Spotting 
-Light 
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● Urinary tract infection (UTI) in pregnancy   Yes                      No    
                                                                If yes (UTI), how many?  
 
● Other infection in pregnancy    Yes                No  
 
 
● Oligohydramnios            Yes                No 
 
 
● Polyhydramnios              Yes                No 
 
 
● Congenital malformation           Yes                No 
        If yes, give type of malformation:   
 
● Premature rupture of membranes (PROM)?    Yes                   No 
 
● Prelabour rupture of membranes?     Yes                  No 
 
● Number of antenatal day unit (ADU) attendances    
 
Reason(s) for antenatal attendance (tick all that apply): 
Abdominal pain Growth scan Severe headaches 
Itching Reduced fetal movement 
Vaginal (PV) bleeding not 
req. admission 
Fainting/dizziness 
Spontaneous rupture of the 
membranes (SROM) 
Chest pain/shortness of 
breath 
Intramuscular 
(I/M) iron 
administration 
Generally unwell Obstetric cholestasis (OC) 
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External cephalic 
version (ECV) 
Urinary tract infection (UTI) Anti-D administered 
PET screen Scoliosis 
Symphysis pubis 
dysfunction (pelvic girdle 
problems) 
Cardiotocography 
(CTG) 
Membrane sweep  
Other reasons:  
 
 
 
 
● Hospital admissions overnight for women to antenatal ward:         nights 
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Birth outcome data  
Labour 
● Onset of labour: 
- Spontaneous  
- Induced 
- Augmented 
- No labour – Elective c/s (caesarean) 
- No labour – Emergency c/s 
 
● Pain relief: (tick all that were taken) 
- Water 
- Tens 
- Entonox (Gas & air) 
- Opiate 
- Epidural 
- Spinal 
- General anaesthetic (GA) 
- General anaesthetic (GA) following failed epidural/spinal 
- Combined spinal-epidural (CSE) 
 
● Mode of delivery: 
- Spontaneous vaginal delivery (SVD) 
- Assisted vaginal breech 
- Ventouse 
- Forceps 
- Elective c/s (caesarean) 
- Emergency c/s  
- Semi-elective c/s (i.e. elective brought forward as an emergency) 
 
1 .              
 
2.                
 
3.                
● Reason for c/s:  
- Not applicable 
- Not available 
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 - Previous c/s 
- Failed induction of labour (IOL) 
- Fetal distress 
- Failure to progress 
- Placenta praevia 
- Antepartum haemorrhage (APH)  
- Failed instrumental 
- Poor obstetric history 
- Failed external cephalic version (ECV) 
- Macrosomia 
- Pre-eclampsia (PET) 
- Obstetric cholestasis (OC) 
- Multiple pregnancies 
- Abdominal Cerclage 
- Breech 
- Fetal abnormality 
- Previous 3rd or 4th degree tear 
- Placental abruption 
- Unstable lie 
- Maternal medical condition 
- Maternal request/tocophobia 
- Suspected scar dehiscence 
- Uterine rupture 
- Cervical fibroid covering internal os 
- Previous gynae. surgery 
- Cord prolapse 
- Severe symphysis pubis dysfunction (pelvic girdle problems) 
- History of back injuries 
- Orthopaedic complication restricting induction 
- Cephalopelvic disproportion 
 
 
● Duration of 1st stage of labour           minutes 
 
● Duration of 2nd stage of labour          minutes 
 
● Duration of 3rd stage of labour           minutes 
         
APPENDIX 6
NIHR Journals Library www.journalslibrary.nihr.ac.uk
102
● Total duration of labour                hours           minutes 
   
Duration of ruptured membranes: 
 
 
 weeks 
 
 days 
 
 hours  
 
 
 
● Blood loss at delivery              mls               estimated               measured               both 
 
 
Outcomes for infant 
 
If birth did not take place: 
 
● Maternal death              Yes                     date  
 
          dd-mm-yyyy  
● Fetal outcome: 
- Alive      Baby 1. 
- Fetal death In utero <24 weeks  Baby  2. 
- Fetal death In utero >24 weeks  Baby  3. 
- Intrapartum death (i.e. at delivery)  
- Neonatal death 
 
 
● Date of delivery of baby      (dd/mm/yyyy) 
 
● Time of delivery of baby                    (hh:mm) 
  
● Gestational age at delivery         +       (weeks + days) 
 
● Age of mother at delivery     (years) 
    : 
DOI: 10.3310/hta19840 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 84
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ussher et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
103
● Number of fetuses  
 
● Baby(ies) sex     
 
1. Male  
    Female 
 
2. Male  
    Female 
 
3. Male  
    Female 
 
● Baby(ies) birth weight  
 
1 .              grammes 
 
2.               grammes 
 
3.               grammes 
 
 
 
● Customised birth weight centile   
(to be calculated using desktop programme)   
1 .         
 
2.            
 
3.          
 
 
● Placental weight                grammes          Unknown  
 
 
● Baby(ies) head circumference     1.       mm     2.   mm    3.        mm        
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 ● Baby(ies) length                         1.       mm     2.    mm    3.       mm         
 
 
●  1 minute Apgar score  1.        2.            3.                  
 
 
●  5 minute Apgar score  1.            2.           3.             
 
● Resuscitation: 
1. Yes                   No 
 
2. Yes                   No 
 
3. Yes                   No 
 
● Baby(ies) cord pH - arterial:   
 
1. 
 
2.   
 
(Record information for twins, but cord pH not recorded for multiple births.) 
 
● Baby(ies) cord pH - venous:   
 
1. 
 
2.   
 
 
● Admission to neonatal intensive care unit (NICU)/special care baby unit (SCBU) 
 
   Yes                   No 
 
● Hospital admissions overnight for women to postnatal ward           nights  
                 
● Total nights admitted to hospital         nights 
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(calculated by totalling antenatal nights (see page 3.) and postnatal nights in hospital) 
 
● Feeding at hospital discharge: 
Infant 1 
- Exclusively breastfed  
- Mixed feeding  
- Exclusively infant formula  
 
Infant 2 
Exclusively breastfed  
- Mixed feeding  
- Exclusively infant formula 
 
Infant 3 
Exclusively breastfed  
- Mixed feeding  
- Exclusively infant formula  
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Appendix 7 Statistical analysis plan
APPENDIX 7: STATISTICAL ANALYSIS PLAN  
Version no. 1.0 
Date: 7th November 2012  
Full trial title: A pragmatic randomised controlled trial of physical activity as an aid to 
smoking cessation during pregnancy 
Acronym: London Exercise And Pregnant smokers (SNAP) trial 
International Standardised Randomised Controlled trial Number: ISRCTN48600346  
Trial sponsor: St George’s University of London 
Chief investigator:  Professor Michael Ussher                                              
Analysis Plan prepared by: Professor Michael Ussher, Professor Sarah Lewis,  
Nominated statisticians for analysis: Professor Sarah Lewis, Professor Michael Ussher, 
Muhammad Riaz 
 
Projected start date: 1st April 2009 
Recruitment to be completed: end of Nov 2012 
Expected completion date: July 2013 (primary endpoints)  
 
Published Trial protocol:  Ussher et al (2012) Physical activity as an aid to smoking 
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1. SYNOPSIS OF STUDY DESIGN AND PROCEDURES 
1.1 Objectives and aims  
The LEAP trial will investigate whether or not a physical activity intervention plus 
behavioural support is more effective than behavioural support alone (control) in achieving 
smoking cessation at ‘end of pregnancy’ for women who are between 10 and 24 weeks 
pregnant, who currently smoke 1 or more cigarettes daily and who smoked 5 or more 
cigarettes daily before pregnancy. We will also determine the cost-effectiveness of the 
intervention.  
1.2 Trial configuration: Multicentre, parallel group with 1:1 allocation between physical 
activity and control. 
1.3 Randomisation procedures 
1.3.1 Points of randomisation and the baseline visit  
After confirming eligibility, informed consent for trial entry is sought.  After consenting to 
trial entry, women are randomised.  Randomisation is via the Nottingham Trials Unit web-
based database and randomisation service.  In each centre the recruiting research midwife 
(RM) has a username and password.  She logs on to the trial website that hosts the trial 
database confirms that the patient eligibility criteria are all met and enters registration data 
about the participant and centre before randomisation is possible. The computer then issues a 
trial number, which is a unique identifier for the trial participant, and a treatment allocation 
code.  
1.3.2 Specify block size, whether randomly varied 
Random permuted blocks of randomly varying size. 
1.3.3 Stratified allocation, or post-stratified analysis 
Randomisation is stratified by trial centre only.  
1.4 Allocation concealment:  
As this is a behavioural intervention, there is no allocation concealment for participants or 
researchers. 
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1.5 Stopping rules determined as part of the protocol 
Stopping rules have not been specified. 
 
1.6 Outcomes 
1.6.1 Primary outcome 
The primary outcome is self-reported, continuous abstinence from smoking between the quit 
date and end of pregnancy, validated by exhaled carbon monoxide (CO) or salivary cotinine.  
Continuous abstinence is defined as having smoked less than 5 cigarettes since the quit day. 
Exhaled CO: The criteria for confirming abstinence is a reading of <8ppm. 
Salivary cotinine: The criteria for confirming abstinence is a value of <10ng/ml. 
End of pregnancy: It is acceptable for this measure to be taken at a follow-up up to 4 weeks 
before birth, at delivery, or within 10 weeks after the birth.  
 
The primary outcome is dichotomous; i.e. abstinent or non-abstinent. 
For a participant to be classed as abstinent from smoking at end of pregnancy (i.e. 
positive primary outcome): 
At 4 weeks post-quit (It is acceptable for this measure to be taken between 25 days to 6 
weeks post-quit): a 
Have you smoked at all since your quit day?= ‘No not even a puff’ or ‘yes just a few puffs’ 
or ‘Yes, between 1 and five cigarettes’ or ‘missing’ a (i.e. any response other than ‘yes, more 
than 5 cigarettes’) 
AND           CO is <8ppm 
AND/OR    cotinine is <10ng/ml 
            OR    CO or cotinine is missingb 
 AND 
DOI: 10.3310/hta19840 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 84
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ussher et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
109
At end of pregnancy: 
Have you smoked at all since your quit day?= ‘No not even a puff’ or ‘yes just a few puffs’ 
or ‘Yes, between 1 and five cigarettes’ (i.e. any response other than ‘5 or more cigarettes’) 
AND           CO is <8ppmb 
AND           cotinine is <10ng/mlc               
For a participant to be classed as non-abstinent from smoking at end of pregnancy (i.e. 
negative primary outcome): 
At 4 weeks or end of pregnancy: 
- Have you smoked at all since your quit day?= ‘yes, more than 5 cigarettes’ 
- CO or salivary cotinine values do not confirm abstinence. 
- Has withdrawn from the study (i.e. refuses follow-up). 
- Fails to set a quit date which the follow-up assessment can be referenced against.  
At end of pregnancy: 
- Refuses to allow biochemical validation 
- Refuses to self-report number of cigarettes smoked. 
- Unable to contact in order to confirm smoking status (i.e. lost to follow-up).  
------------------------------------- 
aSome women will not have data for self-report of smoking or biochemical validation at 4 
weeks. If these women are confirmed as abstinent at end of pregnancy it will be considered as 
a positive primary outcome. All those classed as abstinent at end of pregnancy will 
automatically be classed as abstinent at 4 weeks post-quit. 
bSome participants will only have CO or cotinine and, for these women, a reading in the 
stated range is defined as a positive primary outcome (even without the reading for the other 
biochemical measure). Most participants will have both CO and cotinine and, for these 
women, BOTH readings must fall within the defined ranges to count as a positive outcome.  
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cIf a new normative value becomes available during the trial this will be used. 
------------------------------------- 
 
1.6.2 Secondary outcomes 
Included in paper reporting primary outcomes: 
a) Smoking abstinence 
Self-reported, continuous abstinence from smoking (up to 5 cigarettes allowed) between quit 
date and 4 weeks, with biochemical validation (to compare success rates with NHS 
standards). 
b) Physical activity 
1. Self-reports of physical activity levels at 1, 4 and 6 weeks after the quit date and at end of 
pregnancy. Also, at each time point, the numbers reporting walking as the main physical 
activity. 
2. Record of duration of time on treadmill, during supervised exercise. 
3. Accelerometer record (Actigraph) of minutes of at least moderate intensity physical 
activity, during the first week after the quit date. This data is only for 10% of participants. 
4. Among those in the exercise group, record of pedometer steps (among those choosing to 
wear a pedometer at 1, 2, 3, 4, 5 and 6 weeks after the quit date. 
c) Aids to smoking cessation 
1. Use of nicotine replacement  
2. Use of behavioural support other than that provided in the trial 
Included in other papers: 
a) Smoking abstinence 
1. Self-reported, continuous abstinence from smoking (up to 5 cigarettes allowed) between 
quit date and 6 months after delivery (no biochemical validation). 
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2. Among those women who relapse, levels of smoking reduction between baseline and end 
of pregnancy. 
3. Lapse free smoking abstinence between quit date and 4 weeks and end of pregnancy (both 
biochemically validated) and between quit date and six months (without validation). 
b) Physical activity 
Self-reports of physical activity levels at six months after the birth 
 
c) Psychological outcomes 
1. Weekly urges to smoke at baseline and 1, 2, 3 and four weeks after the quit day. 
2. Daily urges to smoke on each day in the first week following the quit day. 
3. Desire to smoke before and after supervised exercise weekly up to 4 weeks after the quit 
day. 
4. In control group only: Desire to smoke before and after smoking cessation counselling 
weekly up to 4 weeks after the quit day. 
5. Tobacco withdrawal symptoms at baseline and 1 and 4 weeks after the quit day. 
6.  Self-confidence in stopping smoking at baseline, 1 and 4 weeks after the quit day, end of 
pregnancy and 6 months after the birth. 
7. Self-confidence for maintaining regular physical activity at baseline, 1 and 4 weeks after 
the quit day, end of pregnancy and 6 months after the birth. 
8. Self-reported depression at end of pregnancy and 6 months after the birth. 
 
d) Maternal weight 
Maternal gestational weight at baseline, 4 weeks after the quit day and end of pregnancy. 
(Some of the end of pregnancy measures may be up to 10 weeks after the birth). 
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e) Fetal loss and morbidity and other fetal and birth outcomes 
The following perinatal measures are extracted from patient’s hospital records: (i) antenatal 
complications, including any admissions and the reasons for the admissions, (ii) gestation at 
onset/induction of labour (and indication for induction where appropriate), (iii) duration of 
labour and mode of delivery, (iv) Apgar scores of infants, and where available acid-base 
status of infants, and rates of transfer to the neonatal intensive care unit, (v) birth weight and 
placental weight.  
1. Miscarriage (non-live birth prior to 24 weeks gestation) and stillbirth (non-live birth at 24 
weeks gestation or later) 
2. Intrapartum death (i.e. at delivery) 
3. Neonatal death (i.e. from live birth to 28 days) 
4. Intrauterine growth restriction (IUGR) 
5. At 20 week scan, abdominal circumference, head circumference, femur length 
6. Oligohydramnios  (deficiency of amniotic fluid) 
7. Polyhydramnios (excess of amniotic fluid) 
8. Congenital malformation (and type of malformation) 
9. Individualized birth weight Z score (i.e. birth weight adjust for gestational age, maternal 
height, maternal weight at booking and ethnic group). 
10. Unadjusted birth weight and birth weight as Z-score 
11. Apgar score 
12. Cord blood pH 
13. Gestational age at birth 
14. Intraventricular haemorrhage 
15. Neonatal enterocolitis 
16. Neonatal convulsions 
17. Congenital abnormality  
18. Neonatal intensive care unit (NICU) admission  
19. Infant ventilated > 24 hrs 
20. Elective termination  
21. Elective termination undertaken for fetal morbidity judged incompatible with fetal / infant 
survival 
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f)  Maternal morbidity and mortality and other maternal outcomes 
1. Maternal mortality 
2. Gestational hypertension/Pregnancy induced hypertension (PIH) 
3. Pre-eclampsia (PET): 
4. Antepartum haemorrhage (APH) requiring hospital admission 
5. Urinary tract infection (UTI) in pregnancy (and number of infections) 
6. Pre-labour rupture of membranes at pre-term (i.e. before 37 weeks) (PPROM) 
7.  Pre-labour rupture of membranes at term (i.e. 37 weeks onwards) (PROM) 
8. Number of antenatal day unit (ADU) attendances 
9. Hospital admissions overnight for women to antenatal ward: 
10.  Reason/s for antenatal attendance 
11.  Other antenatal complications 
12.  Onset of labour (e.g. induced) 
13.  Pain relief 
14.  Mode of delivery  
15.  If caesarean section, reason for CS 
16.  Duration of three stages of labour and total duration of labour 
17.  Duration of ruptured membranes 
18.  Blood loss at delivery 
19.  Proteinuria 
 
g)  Health economic data  
1.  Duration of maternal hospital admission for childbirth 
2.  Duration of any admission (of baby) to special care 
 
1.7 Determination of Sample Size  
A Cochrane review suggests that approximately 9% of women who are still smoking at the 
time of their first antenatal visit will stop smoking with usual care through to the end of their 
pregnancy, and a further 6% will stop as a result of a smoking cessation programme using 
individual behavioural support. Thus, in our control group we expect a smoking cessation 
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rate of around 15% at the end of pregnancy. Combining our pilot studies 25% (8/32) of 
participants in the treatment group sustained continuous smoking abstinence to the end of 
pregnancy. Therefore in the trial we conservatively estimate an abstinence rate of 23% at end 
of pregnancy in the treatment group, which would be similar to the effect shown for NRT 
with non-pregnant smokers [14]. We aim to recruit 433 women to each arm to detect the 
above absolute difference (8%) in smoking cessation rates between the groups at end of 
pregnancy with a two-sided significance level of 5% and a power of 83%. This calculation is 
based on a chi-squared test with Yate’s correction. 
1.8 Protocol amendments that have statistical implications should be described. 
For the follow-up at end of pregnancy the valid period for assessment was originally 
defined as 38 weeks gestation to two weeks after the birth. This was revised to 36 weeks 
gestation to 10 weeks after the birth.  
2. ANALYSIS CONSIDERATIONS 
2.1 Analysis for primary outcome 
Initially, we will conduct a descriptive comparison of the baseline characteristics of the two 
treatment groups. Our primary outcome measure, continuous abstinence from smoking from 
quit date to end of pregnancy, will be compared between treatment groups using logistic 
regression, adjusted for recruitment centre only, with statistical significance determined by 
the likelihood-ratio test and with the estimate of effect given as the odds ratio and 95% 
confidence interval. Our primary analysis will not adjust for any further variables since effect 
estimates can be sensitive to decisions concerning what variables to adjust for and how these 
are specified. Nevertheless, the adjustment for baseline covariates is often advised. First, to 
correct for any chance imbalances in important prognostic variables following randomisation 
and secondly, because adjusting for highly important prognostic variables in an RCT can 
improve the precision of treatment effect estimates even when the outcome measure is binary 
(Robinson, 1991). Statistical testing for baseline imbalances is not advised and instead key 
covariates should be selected prior to analysis based on the likely magnitude of the 
association with the outcome measure.  Therefore as a sensitivity analysis treatment effects 
will be reported adjusting for the following variables in addition to centre: 
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(i) Nicotine dependence score at baseline (Fagerstrom Test of Cigarette Dependence Score, 
FTCD) 
(ii)  Age of finishing full time education (in years), as a proxy for socioeconomic status. For a 
small number of women still in full time education at the time of enrolment the participant's 
current age will be used instead of age of finishing education. 
(iii) maternal age at baseline 
(iv) Depression score at baseline (Edinburgh Post-natal Depression Scale, EPDS) 
 (v) Partner's smoking status (This was not specified in the published protocol, see section 6, 
p.8 of this SAP).  
If we observe differences between the two groups in use of NRT, or use of behavioural 
support outside of the intervention sessions, then we will conduct a sensitivity analysis to 
examine the effect of controlling for any differences between groups in these variables. We 
will analyse other binary smoking outcomes in a similar way.  
2.2 Unit of analysis considerations 
For outcome measures relating to smoking cessation the women randomised will represent 
the unit of analysis. All other outcomes will be related to these women, except those related 
to the offspring (e.g. birth weight), in which case the offspring will be the unit of analysis 
instead. A small number of children will be born as multiple births (e.g. twins) and data for 
these cases will be clustered rather than independent. The primary analysis will be of 
singleton births and we will carry out a sensitivity analysis, including multiple births allowing 
for the clustering of outcomes. More specifically:  
Outcomes where the offspring is the unit of analysis will comprise singleton births only to 
allow for the fact that observations will be non-independent and that non-singleton births are 
likely to have very different birth outcomes in any case. In a subsidiary analysis multiple 
births will be included and clustering accounted for using an approach previously published 
(Gates S & Blocklehurst P, 2001). This adapts methodology previously created for use with 
cluster randomised RCTs, assuming that each women is regarded as the 'cluster' and her 
number of offspring the cluster size.  
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2.3 Effect modification and sub-group analyses 
For our primary outcome, if the intervention is effective, we will look for effect modification 
by age at leaving full time education and baseline levels of physical activity. Our multiple 
logistic regression models will therefore be augmented with appropriate interaction terms. 
Initially, both age at leaving education and baseline physical activity will be fitted as 
continuous terms to maximise power when testing for an interaction. If evidence of an 
interaction is present (taken as a p-value of < 0.05) then further subgroup analyses will 
dichotomise these variables (at the median) for ease of interpretation. The purpose of these 
models is to establish whether women with low or high levels of education, or high or low 
baseline levels of physical activity, could benefit preferentially from a physical activity 
intervention. If there is evidence of interaction, we will perform subgroup analysis of the 
efficacy of PA compared with usual care in subgroups defined by levels of age at leaving 
full-time education and by levels of baseline physical activity.  
 
2.4  Analysis for secondary outcomes (not in main paper) 
We will compare secondary outcomes, including urges to smoke, withdrawal symptoms, self-
confidence and PA, in the first week of abstinence, and the same variables and maternal 
gestation weight and depression, over subsequent time points, using mixed effects modelling 
to allow for repeated measures, with adjustment for centre. To deal with non-normally 
distributed variables we will use transformations to normality, residual bootstrapping, or 
dichotomising. Differences between groups in perinatal outcomes, including birth-weight and 
gestation, mode of delivery and complications, will be analysed by linear or logistic 
regression, with adjustment for centre.  
 
2.5 Timing of analyses 
Baseline data with be complete in November 2012 and the baseline characteristics of the 
sample will then be analysed using descriptive statistics and the results will be presented in 
tables. 
There will be two further main phases of analyses. The first will be begin around July 2013, 
once the end of pregnancy follow-ups are complete. The second will be conducted for data at 
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six months after delivery and this analysis will commence around February 2014. Data 
collected for secondary outcomes will not be analysed until the trial has ended with respect to 
the primary outcome measure.  
2.6 Analysis populations and missing data conventions 
Analysis will be on an intention-to-treat (ITT), that is, including all those women randomised 
to physical activity or usual care. Participants who, for any reason, have missing outcome 
data on the primary outcome or any secondary smoking outcomes, will be assumed to have 
resumed smoking. 
 We will determine the quantity and distributions of missing data. We will carry out a 
complete case analysis, and we will compare this with an analysis using multiple imputation 
to deal with missing values, which assumes data is missing at random, describing any 
differences in terms of the likely biases in the data.  The exception is smoking outcomes, 
where those with missing data will be assumed to have resumed smoking. 
 
2.7 Protocol Deviations 
Failure to attend treatment sessions will not constitute a protocol deviation. The only possible 
protocol deviation is: Women who choose to withdraw from the trial, and choose not to 
consent for the use of their data for primary or secondary outcomes.  
2.8 Derived variables:  
Low birth weight – births of <2500g 
Preterm birth – births of < 37 weeks gestation 
Post-randomisation fetal death - a composite measure of all fetal deaths after 
randomisation– defined as – all [miscarriages + stillbirths + neonatal deaths + elective 
terminations conducted for fetal abnormalities judged inconsistent with fetal / infant life]. 
Perinatal deaths (a composite measure of all infant deaths following live births) – defined as 
– all [stillbirths + neonatal deaths] 
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2.9 Treatment Compliance and mediation analysis  
We will compare compliance between the PA and control groups in terms of the percentage 
of treatment sessions attended.  If the intervention is effective, we will use mediation analysis 
to examine whether there is evidence that the change in PA levels is the likely causal factor in 
determining smoking abstinence. We will examine the association between treatment group 
and change in PA levels, and the association between level of PA and abstinence. Finally, we 
will include level of PA in a logistic regression model of the association between treatment 
group and abstinence, with mediation assessed using MacKinnon’s causal steps criteria. 
2.10 Software used 
We will use STATA version 11. 
2.11 Levels of significance  
All tests will be two-tailed, using a p value of < 0.05 to indicate statistical significance, and 
95% confidence intervals will be calculated.  
2.13 Format of electronic files for archiving 
Excel and SPSS 
3. ANALYSIS OF PARTICIPANT CHARACTERISTICS 
3.1. Describe methods used to summarise data. 
Continuous data that are approximately normally distributed will be 
summarised in terms of the mean, standard deviation, median, minimum, 
maximum and number of observations.  Skewed data will be presented in 
terms of the maximum, upper quartile, median, lower quartile, minimum and 
number of observations.  Categorical data will be summarised in terms of 
frequency counts and percentages. 
3.2. Disposition 
We will summarise the number of patients screened for entry, excluded prior 
to randomisation by major reason and overall, the number of patients 
randomised and the number entering and completing each phase of the study 
by treatment group and overall. We will use a CONSORT flow chart for this. 
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3.3. Baseline 
We will summarise demographic variables (e.g. age, daily number of 
cigarettes prior to delivery and currently, gestational age at randomisation, 
exhaled CO, ethnic group, education, parity, etc) by treatment group.  
4. ANALYSIS OF ADVERSE EVENTS 
The number of adverse events and serious adverse events will be compared between the two 
groups. There is unlikely to be sufficient adverse events to warrant these being reported in a 
table. 
5. LIST OF PROPOSED SUMMARY TABLES 
The proposed tables to be included in the main publication are presented below. We will also 
produce a CONSORT flow diagram showing exclusions, enrollment and evaluable 
participants.  
6.  Changes to statistical analysis plan relative to published protocol 
After further statistical review, we request that the TSC approve the following amendment: 
1. ‘Partners smoking status’ has been consistently related to success at quitting smoking in 
pregnant women and we proposed adjusting for this variable (see section 2.1 above). 
2. Section 2.3 ‘Effect modification and sub-group analyses’ was not specified in the protocol 
and, if the intervention is effective, we propose including this analysis. 
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 Demographic and smoking characteristics  
 
(give ranges for all variables) 
Exercise group 
n= 
Mean (SD) 
Control group  
n=  
Mean (SD) 
Age (years) (range)   
Age at leaving full-time education    
BMI (kg/m2)   
Weight (kg)   
Gestational age (weeks)                       
Cigarettes smoked daily before pregnancy    
Cigarettes smoked daily at randomization   
FTCD score   
Expired carbon monoxide (ppm)   
EPDS score   
Weekly minutes of PA of at least moderate intensity   
 n/% n/% 
Married or living with partner   
Caucasian†   
Professional/managerial occupation   
Smoked in a previous pregnancy   
Parity§ 
0-1 
2-3 
>4 
  
Previous preterm birth††   
Women with partner who smokes   
High confidence for quitting smoking (rated as very or 
extremely high) 
  
Takes alcohol > twice a week    
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Consumes >3 alcoholic drinks on a drinking day   
EPDS score >12   
High confidence for PA (rated as very or extremely 
confident) 
  
Positive expectation for benefits of PA for quitting 
(rated as moderate or large positive effect) 
  
FTND=Fagerstrom Test of Cigarette Dependence EPDS=Edinburgh Post-natal Depression 
Scale; PA=Physical Activity; BMI=Body Mass Index 
† Race or ethnic group was self-reported. Race was categorized according to standard U.K. 
Census categories.  
§ Parity was defined as the number of previous pregnancies that had progressed beyond 24 
weeks. 
¶ Data exclude XX women in the PA group and XX in the conytrol group who had no 
partner. 
†† Previous preterm birth was defined as any previous pregnancy that lasted from 24 to 37 
weeks. 
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 Compliance  
 Exercise group 
n= 
Mean (SD) 
Control group 
n=  
Mean (SD) 
Time walked on treadmill during supervised 
exercise 
   Baseline 
   one week post-quit 
   4 weeks post-quit 
   6 weeks post-quit 
 NA 
Self-reported weekly minutes of physical 
activity of at least moderate intensity    
   Baseline 
   one week post-quit 
   4 weeks post-quit 
   6 weeks post-quit 
   end of pregnancy  
  
 n/n % n/n % 
Treatment sessions attended   
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 Primary and secondary abstinence outcomes 
 
 
 
Outcome 
Exercise 
group (N=   ) 
Number 
(percent) 
Control  
(N=   ) 
Number 
(percent) 
Odds Ratio 
(95% CI) † 
Adjusted 
Odds 
Ratio 
(95% CI) 
Primary 
   Self-reported continuous 
abstinencea at  
   end of pregnancyb  with biochemical  
   validationc§ 
    
Secondary 
   Self-reported continuous  
abstinence for   
   4 weeks after quit day with  
   validation† 
    
† Odds ratios were adjusted for recruitment center only (as a stratification factor). 
‡ Odds ratios were adjusted for center, Fagerstrom Test of Cigarette Dependence score at 
baseline, partner’s smoking status and age at leaving full-time education. 
aContinuous abstinence is defined as having smoked less than five cigarettes since the quit 
day. 
bEnd of pregnancy is defined as between 36 weeks gestation and 10 weeks after the birth. 
cValidated by either exhaled carbon monoxide or salivary cotinine. 
§The biochemical tests did not validate the report of not smoking (i.e., probable false 
reporting of cessation) in X of X women (X%) in the physical activity group and in X of X 
(X%) receiving usual care alone. 
†§The biochemical tests did not validate the report of not smoking (i.e., probable false 
reporting of cessation) in X of X women (X%) in the physical activity group and in X of X 
(X%) receiving usual care alone. 
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Appendix 8 Patient and public involvement
The LEAP trial was preceded by pilot work30 during which pregnant smokers and ex-smokers wereinterviewed concerning the recruitment methods, study design and interventions. The findings from
these interviews were used in the design of the LEAP trial.
The Trial Steering Committe (TSC) included a lay member who approved the protocol and checked the
patient information sheet and consent form, as well as being involved in monitoring all stages of the study.
This individual was also involved in discussions concerning the dissemination of the findings.
The LEAP trial included qualitative interviews with women who were enrolled in the trial and with
researchers delivering the interventions. This helped us to assess the acceptability of the intervention and
women’s overall experience of being involved in the trial. These interviews also helped us to interpret the
findings and to identify topics for future research.
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Appendix 9 Supplementary data on adverse
events
Serious adverse events
Physical activity group
l Maternal AEs (105 events): early labour (n= 13), fainting/dizziness (n= 9), nausea or vomiting (n= 8),
symphysis pubis dysfunction (n= 8), severe headaches (n= 7), chest pain (n= 6), obstetric cholestasis
(n= 4), oligohydramnios (n= 6), generally unwell (n= 6), deep-vein thrombosis (n= 2), group B
streptococcus (n= 3), pelvic pain (n= 3), polyhydramnios (n= 3), vaginal discharge (n= 3), dermatisis
(n= 2), incompetent cervix (n= 2), uterine contractions during pregnancy (n= 2), abnormal antibodies,
abnormal blood flow to placenta, anaemia, back pain, bicornate uterus, diarrhoea, Graves’ disease,
hind waters rupture, palpitations, positive urine toxicology, post-partum haemorrhage, pregnancy-
related tachycardia, right iliac fossa pain, sciatica, supraventricular tachycardia, thyroid problems,
urinary incontinence, varicose veins (all n= 1).
l Fetal AEs (14 events): congenital malformation (n= 10), abnormal fetal heart rate (n= 1), fetal kidney
problem (n= 1), unstable lie (n= 2).
l Neonatal AEs (15 events): premature birth at < 32 weeks (n= 5), congenital malformations (n= 9)
[exomphalos (n= 2), talipes (n= 2), anomalous pulmonary venous drainage, bilateral cleft lip and
palate, enlarged clitoris, perimembranous and muscular ventricular septal defect, small sacral skin tag
(all n= 1)], shoulder dystocia (n= 1).
Control group
l Maternal AEs (114 events): generally unwell (n= 11), symphysis pubis dysfunction (n= 11),
fainting/dizziness (n= 10), oligohydramnios (n= 10), early labour (n= 8), nausea or vomiting (n= 8),
obstetric cholestasis (n= 7), severe headaches (n= 6), vaginal discharge (n= 5), polyhydramnios (n= 4),
thrombocytopenia (n= 2), back pain (n= 4), diarrhoea (n= 3), oedema (n= 3), epigastric pains (n= 2),
placental insufficiency (n= 2), Bell’s palsy, chest pain, deep-vein thrombosis, epileptic fits, fever,
group B streptococcus, irritable bowel syndrome, leaking pulmonary valve, pelvic pain, leg pain,
persistent proteinuria, rectal bleeding, renal calculi, right iliac fossa pain, scoliosis, sickle cell anaemia,
uterine contractions during pregnancy, vaginal pain (all n= 1).
l Fetal AEs (14 events): congenital malformation (n= 9), unstable lie (n= 2), abnormal fetal heart rate,
static growth on scan (< 10th centile), unprovoked decelerations of fetal heart rate (all n= 1).
l Neonatal AEs (14 events): premature birth at < 32 weeks (n= 9), congenital malformations (n= 5)
[chronic lung condition, extra toe on left foot, gastroschisis, renal dilatation of both kidneys, renal tract
anomaly (all n= 1)].
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Appendix 10 Results of subgroup
cost-effectiveness analysis
The cost-effectiveness calculations were repeated using data from subgroups stratified by age and FTCDscore. In each case, the population was divided approximately in half. The groups considered were
age < 28 years, age > 27 years, FTCD score < 4, FTCD score ≥ 4. In this appendix the point estimate
cost-effectiveness results are shown, followed by the cost-effectiveness scatterplot and cost-effectiveness
acceptability curve derived from the same approach of imputation and bootstrapping as was used for
the complete data set. Note that in each case there is no dominance relationship in the point estimate
results but there is still considerable uncertainty shown on the cost-effectiveness plane and in the
cost-effectiveness acceptability curves. A reasonable interpretation of these results is that there is no
strong evidence of a subgroup effect.
TABLE 23 Results of the incremental cost-effectiveness analysis for women aged < 28 years
Group
Expected
per-participant
costs (£, 2012/13
prices)
Expected
quit rate (%)
Expected
annual costs
(£, 2012/13
prices)
Expected
annual
quitters ICER
PA 4472 0.0542 259,348 3.14 £84,000 per quitter. Note that this result
taken in isolation would suggest that PA
should be preferred at any willingness to
pay below £84,000 per additional
quitter. This is because the differences in
costs and effectiveness are both
negative. However, in context, a more
reasonable interpretation is that there is
no significant difference between the PA
group results and the control group
results for either cost or effectiveness
Control 4757 0.0576 275,932 3.34
Difference −286 −0.0034 −16,584 −0.20
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FIGURE 7 Cost-effectiveness scatterplot for women aged < 28 years.
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 10 20 30 40 50
Pr
o
b
ab
ili
ty
 in
te
rv
en
ti
o
n
 is
 c
o
st
-e
ff
ec
ti
ve
Threshold ICER (£000/additional quitter expected)
FIGURE 8 Cost-effectiveness acceptability curve for women aged < 28 years.
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TABLE 24 Results of the incremental cost-effectiveness analysis for women aged > 27 years
Group
Expected
per-participant
costs (£, 2012/13
prices)
Expected
quit rate (%)
Expected
annual costs
(£, 2012/13
prices)
Expected
annual
quitters ICER
PA 4968 0.101 288,119 5.86 £7200 per quitter. Note that this result
taken in isolation would suggest that PA
should be preferred at any willingness to
pay above £7200 per additional quitter.
However, in context, a more reasonable
interpretation is that there is no
significant difference between the PA
group results and the control group
results for either cost or effectiveness
Control 4738 0.069 274,791 4.02
Difference 230 0.032 13,328 1.84
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FIGURE 9 Cost-effectiveness scatterplot for women aged > 27 years.
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FIGURE 10 Cost-effectiveness acceptability curve for women aged > 27 years.
TABLE 25 Results of the incremental cost-effectiveness analysis for FTCD score of < 4
Group
Expected
per-participant
costs (£, 2012/13
prices)
Expected
quit rate (%)
Expected
annual costs
(£, 2012/13
prices)
Expected
annual
quitters ICER
PA 4620 0.122 267,945 7.06 £4900 per quitter. Note that this result
taken in isolation would suggest that PA
should be preferred at any willingness to
pay above £4900 per additional quitter.
However, in context, a more reasonable
interpretation is that there is no
significant difference between the PA
group results and the control group
results for either cost or effectiveness
Control 4435 0.084 257,242 4.89
Difference 185 0.037 10,703 2.17
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FIGURE 11 Cost-effectiveness scatterplot for FTCD score of < 4.
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FIGURE 12 Cost-effectiveness acceptability curve for FTCD score of < 4.
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TABLE 26 Results of the incremental cost-effectiveness analysis for FTCD score of ≥ 4
Group
Expected
per-participant
costs (£, 2012/13
prices)
Expected
quit rate
(%)
Expected
annual costs
(£, 2012/13
prices)
Expected
annual
quitters ICER
PA 4772 0.0468 276,788 2.71 £124,000 per quitter. Note that this result
taken in isolation would suggest that PA
should be preferred at any willingness to
pay below £124,000 per additional quitter.
This is because the differences in costs and
effectiveness are both negative. However, in
context, a more reasonable interpretation is
that there is no significant difference
between the PA group results and the
control group results for either cost
or effectiveness
Control 4976 0.0485 288,630 2.81
Difference −204 −0.0016 −11,842 −0.10
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FIGURE 13 Cost-effectiveness scatterplot for FTCD score of ≥ 4.
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FIGURE 14 Cost-effectiveness acceptability curve for FTCD score of ≥ 4.
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